Retinoid	B-protein
X	I-protein
receptor	I-protein
(	O
RXR	B-protein
)	O
agonist-induced	O
activation	O
of	O
dominant-negative	O
RXR	B-protein
-retinoic	O
acid	O
receptor	O
alpha403	O
heterodimers	O
is	O
developmentally	O
regulated	O
during	O
myeloid	O
differentiation	O
.	O

The	O
multiple	O
biologic	O
activities	O
of	O
retinoic	O
acid	O
(	O
RA	O
)	O
are	O
mediated	O
through	O
RAR	B-protein
and	O
retinoid	B-protein
X	I-protein
receptor	I-protein
(	I-protein
RXR	I-protein
)	I-protein
nuclear	I-protein
receptors	I-protein
that	O
interact	O
with	O
specific	O
DNA	B-DNA
target	I-DNA
sequences	I-DNA
as	O
heterodimers	B-protein
(	O
RXR-RAR	B-protein
)	O
or	O
homodimers	B-protein
(	O
RXR-RXR	B-protein
)	O
.	O

RA	O
receptor	O
activation	O
appears	O
critical	O
to	O
regulating	O
important	O
aspects	O
of	O
hematopoiesis	O
,	O
since	O
transducing	O
a	O
COOH-terminally	B-protein
truncated	I-protein
RARalpha	I-protein
exhibiting	O
dominant-negative	O
activity	O
(	O
RARalpha403	B-protein
)	O
into	O
normal	O
mouse	O
bone	O
marrow	O
generates	O
hematopoietic	B-cell_line
growth	I-cell_line
factor-dependent	I-cell_line
cell	I-cell_line
lines	I-cell_line
frozen	O
at	O
the	O
multipotent	O
progenitor	O
(	O
EML	O
)	O
or	O
committed	O
promyelocyte	O
(	O
MPRO	O
)	O
stages	O
.	O

Nevertheless	O
,	O
relatively	O
high	O
,	O
pharmacological	O
concentrations	O
of	O
RA	O
(	O
1	O
to	O
10	O
&	O
mgr	O
;	O
M	O
)	O
overcome	O
these	O
differentiation	O
blocks	O
and	O
induce	O
terminal	O
granulocytic	O
differentiation	O
of	O
the	O
MPRO	B-cell_type
promyelocytes	I-cell_type
while	O
potentiating	O
interleukin-3	B-protein
(	O
IL-3	B-protein
)	O
-induced	O
commitment	O
of	O
EML	B-cell_type
cells	I-cell_type
to	O
the	O
granulocyte/monocyte	O
lineage	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
utilized	O
RXR	B-protein
-and	O
RAR	B-protein
-specific	O
agonists	O
and	O
antagonists	O
to	O
determine	O
how	O
RA	O
overcomes	O
the	O
dominant-negative	O
activity	O
of	O
the	O
truncated	B-protein
RARalpha	I-protein
in	O
these	O
different	O
myeloid	O
developmental	O
stages	O
.	O

Unexpectedly	O
,	O
we	O
observed	O
that	O
an	O
RXR	B-protein
-specific	O
,	O
rather	O
than	O
an	O
RAR	B-protein
-specific	O
,	O
agonist	O
induces	O
terminal	O
granulocytic	O
differentiation	O
of	O
MPRO	B-cell_type
promyelocytes	I-cell_type
,	O
and	O
this	O
differentiation	O
is	O
associated	O
with	O
activation	O
of	O
DNA	B-DNA
response	I-DNA
elements	I-DNA
corresponding	O
to	O
RAR-RXR	B-protein
heterodimers	I-protein
rather	O
than	O
RXR-RXR	B-protein
homodimers	I-protein
.	O

This	O
RXR	B-protein
agonist	O
activity	O
is	O
blocked	O
by	O
RAR	B-protein
-specific	O
antagonists	O
,	O
suggesting	O
extensive	O
cross-talk	O
between	O
the	O
partners	O
of	O
the	O
RXR	B-protein
-RARalpha403	I-protein
heterodimer	I-protein
.	O

In	O
contrast	O
,	O
in	O
the	O
more	O
immature	O
,	O
multipotent	O
EML	B-cell_type
cells	I-cell_type
we	O
observed	O
that	O
this	O
RXR	B-protein
-specific	O
agonist	O
is	O
inactive	O
either	O
in	O
potentiating	O
IL-3	B-protein
-mediated	O
commitment	O
of	O
EML	B-cell_type
cells	I-cell_type
to	O
the	O
granulocyte	B-cell_type
lineage	I-cell_type
or	O
in	O
transactivating	O
RAR-RXR	B-DNA
response	I-DNA
elements	I-DNA
.	O

RA	O
-triggered	O
GALdbd-	O
RARalpha	B-protein
hybrid	O
activity	O
in	O
these	O
cells	O
indicates	O
that	O
the	O
multipotent	O
EML	B-cell_type
cells	I-cell_type
harbor	O
substantial	O
nuclear	O
hormone	O
receptor	O
coactivator	B-protein
activity	O
.	O

However	O
,	O
the	O
histone	B-protein
deacetylase	I-protein
(	I-protein
HDAC	I-protein
)	I-protein
inhibitor	I-protein
trichostatin	O
A	O
readily	O
activates	O
an	O
RXR-RAR	B-DNA
reporter	I-DNA
construct	I-DNA
in	O
the	O
multipotent	O
EML	B-cell_type
cells	I-cell_type
but	O
not	O
in	O
the	O
committed	O
MPRO	B-cell_type
promyelocytes	I-cell_type
,	O
indicating	O
that	O
differences	O
in	O
HDAC-containing	B-protein
repressor	I-protein
complexes	I-protein
in	O
these	O
two	O
closely	O
related	O
but	O
distinct	O
hematopoietic	B-cell_type
lineages	I-cell_type
might	O
account	O
for	O
the	O
differential	O
activation	O
of	O
the	O
RXR-RARalpha403	B-protein
heterodimers	I-protein
that	O
we	O
observed	O
at	O
these	O
different	O
stages	O
of	O
myeloid	O
development	O
.	O

MoLECcULAR	NULL
AND	NULL
CELLULAR	NULL
BroLoGY	NULL
,	NULL
May	NULL
1999	NULL
,	NULL
p.	NULL
3372-3382	NULL
0270-7306/99/	NULL
$	NULL
04.00+0	NULL
Vol	NULL
.	NULL

19	NULL
,	NULL
No	NULL
.	NULL

5	NULL
Copyright	NULL
©	NULL
1999	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
.	NULL

All	NULL
Rights	NULL
Reserved	NULL
.	NULL

Retinoid	NULL
X	NULL
Receptor	NULL
(	NULL
RXR	NULL
)	NULL
Agonist-Induced	NULL
Activation	NULL
of	NULL
Dominant-Negative	NULL
RXR-Retinoic	NULL
Acid	NULL
Receptor	NULL
«	NULL
403	NULL
Heterodimers	NULL
Is	NULL
Developmentally	NULL
Regulated	NULL
during	NULL
Myeloid	NULL
Differentiation	NULL
BARTON	NULL
S.	NULL
JOHNSON	NULL
,	NULL
!	NULL

ROSHANTHA	NULL
A.	NULL
S.	NULL
CHANDRARATNA	NULL
,	NULL
*	NULL
``	NULL
RICHARD	NULL
A.	NULL
HEYMAN	NULL
,	NULL
*	NULL
ELIZABETH	NULL
A.	NULL
ALLEGRETTO	NULL
,	NULL
*	NULL
LeMOYNE	NULL
MUELLER	NULL
,	NULL
``	NULL
anp	NULL
STEVEN	NULL
J.	NULL
COLLINS®*	NULL
Division	NULL
of	NULL
Hospital	NULL
Dentistry	NULL
,	NULL
University	NULL
of	NULL
Washington	NULL
,	NULL
Seattle	NULL
,	NULL
Washington	NULL
98195	NULL
``	NULL
;	NULL
Retinoid	NULL
Research	NULL
,	NULL
Departments	NULL
of	NULL
Biology	NULL
and	NULL
Chemistry	NULL
,	NULL
``	NULL
Allergan	NULL
Pharmaceuticals	NULL
,	NULL
Irvine	NULL
,	NULL
California	NULL
92715	NULL
;	NULL
Department	NULL
of	NULL
Retinoid	NULL
Research	NULL
,	NULL
Ligand	NULL
Pharmaceuticals	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
California	NULL
92121	NULL
``	NULL
;	NULL
and	NULL
Division	NULL
of	NULL
Molecular	NULL
Medicine	NULL
,	NULL
Fred	NULL
Hutchinson	NULL
Cancer	NULL
Research	NULL
Center	NULL
,	NULL
Seattle	NULL
,	NULL
Washington	NULL
981	NULL
09°	NULL
Received	NULL
31	NULL
August	NULL
1998/Returned	NULL
for	NULL
modification	NULL
20	NULL
November	NULL
1998/Accepted	NULL
25	NULL
January	NULL
1999	NULL
The	NULL
multiple	NULL
biologic	NULL
activities	NULL
of	NULL
retinoic	NULL
acid	NULL
(	NULL
RA	NULL
)	NULL
are	NULL
mediated	NULL
through	NULL
RAR	NULL
and	NULL
retinoid	NULL
X	NULL
receptor	NULL
(	NULL
RXR	NULL
)	NULL
nuclear	NULL
receptors	NULL
that	NULL
interact	NULL
with	NULL
specific	NULL
DNA	NULL
target	NULL
sequences	NULL
as	NULL
heterodimers	NULL
(	NULL
RXR-RAR	NULL
)	NULL
or	NULL
homodimers	NULL
(	NULL
RXR-RXR	NULL
)	NULL
.	NULL

RA	NULL
receptor	NULL
activation	NULL
appears	NULL
critical	NULL
to	NULL
regulating	NULL
important	NULL
aspects	NULL
of	NULL
hemato-poiesis	NULL
,	NULL
since	NULL
transducing	NULL
a	NULL
COOH-terminally	NULL
truncated	NULL
RARa	NULL
«	NULL
exhibiting	NULL
dominant-negative	NULL
activity	NULL
(	NULL
RARa403	NULL
)	NULL
into	NULL
normal	NULL
mouse	NULL
bone	NULL
marrow	NULL
generates	NULL
hematopoietic	NULL
growth	NULL
factor-dependent	NULL
cell	NULL
lines	NULL
frozen	NULL
at	NULL
the	NULL
multipotent	NULL
progenitor	NULL
(	NULL
EML	NULL
)	NULL
or	NULL
committed	NULL
promyelocyte	NULL
(	NULL
MPRO	NULL
)	NULL
stages	NULL
.	NULL

Nevertheless	NULL
,	NULL
relatively	NULL
high	NULL
,	NULL
pharmacological	NULL
concentrations	NULL
of	NULL
RA	NULL
(	NULL
1	NULL
to	NULL
10	NULL
mM	NULL
)	NULL
overcome	NULL
these	NULL
differentiation	NULL
blocks	NULL
and	NULL
induce	NULL
terminal	NULL
granulocytic	NULL
differentiation	NULL
of	NULL
the	NULL
MPRO	NULL
promyelocytes	NULL
while	NULL
potentiating	NULL
interleukin-3	NULL
(	NULL
IL-3	NULL
)	NULL
-induced	NULL
commitment	NULL
of	NULL
EML	NULL
cells	NULL
to	NULL
the	NULL
granulocyte/monocyte	NULL
lineage	NULL
.	NULL

In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
we	NULL
utilized	NULL
RXR-	NULL
and	NULL
RAR-specific	NULL
agonists	NULL
and	NULL
antagonists	NULL
to	NULL
determine	NULL
how	NULL
RA	NULL
overcomes	NULL
the	NULL
dominant-negative	NULL
activity	NULL
of	NULL
the	NULL
truncated	NULL
RARa	NULL
«	NULL
in	NULL
these	NULL
different	NULL
myeloid	NULL
developmental	NULL
stages	NULL
.	NULL

Unexpectedly	NULL
,	NULL
we	NULL
observed	NULL
that	NULL
an	NULL
RXR-specific	NULL
,	NULL
rather	NULL
than	NULL
an	NULL
RAR-specific	NULL
,	NULL
agonist	NULL
induces	NULL
terminal	NULL
granulocytic	NULL
differentiation	NULL
of	NULL
MPRO	NULL
promyelocytes	NULL
,	NULL
and	NULL
this	NULL
differentiation	NULL
is	NULL
associated	NULL
with	NULL
activation	NULL
of	NULL
DNA	NULL
response	NULL
elements	NULL
corresponding	NULL
to	NULL
RAR-RXR	NULL
heterodimers	NULL
rather	NULL
than	NULL
RXR-RXR	NULL
homodimers	NULL
.	NULL

This	NULL
RXR	NULL
agonist	NULL
activity	NULL
is	NULL
blocked	NULL
by	NULL
RAR-specific	NULL
antagonists	NULL
,	NULL
suggesting	NULL
extensive	NULL
cross-talk	NULL
between	NULL
the	NULL
partners	NULL
of	NULL
the	NULL
RXR-RARa403	NULL
heterodimer	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
in	NULL
the	NULL
more	NULL
immature	NULL
,	NULL
multipotent	NULL
EML	NULL
cells	NULL
we	NULL
observed	NULL
that	NULL
this	NULL
RXR-specific	NULL
agonist	NULL
is	NULL
inactive	NULL
either	NULL
in	NULL
potentiating	NULL
IL-3-mediated	NULL
commitment	NULL
of	NULL
EML	NULL
cells	NULL
to	NULL
the	NULL
granulocyte	NULL
lineage	NULL
or	NULL
in	NULL
transactivating	NULL
RAR-RXR	NULL
response	NULL
elements	NULL
.	NULL

RA-triggered	NULL
GALq	NULL
,	NULL
,	NULL
q-RARa	NULL
«	NULL
hybrid	NULL
activity	NULL
in	NULL
these	NULL
cells	NULL
indicates	NULL
that	NULL
the	NULL
multipotent	NULL
EML	NULL
cells	NULL
harbor	NULL
substantial	NULL
nuclear	NULL
hormone	NULL
receptor	NULL
coactivator	NULL
activity	NULL
.	NULL

However	NULL
,	NULL
the	NULL
histone	NULL
deacetylase	NULL
(	NULL
HDAC	NULL
)	NULL
inhibitor	NULL
trichostatin	NULL
A	NULL
readily	NULL
activates	NULL
an	NULL
RXR-RAR	NULL
reporter	NULL
construct	NULL
in	NULL
the	NULL
multipotent	NULL
EML	NULL
cells	NULL
but	NULL
not	NULL
in	NULL
the	NULL
committed	NULL
MPRO	NULL
promyelocytes	NULL
,	NULL
indicating	NULL
that	NULL
differences	NULL
in	NULL
HDAC-containing	NULL
repressor	NULL
complexes	NULL
in	NULL
these	NULL
two	NULL
closely	NULL
related	NULL
but	NULL
distinct	NULL
hematopoietic	NULL
lineages	NULL
might	NULL
account	NULL
for	NULL
the	NULL
differential	NULL
activation	NULL
of	NULL
the	NULL
RXR-RARa	NULL
«	NULL
403	NULL
heterodimers	NULL
that	NULL
we	NULL
observed	NULL
at	NULL
these	NULL
different	NULL
stages	NULL
of	NULL
myeloid	NULL
development	NULL
.	NULL

The	NULL
biologic	NULL
effects	NULL
of	NULL
retinoic	NULL
acid	NULL
(	NULL
RA	NULL
)	NULL
are	NULL
critical	NULL
in	NULL
regulating	NULL
development	NULL
and	NULL
differentiation	NULL
of	NULL
diverse	NULL
cell	NULL
types	NULL
.	NULL

RA	NULL
exerts	NULL
these	NULL
effects	NULL
through	NULL
specific	NULL
nuclear	NULL
receptors	NULL
possessing	NULL
discrete	NULL
DNA-binding	NULL
and	NULL
RA	NULL
(	NULL
ligand	NULL
)	NULL
-binding	NULL
domains	NULL
.	NULL

Two	NULL
general	NULL
families	NULL
of	NULL
RA	NULL
receptors	NULL
include	NULL
the	NULL
RARs	NULL
and	NULL
retinoid	NULL
X	NULL
receptors	NULL
(	NULL
RXRs	NULL
)	NULL
,	NULL
both	NULL
containing	NULL
at	NULL
least	NULL
three	NULL
members	NULL
designated	NULL
«	NULL
,	NULL
B	NULL
,	NULL
and	NULL
y	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
RA	NULL
are	NULL
thought	NULL
to	NULL
be	NULL
mediated	NULL
through	NULL
either	NULL
RXR-RAR	NULL
heterodimers	NULL
or	NULL
RXR-RXR	NULL
homodimers	NULL
that	NULL
regulate	NULL
gene	NULL
transcription	NULL
by	NULL
interacting	NULL
with	NULL
specific	NULL
response	NULL
elements	NULL
in	NULL
their	NULL
respective	NULL
target	NULL
gene	NULL
promoters	NULL
(	NULL
30	NULL
,	NULL
41	NULL
)	NULL
.	NULL

Hematopoietic	NULL
cells	NULL
preferentially	NULL
express	NULL
RARa	NULL
(	NULL
12	NULL
,	NULL
36	NULL
)	NULL
,	NULL
and	NULL
we	NULL
have	NULL
previously	NULL
observed	NULL
that	NULL
the	NULL
RA-mediated	NULL
granulocytic	NULL
differentiation	NULL
of	NULL
HL-60	NULL
leukemia	NULL
cells	NULL
is	NULL
directly	NULL
mediated	NULL
through	NULL
RARa	NULL
(	NULL
9	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
central	NULL
role	NULL
that	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
Division	NULL
of	NULL
Molecular	NULL
Medicine	NULL
,	NULL
Fred	NULL
Hutchinson	NULL
Cancer	NULL
Research	NULL
Center	NULL
,	NULL
1100	NULL
Fairview	NULL
Ave.	NULL
,	NULL
North	NULL
,	NULL
Seattle	NULL
,	NULL
WA	NULL
98109	NULL
.	NULL

Phone	NULL
:	NULL
(	NULL
206	NULL
)	NULL
667-4389	NULL
.	NULL

Fax	NULL
:	NULL
(	NULL
206	NULL
)	NULL
667-6523	NULL
.	NULL

E-mail	NULL
:	NULL
3372	NULL
RARa	NULL
plays	NULL
in	NULL
granulocytic	NULL
differentiation	NULL
is	NULL
further	NULL
indicated	NULL
by	NULL
the	NULL
observation	NULL
that	NULL
RARa	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
15	NULL
;	NULL
17	NULL
translocation	NULL
that	NULL
characterizes	NULL
most	NULL
cases	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
(	NULL
APL	NULL
)	NULL
(	NULL
2	NULL
,	NULL
13	NULL
,	NULL
29	NULL
)	NULL
,	NULL
a	NULL
subtype	NULL
of	NULL
human	NULL
leukemia	NULL
that	NULL
is	NULL
uniquely	NULL
sensitive	NULL
to	NULL
RA-induced	NULL
granulocytic	NULL
differentiation	NULL
(	NULL
4	NULL
,	NULL
5	NULL
,	NULL
26	NULL
,	NULL
59	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
dramatic	NULL
response	NULL
of	NULL
APL	NULL
cells	NULL
to	NULL
RA	NULL
appears	NULL
confined	NULL
to	NULL
this	NULL
particular	NULL
subtype	NULL
of	NULL
human	NULL
leukemia	NULL
,	NULL
and	NULL
most	NULL
other	NULL
forms	NULL
of	NULL
human	NULL
myelogenous	NULL
leukemia	NULL
exhibit	NULL
little	NULL
if	NULL
any	NULL
response	NULL
to	NULL
retinoids	NULL
(	NULL
4	NULL
,	NULL
42	NULL
)	NULL
.	NULL

One	NULL
important	NULL
approach	NULL
in	NULL
defining	NULL
the	NULL
biologic	NULL
role	NULL
of	NULL
RA	NULL
receptors	NULL
in	NULL
controlling	NULL
the	NULL
differentiation	NULL
of	NULL
specific	NULL
cell	NULL
lineages	NULL
involves	NULL
the	NULL
use	NULL
of	NULL
RA	NULL
receptor	NULL
constructs	NULL
exhibiting	NULL
dominant-negative	NULL
activity	NULL
.	NULL

Truncating	NULL
or	NULL
introducing	NULL
specific	NULL
point	NULL
mutations	NULL
into	NULL
the	NULL
COOH-terminal	NULL
end	NULL
of	NULL
RARa	NULL
results	NULL
in	NULL
an	NULL
altered	NULL
RA	NULL
receptor	NULL
that	NULL
inhibits	NULL
the	NULL
function	NULL
of	NULL
normal	NULL
RA	NULL
receptors	NULL
(	NULL
10	NULL
,	NULL
11	NULL
,	NULL
15	NULL
,	NULL
45	NULL
,	NULL
47	NULL
)	NULL
.	NULL

Such	NULL
dominant-negative	NULL
constructs	NULL
inhibit	NULL
RA	NULL
activity	NULL
in	NULL
a	NULL
number	NULL
of	NULL
different	NULL
cell	NULL
types	NULL
,	NULL
including	NULL
cultured	NULL
CV1	NULL
cells	NULL
(	NULL
11	NULL
,	NULL
45	NULL
)	NULL
,	NULL
transgenic	NULL
mouse	NULL
epidermis	NULL
(	NULL
27	NULL
,	NULL
48	NULL
)	NULL
,	NULL
multipotent	NULL
embryonal	NULL
carcinoma	NULL
cells	NULL
(	NULL
10	NULL
,	NULL
11	NULL
)	NULL
,	NULL
and	NULL
mammary	NULL
epithelial	NULL
cells	NULL
(	NULL
50	NULL
)	NULL
.	NULL

The	NULL
truncated	NULL
recep-	NULL
Vor	NULL
.	NULL

19	NULL
,	NULL
1999	NULL
tors	NULL
lack	NULL
the	NULL
COOH-terminal	NULL
activation	NULL
domain	NULL
(	NULL
AF2	NULL
)	NULL
while	NULL
retaining	NULL
the	NULL
DNA-binding	NULL
domain	NULL
as	NULL
well	NULL
as	NULL
the	NULL
ability	NULL
to	NULL
heterodimerize	NULL
with	NULL
RXR	NULL
(	NULL
11	NULL
,	NULL
15	NULL
)	NULL
.	NULL

It	NULL
is	NULL
likely	NULL
that	NULL
the	NULL
truncated	NULL
RA	NULL
receptor	NULL
acts	NULL
as	NULL
a	NULL
dominant	NULL
negative	NULL
by	NULL
competing	NULL
with	NULL
the	NULL
normal	NULL
RA	NULL
receptors	NULL
in	NULL
the	NULL
formation	NULL
of	NULL
biologically	NULL
active	NULL
RXR-RAR	NULL
heterodimers	NULL
.	NULL

In	NULL
our	NULL
own	NULL
studies	NULL
,	NULL
we	NULL
have	NULL
observed	NULL
that	NULL
introducing	NULL
a	NULL
mutated	NULL
RARa	NULL
harboring	NULL
a	NULL
59-amino-acid	NULL
truncation	NULL
at	NULL
the	NULL
COOH	NULL
terminus	NULL
(	NULL
designated	NULL
RARa403	NULL
)	NULL
into	NULL
normal	NULL
mouse	NULL
bone	NULL
marrow	NULL
generates	NULL
hematopoietic	NULL
growth	NULL
factor-dependent	NULL
cells	NULL
frozen	NULL
at	NULL
distinct	NULL
stages	NULL
of	NULL
myeloid	NULL
differentiation	NULL
(	NULL
53	NULL
,	NULL
54	NULL
)	NULL
.	NULL

These	NULL
include	NULL
gran-ulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
(	NULL
GM-CSF	NULL
)	NULL
-de-pendent	NULL
MPRO	NULL
cells	NULL
,	NULL
which	NULL
are	NULL
frozen	NULL
at	NULL
the	NULL
promyelocyte	NULL
stage	NULL
of	NULL
granulocyte	NULL
differentiation	NULL
(	NULL
53	NULL
)	NULL
,	NULL
and	NULL
the	NULL
more	NULL
primitive	NULL
SCF	NULL
(	NULL
stem	NULL
cell	NULL
factor	NULL
or	NULL
kit	NULL
ligand	NULL
)	NULL
-dependent	NULL
EML	NULL
cells	NULL
,	NULL
which	NULL
are	NULL
multipotent	NULL
and	NULL
exhibit	NULL
erythroid	NULL
,	NULL
lymphoid	NULL
,	NULL
and	NULL
myeloid	NULL
potential	NULL
(	NULL
54	NULL
)	NULL
.	NULL

Curiously	NULL
,	NULL
in	NULL
these	NULL
hematopoietic	NULL
cell	NULL
lines	NULL
the	NULL
effect	NULL
of	NULL
the	NULL
dominant-negative	NULL
RARa403	NULL
construct	NULL
does	NULL
not	NULL
appear	NULL
to	NULL
be	NULL
absolute	NULL
but	NULL
can	NULL
be	NULL
overcome	NULL
with	NULL
the	NULL
addition	NULL
of	NULL
relatively	NULL
high	NULL
,	NULL
pharmacological	NULL
concentrations	NULL
of	NULL
RA	NULL
.	NULL

Thus	NULL
,	NULL
RA	NULL
(	NULL
1	NULL
to	NULL
10	NULL
wM	NULL
)	NULL
induces	NULL
terminal	NULL
granulocytic	NULL
differentiation	NULL
of	NULL
the	NULL
GM-CSF-dependent	NULL
MPRO	NULL
cells	NULL
(	NULL
53	NULL
)	NULL
,	NULL
while	NULL
in	NULL
the	NULL
pluripotent	NULL
,	NULL
SCF-dependent	NULL
EML	NULL
cells	NULL
,	NULL
RA	NULL
potentiates	NULL
the	NULL
interleukin-3	NULL
(	NULL
IL-3	NULL
)	NULL
-mediated	NULL
commitment	NULL
of	NULL
these	NULL
cells	NULL
to	NULL
the	NULL
granulocyte/monocyte	NULL
lineage	NULL
(	NULL
54	NULL
)	NULL
.	NULL

We	NULL
initiated	NULL
the	NULL
present	NULL
studies	NULL
to	NULL
determine	NULL
the	NULL
mechanism	NULL
by	NULL
which	NULL
such	NULL
relatively	NULL
high	NULL
concentrations	NULL
of	NULL
RA	NULL
overcome	NULL
the	NULL
dominant-negative	NULL
activity	NULL
of	NULL
the	NULL
RARa403	NULL
construct	NULL
in	NULL
the	NULL
MPRO	NULL
and	NULL
EML	NULL
hematopoietic	NULL
cell	NULL
lines	NULL
and	NULL
presumably	NULL
trigger	NULL
activation	NULL
of	NULL
the	NULL
aberrant	NULL
RXR-RARa403	NULL
heterodimer	NULL
.	NULL

Our	NULL
approach	NULL
involved	NULL
assessing	NULL
the	NULL
effect	NULL
of	NULL
different	NULL
synthetic	NULL
retinoids	NULL
with	NULL
specific	NULL
activity	NULL
as	NULL
RXR	NULL
or	NULL
RAR	NULL
agonists	NULL
and/or	NULL
RXR	NULL
or	NULL
RAR	NULL
antagonists	NULL
on	NULL
both	NULL
the	NULL
terminal	NULL
differentiation	NULL
of	NULL
the	NULL
MPRO	NULL
promyelocytes	NULL
and	NULL
the	NULL
granulocyte	NULL
lineage	NULL
commitment	NULL
of	NULL
the	NULL
pluripotent	NULL
EML	NULL
cells	NULL
.	NULL

Surprisingly	NULL
,	NULL
we	NULL
observed	NULL
that	NULL
granulocytic	NULL
differentiation	NULL
of	NULL
the	NULL
MPRO	NULL
promyelocytes	NULL
is	NULL
induced	NULL
by	NULL
RXR-	NULL
rather	NULL
than	NULL
RAR	NULL
-specific	NULL
agonists	NULL
,	NULL
and	NULL
transient-transfection	NULL
studies	NULL
indicated	NULL
that	NULL
this	NULL
differentiation	NULL
is	NULL
associated	NULL
with	NULL
activation	NULL
of	NULL
RXR-RAR	NULL
rather	NULL
than	NULL
RXR-RXR	NULL
response	NULL
elements	NULL
.	NULL

However	NULL
,	NULL
this	NULL
potent	NULL
effect	NULL
of	NULL
the	NULL
RXR	NULL
agonist	NULL
on	NULL
RXR-RAR	NULL
activation	NULL
appears	NULL
to	NULL
be	NULL
developmentally	NULL
regulated	NULL
during	NULL
myeloid	NULL
differentiation	NULL
,	NULL
because	NULL
we	NULL
could	NULL
detect	NULL
little	NULL
if	NULL
any	NULL
effect	NULL
of	NULL
the	NULL
same	NULL
RXR	NULL
agonist	NULL
in	NULL
the	NULL
multipotent	NULL
EML	NULL
cells	NULL
,	NULL
in	NULL
which	NULL
the	NULL
developmental	NULL
block	NULL
is	NULL
at	NULL
a	NULL
more	NULL
immature	NULL
progenitor	NULL
stage	NULL
.	NULL

Moreover	NULL
,	NULL
utilizing	NULL
histone	NULL
deacetylase	NULL
(	NULL
HDAC	NULL
)	NULL
inhibitors	NULL
we	NULL
observed	NULL
significant	NULL
differences	NULL
in	NULL
HDAC	NULL
repressor	NULL
complexes	NULL
between	NULL
the	NULL
multipotent	NULL
EML	NULL
cells	NULL
and	NULL
the	NULL
committed	NULL
MPRO	NULL
promyelocytes	NULL
that	NULL
might	NULL
account	NULL
for	NULL
the	NULL
differential	NULL
activation	NULL
of	NULL
RXR-RAR	NULL
response	NULL
elements	NULL
in	NULL
these	NULL
two	NULL
related	NULL
but	NULL
distinct	NULL
hematopoietic	NULL
lineages	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
cultures	NULL
.	NULL

MPRO	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
Dulbecco	NULL
minimal	NULL
essential	NULL
medium	NULL
(	NULL
DMEM	NULL
)	NULL
(	NULL
GIBCO	NULL
,	NULL
Grand	NULL
Island	NULL
,	NULL
N.Y.	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
and	NULL
1	NULL
%	NULL
L-glutamine	NULL
.	NULL

These	NULL
cells	NULL
are	NULL
absolutely	NULL
dependent	NULL
upon	NULL
GM-CSF	NULL
(	NULL
recombinant	NULL
murine	NULL
GM-CSF	NULL
at	NULL
5	NULL
to	NULL
10	NULL
ng/m	NULL
!	NULL
)	NULL

(	NULL
Peprotech	NULL
,	NULL
Rocky	NULL
Hill	NULL
,	NULL
NJ	NULL
.	NULL
)	NULL

.	NULL

EML	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
Iscove	NULL
modified	NULL
Dulbecco	NULL
medium	NULL
(	NULL
IMDM	NULL
)	NULL
supplemented	NULL
with	NULL
2	NULL
%	NULL
horse	NULL
serum	NULL
(	NULL
GIBCO	NULL
)	NULL
and	NULL
1	NULL
%	NULL
1-glutamine	NULL
.	NULL

These	NULL
cells	NULL
are	NULL
absolutely	NULL
dependent	NULL
upon	NULL
SCF	NULL
(	NULL
100	NULL
ng/m	NULL
!	NULL
)	NULL

(	NULL
Peprotech	NULL
)	NULL
.	NULL

A	NULL
Friend	NULL
murine	NULL
erythroleukemia	NULL
cell	NULL
line	NULL
(	NULL
MEL	NULL
)	NULL
was	NULL
cultured	NULL
in	NULL
DMEM	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
.	NULL

These	NULL
cells	NULL
were	NULL
stably	NULL
transduced	NULL
with	NULL
a	NULL
retroviral	NULL
vector	NULL
harboring	NULL
human	NULL
RARa	NULL
«	NULL
(	NULL
LRARaSN	NULL
)	NULL
as	NULL
previously	NULL
detailed	NULL
(	NULL
9	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
cultured	NULL
in	NULL
a	NULL
37°C	NULL
incubator	NULL
with	NULL
5	NULL
%	NULL
CO	NULL
,	NULL
-95	NULL
%	NULL
air	NULL
.	NULL

Receptor-specific	NULL
synthetic	NULL
retinoids	NULL
.	NULL

Synthetic	NULL
retinoids	NULL
that	NULL
were	NULL
specific	NULL
for	NULL
either	NULL
RXR	NULL
or	NULL
RAR	NULL
were	NULL
screened	NULL
by	NULL
both	NULL
direct	NULL
ligand	NULL
binding	NULL
assays	NULL
and	NULL
transactivation	NULL
assays	NULL
.	NULL

The	NULL
ligand	NULL
binding	NULL
screen	NULL
involved	NULL
determining	NULL
the	NULL
ability	NULL
of	NULL
a	NULL
given	NULL
retinoid	NULL
to	NULL
competitively	NULL
inhibit	NULL
specific	NULL
binding	NULL
of	NULL
all-trans	NULL
[	NULL
PHJRA	NULL
RA	NULL
RECEPTOR	NULL
ACTIVATION	NULL
IN	NULL
MYELOPOIESIS	NULL
|	NULL
3373	NULL
(	NULL
PHJATRA	NULL
)	NULL
or	NULL
9-cis-	NULL
[	NULL
°HJRA	NULL
to	NULL
baculovirus-expressed	NULL
RARs	NULL
and	NULL
RXRs	NULL
(	NULL
3	NULL
,	NULL
22	NULL
)	NULL
.	NULL

Receptor-specific	NULL
agonists	NULL
were	NULL
identified	NULL
by	NULL
their	NULL
ability	NULL
to	NULL
transactivate	NULL
a	NULL
luciferase	NULL
reporter	NULL
construct	NULL
driven	NULL
by	NULL
either	NULL
an	NULL
RAR-RXR	NULL
(	NULL
TRE	NULL
pal-Luc	NULL
)	NULL
(	NULL
55	NULL
)	NULL
or	NULL
an	NULL
RXR-RXR	NULL
(	NULL
pTK-CRBPII-Luc	NULL
)	NULL
(	NULL
40	NULL
)	NULL
selective	NULL
element	NULL
in	NULL
CV1	NULL
cells	NULL
.	NULL

RAR	NULL
and	NULL
RXR	NULL
selective	NULL
antagonists	NULL
were	NULL
identified	NULL
by	NULL
their	NULL
ability	NULL
to	NULL
inhibit	NULL
ATRA-mediated	NULL
transactivation	NULL
of	NULL
RAR-RXR	NULL
response	NULL
elements	NULL
(	NULL
28	NULL
)	NULL
or	NULL
9-cis-RA-mediated	NULL
activation	NULL
of	NULL
RXR-RXR	NULL
response	NULL
elements	NULL
(	NULL
35	NULL
)	NULL
.	NULL

The	NULL
compounds	NULL
utilized	NULL
in	NULL
the	NULL
present	NULL
study	NULL
were	NULL
the	NULL
RAR	NULL
(	NULL
a	NULL
,	NULL
B	NULL
,	NULL
y	NULL
)	NULL
selective	NULL
panagonist	NULL
(	NULL
AGN	NULL
193695	NULL
)	NULL
,	NULL
the	NULL
RXR	NULL
(	NULL
«	NULL
,	NULL
B	NULL
,	NULL
y	NULL
)	NULL
selective	NULL
panagonist	NULL
(	NULL
AGN	NULL
194204	NULL
)	NULL
(	NULL
58	NULL
)	NULL
,	NULL
the	NULL
RAR	NULL
antagonist	NULL
(	NULL
AGN	NULL
193109	NULL
)	NULL
(	NULL
28	NULL
)	NULL
,	NULL
and	NULL
the	NULL
RXR	NULL
antagonist	NULL
(	NULL
LGN100849	NULL
)	NULL
(	NULL
51	NULL
)	NULL
.	NULL

These	NULL
compounds	NULL
were	NULL
dissolved	NULL
at	NULL
5	NULL
mM	NULL
concentrations	NULL
in	NULL
dimethyl	NULL
sulfoxide	NULL
and	NULL
stored	NULL
at	NULL
-70°C	NULL
in	NULL
small	NULL
aliquots	NULL
until	NULL
use	NULL
.	NULL

Trichostatin	NULL
A	NULL
(	NULL
TSA	NULL
)	NULL
was	NULL
obtained	NULL
from	NULL
Wako	NULL
Chemicals	NULL
USA	NULL
(	NULL
Richmond	NULL
,	NULL
Va.	NULL
)	NULL
.	NULL

Construction	NULL
of	NULL
GALgpg-RAR	NULL
hybrid	NULL
.	NULL

We	NULL
synthesized	NULL
two	NULL
oligonucleotides	NULL
,	NULL
one	NULL
corresponding	NULL
to	NULL
codons	NULL
135	NULL
to	NULL
142	NULL
of	NULL
human	NULL
RARa	NULL
«	NULL
(	NULL
17	NULL
)	NULL
(	NULL
5	NULL
'	NULL
ACGTGAA	NULL
TTCGTGACCCGGAACCGCTGCCAGTAC	NULL
3	NULL
``	NULL
)	NULL
and	NULL
the	NULL
other	NULL
corresponding	NULL
to	NULL
nucleotides	NULL
1601	NULL
to	NULL
1625	NULL
in	NULL
the	NULL
3	NULL
'	NULL
untranslated	NULL
region	NULL
of	NULL
human	NULL
RARa	NULL
«	NULL
(	NULL
5	NULL
'	NULL
ACGTGAATTCTTTTTCCCCAGGGAAGGTCCCCAGTACTG-3	NULL
'	NULL
)	NULL
.	NULL

EcoRI	NULL
sites	NULL
were	NULL
included	NULL
at	NULL
the	NULL
5	NULL
'	NULL
ends	NULL
of	NULL
both	NULL
these	NULL
oligonucleotides	NULL
(	NULL
underlined	NULL
)	NULL
.	NULL

With	NULL
the	NULL
retroviral	NULL
vector	NULL
construct	NULL
LRARaSN	NULL
(	NULL
9	NULL
)	NULL
as	NULL
the	NULL
template	NULL
,	NULL
these	NULL
oligonucleotides	NULL
were	NULL
used	NULL
as	NULL
primers	NULL
to	NULL
PCR	NULL
amplify	NULL
a	NULL
1.1-kb	NULL
RARa	NULL
fragment	NULL
harboring	NULL
codons	NULL
135	NULL
to	NULL
462	NULL
of	NULL
RARa	NULL
.	NULL

This	NULL
fragment	NULL
was	NULL
digested	NULL
with	NULL
EcoRI	NULL
and	NULL
then	NULL
cloned	NULL
in	NULL
the	NULL
in-frame	NULL
sense	NULL
direction	NULL
into	NULL
the	NULL
EcoRI-digested	NULL
GALg,4	NULL
(	NULL
1-147	NULL
)	NULL
expression	NULL
vector	NULL
,	NULL
pSG424	NULL
(	NULL
46	NULL
)	NULL
.	NULL

Plasmids	NULL
.	NULL

Two	NULL
luciferase	NULL
reporter	NULL
plasmids	NULL
based	NULL
on	NULL
the	NULL
plasmid	NULL
designated	NULL
AMTV-Luc	NULL
(	NULL
23	NULL
)	NULL
,	NULL
which	NULL
contains	NULL
the	NULL
MTV	NULL
long	NULL
terminal	NULL
repeat	NULL
in	NULL
which	NULL
the	NULL
glucocorticoid	NULL
response	NULL
elements	NULL
have	NULL
been	NULL
deleted	NULL
and	NULL
replaced	NULL
with	NULL
DR5	NULL
(	NULL
RAR-RXR	NULL
)	NULL
and	NULL
DR1	NULL
(	NULL
RXR-RXR	NULL
)	NULL
response	NULL
elements	NULL
,	NULL
were	NULL
used	NULL
.	NULL

The	NULL
DR5	NULL
Luc	NULL
plasmid	NULL
(	NULL
A5-Luc	NULL
)	NULL
harbors	NULL
the	NULL
sequence	NULL
AGCTTTCAGGTCACCAGGAG	NULL
GTCAGAA	NULL
(	NULL
5-bp	NULL
spacer	NULL
underlined	NULL
)	NULL
.	NULL

The	NULL
DR1	NULL
plasmid	NULL
(	NULL
MTV-DR-1-Luc	NULL
)	NULL
is	NULL
identical	NULL
,	NULL
with	NULL
the	NULL
exception	NULL
of	NULL
the	NULL
response	NULL
element	NULL
,	NULL
which	NULL
is	NULL
one	NULL
copy	NULL
of	NULL
the	NULL
cytosolic	NULL
retinol-binding	NULL
protein	NULL
II	NULL
promoter	NULL
sequence	NULL
(	NULL
40	NULL
)	NULL
,	NULL
AGCTTACAGGT	NULL
CACAGGTCACAGGTCACAGTTCATTT	NULL
(	NULL
single-base	NULL
spacer	NULL
underlined	NULL
)	NULL
.	NULL

The	NULL
growth	NULL
hormone	NULL
expression	NULL
plasmid	NULL
pCMVGH	NULL
,	NULL
which	NULL
serves	NULL
as	NULL
an	NULL
internal	NULL
control	NULL
for	NULL
transfection	NULL
efficiency	NULL
,	NULL
has	NULL
been	NULL
previously	NULL
described	NULL
(	NULL
1	NULL
)	NULL
.	NULL

As	NULL
the	NULL
reporter	NULL
for	NULL
assessing	NULL
activity	NULL
of	NULL
the	NULL
hybrid	NULL
,	NULL
we	NULL
utilized	NULL
the	NULL
p	NULL
(	NULL
UAS	NULL
)	NULL
s-	NULL
GL3	NULL
construct	NULL
,	NULL
which	NULL
harbors	NULL
five	NULL
Gal4	NULL
binding	NULL
sites	NULL
(	NULL
17-mers	NULL
)	NULL
cloned	NULL
into	NULL
the	NULL
polylinker	NULL
of	NULL
the	NULL
pGL3-promoter	NULL
vector	NULL
(	NULL
Promega	NULL
,	NULL
Madison	NULL
,	NULL
Wis.	NULL
)	NULL
.	NULL

RARa	NULL
antibodies	NULL
.	NULL

Anti-human	NULL
RARa	NULL
«	NULL
amino-terminal	NULL
monoclonal	NULL
antibodies	NULL
were	NULL
generated	NULL
against	NULL
peptides	NULL
corresponding	NULL
to	NULL
amino	NULL
acids	NULL
10	NULL
to	NULL
25	NULL
near	NULL
the	NULL
amino	NULL
terminus	NULL
of	NULL
human	NULL
RARa	NULL
«	NULL
.	NULL

This	NULL
peptide	NULL
contained	NULL
a	NULL
glycine-cysteine	NULL
linker	NULL
for	NULL
conjugation	NULL
to	NULL
keyhole	NULL
limpet	NULL
hemocyanin	NULL
(	NULL
KLH-CG-10TP	NULL
GGGHLNGYPVPPYA25	NULL
)	NULL
.	NULL

Mice	NULL
were	NULL
immunized	NULL
with	NULL
the	NULL
conjugated	NULL
peptide	NULL
in	NULL
Freund	NULL
's	NULL
complete	NULL
adjuvant	NULL
and	NULL
boosted	NULL
with	NULL
peptide	NULL
in	NULL
Freund	NULL
's	NULL
incomplete	NULL
adjuvant	NULL
.	NULL

Fusions	NULL
were	NULL
performed	NULL
,	NULL
and	NULL
resulting	NULL
hybridomas	NULL
were	NULL
cloned	NULL
and	NULL
screened	NULL
for	NULL
activity	NULL
by	NULL
enzyme-linked	NULL
immunosorbent	NULL
assay	NULL
against	NULL
free	NULL
peptide	NULL
and	NULL
by	NULL
Western	NULL
blotting	NULL
with	NULL
recombinantly	NULL
expressed	NULL
human	NULL
RARa	NULL
.	NULL

The	NULL
appropriate	NULL
clonal	NULL
producers	NULL
were	NULL
expanded	NULL
,	NULL
and	NULL
antibodies	NULL
were	NULL
purified	NULL
from	NULL
cell	NULL
culture	NULL
supernatant	NULL
by	NULL
protein	NULL
G-Sepharose	NULL
.	NULL

A	NULL
rabbit	NULL
polyclonal	NULL
immuno-globulin	NULL
G	NULL
generated	NULL
against	NULL
amino	NULL
acids	NULL
443	NULL
to	NULL
462	NULL
at	NULL
the	NULL
COOH	NULL
terminus	NULL
of	NULL
human	NULL
RARe	NULL
and	NULL
supplied	NULL
as	NULL
TransCruz	NULL
Gel	NULL
Supershift	NULL
reagent	NULL
was	NULL
purchased	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
(	NULL
Santa	NULL
Cruz	NULL
,	NULL
Calif.	NULL
)	NULL
.	NULL

Assay	NULL
of	NULL
MPRO	NULL
granulocytic	NULL
differentiation	NULL
.	NULL

MPRO	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
their	NULL
standard	NULL
growth	NULL
medium	NULL
harboring	NULL
GM-CSF	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
different	NULL
concentrations	NULL
of	NULL
retinoids	NULL
.	NULL

After	NULL
5	NULL
days	NULL
of	NULL
culture	NULL
,	NULL
differential	NULL
counts	NULL
were	NULL
performed	NULL
on	NULL
Wright-Giemsa-stained	NULL
cytospin	NULL
preparations	NULL
of	NULL
0.2-ml	NULL
samples	NULL
of	NULL
the	NULL
cell	NULL
suspension	NULL
(	NULL
approximately	NULL
10°	NULL
cells	NULL
)	NULL
.	NULL

By	NULL
morphology	NULL
,	NULL
mature	NULL
granulocytes	NULL
harboring	NULL
lobulated	NULL
or	NULL
doughnut-shaped	NULL
nuclei	NULL
and	NULL
pale	NULL
cytoplasm	NULL
are	NULL
readily	NULL
distinguished	NULL
from	NULL
immature	NULL
MPRO	NULL
promyelocytes	NULL
(	NULL
53	NULL
)	NULL
.	NULL

Assay	NULL
of	NULL
EML	NULL
CFU-GM	NULL
generation	NULL
.	NULL

EML	NULL
cells	NULL
were	NULL
cultured	NULL
at	NULL
10*/ml	NULL
in	NULL
growth	NULL
medium	NULL
supplemented	NULL
with	NULL
SCF	NULL
or	NULL
SCF	NULL
plus	NULL
IL-3	NULL
plus	NULL
different	NULL
concentrations	NULL
of	NULL
retinoid	NULL
agonists	NULL
and	NULL
antagonists	NULL
.	NULL

All	NULL
experiments	NULL
involving	NULL
CFU-GM	NULL
generation	NULL
were	NULL
performed	NULL
on	NULL
EML	NULL
cells	NULL
between	NULL
passage	NULL
10	NULL
and	NULL
passage	NULL
20	NULL
.	NULL

The	NULL
sources	NULL
of	NULL
IL-3	NULL
included	NULL
either	NULL
5	NULL
%	NULL
WEHI	NULL
3B-conditioned	NULL
medium	NULL
or	NULL
murine	NULL
recombinant	NULL
IL-3	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
(	NULL
Peprotech	NULL
)	NULL
with	NULL
equivalent	NULL
results	NULL
obtained	NULL
with	NULL
cither	NULL
source	NULL
of	NULL
IL-3	NULL
.	NULL

Following	NULL
1	NULL
to	NULL
3	NULL
days	NULL
of	NULL
this	NULL
liquid	NULL
suspension	NULL
culture	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
harvested	NULL
and	NULL
washed	NULL
and	NULL
5	NULL
x	NULL
10°	NULL
cells	NULL
were	NULL
resuspended	NULL
in	NULL
0.7	NULL
ml	NULL
of	NULL
IMDM	NULL
supplemented	NULL
with	NULL
0.75	NULL
ml	NULL
of	NULL
2.2	NULL
%	NULL
methylcellulose	NULL
(	NULL
Methocult	NULL
;	NULL
Stem	NULL
Cell	NULL
Technologies	NULL
,	NULL
Vancouver	NULL
,	NULL
British	NULL
Columbia	NULL
,	NULL
Canada	NULL
)	NULL
,	NULL
5	NULL
%	NULL
horse	NULL
serum	NULL
,	NULL
and	NULL
10	NULL
ng	NULL
of	NULL
murine	NULL
recombinant	NULL
GM-CSF	NULL
(	NULL
Peprotech	NULL
)	NULL
per	NULL
ml	NULL
.	NULL

Cultures	NULL
were	NULL
incubated	NULL
in	NULL
12-well	NULL
plates	NULL
(	NULL
0.7	NULL
ml/plate	NULL
)	NULL
,	NULL
and	NULL
GM-CSF-dependent	NULL
colonies	NULL
(	NULL
>	NULL
20	NULL
cells	NULL
)	NULL
were	NULL
counted	NULL
following	NULL
5	NULL
to	NULL
7	NULL
days	NULL
of	NULL
incubation	NULL
in	NULL
a	NULL
humidified	NULL
incubator	NULL
.	NULL

Derivation	NULL
of	NULL
MPRO-like	NULL
cells	NULL
from	NULL
EML	NULL
cells	NULL
.	NULL

EML	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
their	NULL
standard	NULL
SCF-containing	NULL
growth	NULL
medium	NULL
for	NULL
2	NULL
days	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
IL-3	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
and	NULL
ATRA	NULL
(	NULL
10	NULL
M	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
washed	NULL
,	NULL
resuspended	NULL
in	NULL
medium	NULL
containing	NULL
GM-CSF	NULL
alone	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
,	NULL
and	NULL
plated	NULL
in	NULL
96-well	NULL
microtiter	NULL
dishes	NULL
.	NULL

After	NULL
3	NULL
to	NULL
4	NULL
days	NULL
of	NULL
culture	NULL
,	NULL
GM-CSF-dependent	NULL
cell	NULL
growth	NULL
was	NULL
readily	NULL
detected	NULL
,	NULL
and	NULL
these	NULL
cells	NULL
were	NULL
subsequently	NULL
expanded	NULL
to	NULL
generate	NULL
the	NULL
MPRO-like	NULL
cell	NULL
lines	NULL
.	NULL

Transactivation	NULL
assays	NULL
.	NULL

Both	NULL
EML	NULL
cells	NULL
and	NULL
MPRO	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
by	NULL
electroporation	NULL
.	NULL

For	NULL
EML	NULL
cells	NULL
,	NULL
10	NULL
``	NULL
cells	NULL
were	NULL
harvested	NULL
,	NULL
washed	NULL
3374	NULL
JOHNSON	NULL
ET	NULL
AL	NULL
.	NULL

twice	NULL
with	NULL
phosphate-buffered	NULL
saline	NULL
,	NULL
and	NULL
resuspended	NULL
in	NULL
0.8	NULL
ml	NULL
of	NULL
IMDM	NULL
supplemented	NULL
with	NULL
2	NULL
to	NULL
5	NULL
%	NULL
horse	NULL
serum	NULL
,	NULL
SCF	NULL
,	NULL
and	NULL
10	NULL
mM	NULL
HEPES	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
.	NULL

Forty	NULL
micrograms	NULL
of	NULL
the	NULL
DR5	NULL
or	NULL
DR1	NULL
luciferase	NULL
reporter	NULL
construct	NULL
together	NULL
with	NULL
20	NULL
ug	NULL
of	NULL
pCMVGH	NULL
plasmid	NULL
(	NULL
1	NULL
)	NULL
was	NULL
added	NULL
,	NULL
and	NULL
the	NULL
solution	NULL
was	NULL
placed	NULL
in	NULL
0.4-cm	NULL
electroporation	NULL
cuvettes	NULL
,	NULL
kept	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
10	NULL
to	NULL
15	NULL
min	NULL
,	NULL
and	NULL
then	NULL
electroporated	NULL
at	NULL
950	NULL
F	NULL
,	NULL
270	NULL
V	NULL
,	NULL
with	NULL
a	NULL
Bio-Rad	NULL
(	NULL
Hercules	NULL
,	NULL
Calif.	NULL
)	NULL
Gene	NULL
Pulser	NULL
II	NULL
electroporator	NULL
.	NULL

The	NULL
identical	NULL
transfection	NULL
procedure	NULL
was	NULL
utilized	NULL
for	NULL
MPRO	NULL
cells	NULL
except	NULL
that	NULL
the	NULL
electroporation	NULL
medium	NULL
was	NULL
DMEM	NULL
supplemented	NULL
with	NULL
20	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
,	NULL
10	NULL
mM	NULL
HEPES	NULL
,	NULL
and	NULL
GM-CSF	NULL
,	NULL
and	NULL
electroporation	NULL
parameters	NULL
were	NULL
700	NULL
wF	NULL
and	NULL
450	NULL
V.	NULL
Following	NULL
electroporation	NULL
,	NULL
the	NULL
cuvettes	NULL
were	NULL
immediately	NULL
placed	NULL
at	NULL
4°C	NULL
for	NULL
10	NULL
min	NULL
,	NULL
and	NULL
the	NULL
cells	NULL
were	NULL
then	NULL
cultured	NULL
overnight	NULL
at	NULL
approximately	NULL
105/ml	NULL
in	NULL
10	NULL
ml	NULL
of	NULL
their	NULL
respective	NULL
growth	NULL
media	NULL
supplemented	NULL
with	NULL
different	NULL
concentrations	NULL
of	NULL
RAR	NULL
and	NULL
RXR	NULL
agonists	NULL
and	NULL
antagonists	NULL
.	NULL

Reporter	NULL
gene	NULL
assays	NULL
.	NULL

The	NULL
electroporated	NULL
cells	NULL
were	NULL
cultured	NULL
for	NULL
18	NULL
to	NULL
24	NULL
h	NULL
under	NULL
standard	NULL
conditions	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
pelleted	NULL
,	NULL
and	NULL
1	NULL
ml	NULL
of	NULL
supernatant	NULL
medium	NULL
was	NULL
harvested	NULL
and	NULL
subjected	NULL
to	NULL
the	NULL
human	NULL
growth	NULL
hormone	NULL
assay	NULL
with	NULL
the	NULL
Allegro	NULL
growth	NULL
hormone	NULL
assay	NULL
kit	NULL
(	NULL
Nichols	NULL
Institute	NULL
,	NULL
Capistrano	NULL
,	NULL
Calif.	NULL
)	NULL
.	NULL

The	NULL
cell	NULL
pellet	NULL
was	NULL
lysed	NULL
,	NULL
and	NULL
following	NULL
centrifugation	NULL
at	NULL
13,200	NULL
rpm	NULL
for	NULL
20	NULL
s	NULL
,	NULL
the	NULL
supernatant	NULL
was	NULL
harvested	NULL
and	NULL
assayed	NULL
for	NULL
luciferase	NULL
activity	NULL
with	NULL
the	NULL
Promega	NULL
luciferase	NULL
assay	NULL
kit	NULL
.	NULL

The	NULL
cell	NULL
lysate	NULL
supernatant	NULL
was	NULL
also	NULL
assayed	NULL
for	NULL
protein	NULL
content	NULL
with	NULL
the	NULL
Pierce	NULL
Micro	NULL
bicinchoninic	NULL
acid	NULL
kit	NULL
(	NULL
Rockford	NULL
,	NULL
III	NULL
.	NULL
)	NULL

according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
directions	NULL
.	NULL

Final	NULL
luciferase	NULL
activity	NULL
was	NULL
determined	NULL
following	NULL
correction	NULL
for	NULL
both	NULL
transfection	NULL
efficiency	NULL
,	NULL
with	NULL
the	NULL
growth	NULL
hormone	NULL
activity	NULL
as	NULL
an	NULL
internal	NULL
control	NULL
,	NULL
and	NULL
cell	NULL
number	NULL
,	NULL
with	NULL
protein	NULL
content	NULL
as	NULL
the	NULL
internal	NULL
control	NULL
.	NULL

All	NULL
experiments	NULL
were	NULL
done	NULL
a	NULL
minimum	NULL
of	NULL
three	NULL
times	NULL
.	NULL

Nuclear	NULL
extracts	NULL
.	NULL

Cultured	NULL
cells	NULL
(	NULL
5	NULL
X	NULL
10°	NULL
to	NULL
1	NULL
X	NULL
10°	NULL
)	NULL
were	NULL
washed	NULL
twice	NULL
in	NULL
ice-cold	NULL
phosphate-buffered	NULL
saline	NULL
plus	NULL
2	NULL
mM	NULL
EDTA	NULL
,	NULL
pH	NULL
7.4	NULL
.	NULL

The	NULL
remainder	NULL
of	NULL
the	NULL
extraction	NULL
was	NULL
performed	NULL
on	NULL
ice	NULL
.	NULL

The	NULL
cell	NULL
pellets	NULL
were	NULL
resuspended	NULL
in	NULL
5	NULL
ml	NULL
of	NULL
hypotonic	NULL
buffer	NULL
(	NULL
10	NULL
mM	NULL
HEPES	NULL
[	NULL
pH	NULL
7.9	NULL
]	NULL
,	NULL
750	NULL
M	NULL
spermidine	NULL
,	NULL
150	NULL
wM	NULL
spermine	NULL
,	NULL
0.1	NULL
mM	NULL
EDTA	NULL
[	NULL
pH	NULL
8.0	NULL
]	NULL
,	NULL
0.1	NULL
mM	NULL
EGTA	NULL
,	NULL
1	NULL
mM	NULL
dithiothreitol	NULL
[	NULL
DTT	NULL
]	NULL
[	NULL
in	NULL
NaAc	NULL
)	NULL
,	NULL
10	NULL
mM	NULL
KCI	NULL
)	NULL
supplemented	NULL
with	NULL
specific	NULL
protease	NULL
inhibitors	NULL
.	NULL

Since	NULL
both	NULL
EML	NULL
and	NULL
MPRO	NULL
cells	NULL
harbor	NULL
significant	NULL
protease	NULL
activity	NULL
,	NULL
these	NULL
protease	NULL
inhibitors	NULL
were	NULL
critical	NULL
and	NULL
included	NULL
0.5	NULL
mg	NULL
of	NULL
AEBSF	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
)	NULL
per	NULL
ml	NULL
,	NULL
2	NULL
wg	NULL
of	NULL
aprotinin	NULL
(	NULL
Calbiochem	NULL
)	NULL
per	NULL
ml	NULL
,	NULL
50	NULL
pg	NULL
of	NULL
antipain	NULL
(	NULL
Calbiochem	NULL
)	NULL
per	NULL
ml	NULL
,	NULL
40	NULL
pg	NULL
of	NULL
bestatin	NULL
(	NULL
Calbiochem	NULL
)	NULL
per	NULL
ml	NULL
,	NULL
10	NULL
ug	NULL
of	NULL
E-64	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
)	NULL
per	NULL
ml	NULL
,	NULL
0.5	NULL
pg	NULL
of	NULL
leupeptin	NULL
(	NULL
Sigma	NULL
)	NULL
per	NULL
ml	NULL
,	NULL
and	NULL
0.7	NULL
pg	NULL
of	NULL
pepstatin	NULL
A	NULL
(	NULL
Sigma	NULL
)	NULL
per	NULL
ml	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
pelleted	NULL
again	NULL
,	NULL
resuspended	NULL
in	NULL
10	NULL
ml	NULL
of	NULL
hypotonic	NULL
buffer	NULL
with	NULL
the	NULL
above-listed	NULL
protease	NULL
inhibitors	NULL
,	NULL
allowed	NULL
to	NULL
swell	NULL
on	NULL
ice	NULL
for	NULL
10	NULL
to	NULL
15	NULL
min	NULL
,	NULL
and	NULL
then	NULL
Dounce	NULL
homogenized	NULL
with	NULL
20	NULL
to	NULL
30	NULL
strokes	NULL
of	NULL
the	NULL
tight	NULL
(	NULL
A	NULL
)	NULL
pestle	NULL
.	NULL

To	NULL
the	NULL
lysed	NULL
cells	NULL
was	NULL
added	NULL
1	NULL
ml	NULL
of	NULL
sucrose	NULL
restore	NULL
buffer	NULL
(	NULL
50	NULL
mM	NULL
HEPES	NULL
[	NULL
pH	NULL
7.9	NULL
]	NULL
,	NULL
750	NULL
M	NULL
spermidine	NULL
,	NULL
150	NULL
wM	NULL
spermine	NULL
,	NULL
0.2	NULL
mM	NULL
EDTA	NULL
[	NULL
pH	NULL
8.0	NULL
]	NULL
,	NULL
1	NULL
mM	NULL
DTT	NULL
[	NULL
in	NULL
NaAc	NULL
]	NULL
,	NULL
10	NULL
mM	NULL
KCI	NULL
,	NULL
75	NULL
%	NULL
RNase-free	NULL
sucrose	NULL
)	NULL
,	NULL
which	NULL
was	NULL
mixed	NULL
with	NULL
two	NULL
strokes	NULL
of	NULL
the	NULL
Dounce	NULL
homogenizer	NULL
.	NULL

The	NULL
nuclei	NULL
were	NULL
pelleted	NULL
at	NULL
10,000	NULL
rpm	NULL
in	NULL
chilled	NULL
Corex	NULL
tubes	NULL
at	NULL
4°C	NULL
in	NULL
a	NULL
Sorvall	NULL
rotor	NULL
.	NULL

The	NULL
nuclear	NULL
pellet	NULL
was	NULL
washed	NULL
once	NULL
with	NULL
5	NULL
ml	NULL
of	NULL
ice-cold	NULL
hypotonic	NULL
buffer	NULL
plus	NULL
the	NULL
above-described	NULL
protease	NULL
inhibitors	NULL
plus	NULL
250	NULL
pl	NULL
of	NULL
sucrose	NULL
restore	NULL
buffer	NULL
.	NULL

The	NULL
nuclei	NULL
were	NULL
spun	NULL
again	NULL
for	NULL
30	NULL
s	NULL
at	NULL
10,000	NULL
rpm	NULL
at	NULL
4°C	NULL
,	NULL
washed	NULL
in	NULL
10	NULL
ml	NULL
of	NULL
ice-cold	NULL
sucrose	NULL
buffer	NULL
(	NULL
0.32	NULL
M	NULL
sucrose	NULL
,	NULL
1.5	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
0.1	NULL
mM	NULL
EDTA	NULL
[	NULL
pH	NULL
8.0	NULL
]	NULL
,	NULL
10	NULL
mM	NULL
Tris	NULL
[	NULL
pH	NULL
8.0	NULL
]	NULL
,	NULL
1	NULL
mM	NULL
DTT	NULL
plus	NULL
protease	NULL
inhibitors	NULL
)	NULL
,	NULL
pelleted	NULL
for	NULL
20	NULL
s	NULL
,	NULL
and	NULL
then	NULL
resuspended	NULL
in	NULL
400	NULL
pl	NULL
of	NULL
low-salt	NULL
nuclear	NULL
resuspension	NULL
buffer	NULL
(	NULL
20	NULL
mM	NULL
HEPES	NULL
[	NULL
pH	NULL
7.9	NULL
]	NULL
,	NULL
25	NULL
%	NULL
glycerol	NULL
,	NULL
1.5	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
20	NULL
mM	NULL
KCI	NULL
,	NULL
0.2	NULL
mM	NULL
EDTA	NULL
,	NULL
0.5	NULL
mM	NULL
DTT	NULL
)	NULL
plus	NULL
protease	NULL
inhibitors	NULL
.	NULL

Three	NULL
aliquots	NULL
of	NULL
high-salt	NULL
nuclear	NULL
resuspension	NULL
buffer	NULL
(	NULL
same	NULL
as	NULL
low-salt	NULL
buffer	NULL
except	NULL
with	NULL
800	NULL
mM	NULL
KCI	NULL
)	NULL
were	NULL
slowly	NULL
added	NULL
and	NULL
gently	NULL
mixed	NULL
with	NULL
the	NULL
pipette	NULL
tip	NULL
,	NULL
and	NULL
the	NULL
pellets	NULL
were	NULL
kept	NULL
on	NULL
ice	NULL
for	NULL
20	NULL
min	NULL
with	NULL
gentle	NULL
mixing	NULL
every	NULL
5	NULL
min	NULL
.	NULL

Two	NULL
milliliters	NULL
of	NULL
diluent	NULL
buffer	NULL
(	NULL
20	NULL
mM	NULL
HEPES	NULL
[	NULL
pH	NULL
7.9	NULL
]	NULL
,	NULL
25	NULL
%	NULL
glycerol	NULL
,	NULL
0.1	NULL
mM	NULL
EDTA	NULL
,	NULL
0.5	NULL
mM	NULL
DTT	NULL
)	NULL
plus	NULL
protease	NULL
inhibitors	NULL
was	NULL
added	NULL
,	NULL
and	NULL
the	NULL
nuclei	NULL
were	NULL
spun	NULL
at	NULL
10,000	NULL
rpm	NULL
in	NULL
a	NULL
4°C	NULL
Sorvall	NULL
rotor	NULL
for	NULL
20	NULL
min	NULL
.	NULL

The	NULL
nuclear	NULL
extract	NULL
(	NULL
supernatant	NULL
)	NULL
was	NULL
removed	NULL
and	NULL
stored	NULL
in	NULL
aliquots	NULL
frozen	NULL
at	NULL
-80°C	NULL
until	NULL
use	NULL
.	NULL

Electromobility	NULL
shift	NULL
assay	NULL
(	NULL
EMSA	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
(	NULL
10	NULL
g	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
4	NULL
ug	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
)	NULL
in	NULL
10	NULL
mM	NULL
Tris	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
-50	NULL
mM	NULL
NaCl-1	NULL
mM	NULL
DTT-1	NULL
mM	NULL
EDTA	NULL
(	NULL
pH	NULL
8.0	NULL
)	NULL
-5	NULL
%	NULL
glycerol	NULL
followed	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
4,000	NULL
cpm	NULL
of	NULL
*°P-labelled	NULL
probe	NULL
.	NULL

The	NULL
protease	NULL
inhibitors	NULL
described	NULL
above	NULL
for	NULL
the	NULL
nuclear	NULL
extract	NULL
procedure	NULL
were	NULL
also	NULL
included	NULL
.	NULL

For	NULL
the	NULL
gel	NULL
super-shifts	NULL
,	NULL
the	NULL
appropriate	NULL
anti-RARa	NULL
«	NULL
antibody	NULL
was	NULL
added	NULL
to	NULL
the	NULL
nuclear	NULL
extracts	NULL
alone	NULL
,	NULL
and	NULL
the	NULL
mixture	NULL
was	NULL
incubated	NULL
at	NULL
25°C	NULL
for	NULL
10	NULL
to	NULL
15	NULL
min	NULL
prior	NULL
to	NULL
the	NULL
addition	NULL
of	NULL
the	NULL
labelled	NULL
probe	NULL
.	NULL

The	NULL
reaction	NULL
mixture	NULL
was	NULL
incubated	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
an	NULL
additional	NULL
10	NULL
to	NULL
15	NULL
min	NULL
and	NULL
then	NULL
loaded	NULL
onto	NULL
a	NULL
5	NULL
%	NULL
poly-acrylamide	NULL
gel	NULL
prerun	NULL
at	NULL
100	NULL
V	NULL
for	NULL
30	NULL
min	NULL
in	NULL
250	NULL
mM	NULL
Tris	NULL
(	NULL
pH	NULL
8.3	NULL
)	NULL
-1.9	NULL
M	NULL
glycine-10	NULL
mM	NULL
EDTA	NULL
.	NULL

The	NULL
gel	NULL
was	NULL
run	NULL
at	NULL
100	NULL
V	NULL
for	NULL
5	NULL
to	NULL
7	NULL
h	NULL
at	NULL
4°C	NULL
with	NULL
recirculation	NULL
.	NULL

The	NULL
gel	NULL
was	NULL
dried	NULL
and	NULL
autoradiographed	NULL
overnight	NULL
.	NULL

The	NULL
probes	NULL
included	NULL
a	NULL
138-bp	NULL
fragment	NULL
from	NULL
the	NULL
actin	NULL
promoter	NULL
for	NULL
use	NULL
as	NULL
a	NULL
control	NULL
for	NULL
the	NULL
nuclear	NULL
extract	NULL
integrity	NULL
.	NULL

The	NULL
BRARE	NULL
probe	NULL
corresponded	NULL
to	NULL
the	NULL
DR5	NULL
RA	NULL
response	NULL
element	NULL
in	NULL
the	NULL
RARB	NULL
promoter	NULL
,	NULL
5°	NULL
GAGGGTAGGGTTCACCGAA	NULL
AGTTCACTCG	NULL
3	NULL
'	NULL
(	NULL
the	NULL
5-bp	NULL
spacer	NULL
is	NULL
underlined	NULL
)	NULL
.	NULL

This	NULL
oligonucleotide	NULL
was	NULL
annealed	NULL
with	NULL
its	NULL
complementary	NULL
oligonucleotide	NULL
by	NULL
heating	NULL
to	NULL
70°C	NULL
.	NULL

Probes	NULL
were	NULL
end	NULL
labelled	NULL
with	NULL
Klenow	NULL
fragment	NULL
.	NULL

Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

RESULTS	NULL
MPRO	NULL
and	NULL
EML	NULL
cells	NULL
as	NULL
models	NULL
of	NULL
myeloid	NULL
differentiation	NULL
.	NULL

The	NULL
hematopoietic	NULL
growth	NULL
factor-dependent	NULL
cell	NULL
lines	NULL
utilized	NULL
in	NULL
these	NULL
studies	NULL
were	NULL
previously	NULL
derived	NULL
by	NULL
transducing	NULL
a	NULL
dominant-negative	NULL
human	NULL
RARa	NULL
construct	NULL
that	NULL
harbors	NULL
a	NULL
59-ami-no-acid	NULL
truncation	NULL
at	NULL
the	NULL
COOH	NULL
terminus	NULL
(	NULL
RARa403	NULL
)	NULL
into	NULL
normal	NULL
mouse	NULL
bone	NULL
marrow	NULL
(	NULL
53	NULL
,	NULL
54	NULL
)	NULL
.	NULL

The	NULL
GM-CSF-dependent	NULL
MPRO	NULL
cells	NULL
express	NULL
relatively	NULL
high	NULL
levels	NULL
of	NULL
the	NULL
RARa403	NULL
mRNA	NULL
and	NULL
are	NULL
predominantly	NULL
promyelocytes	NULL
,	NULL
which	NULL
can	NULL
be	NULL
induced	NULL
to	NULL
terminally	NULL
differentiate	NULL
to	NULL
granulocytes	NULL
by	NULL
relatively	NULL
high	NULL
(	NULL
1	NULL
to	NULL
10	NULL
wM	NULL
)	NULL
concentrations	NULL
of	NULL
ATRA	NULL
(	NULL
53	NULL
)	NULL
.	NULL

The	NULL
SCF-dependent	NULL
EML	NULL
cells	NULL
are	NULL
multipotent	NULL
(	NULL
having	NULL
erythroid	NULL
,	NULL
lymphoid	NULL
,	NULL
and	NULL
myeloid	NULL
potential	NULL
)	NULL
,	NULL
but	NULL
with	NULL
the	NULL
addition	NULL
of	NULL
IL-3	NULL
and	NULL
ATRA	NULL
(	NULL
again	NULL
1	NULL
to	NULL
10	NULL
uM	NULL
)	NULL
,	NULL
the	NULL
EML	NULL
cells	NULL
commit	NULL
to	NULL
GM-CSF-dependent	NULL
granulocyte/monocyte	NULL
precursors	NULL
as	NULL
assessed	NULL
by	NULL
standard	NULL
CFU-GM	NULL
assays	NULL
in	NULL
semisolid	NULL
medium	NULL
(	NULL
54	NULL
)	NULL
.	NULL

EMSA	NULL
complexes	NULL
harboring	NULL
the	NULL
dominant-negative	NULL
RARa403	NULL
predominate	NULL
in	NULL
EML	NULL
and	NULL
MPRO	NULL
cells	NULL
.	NULL

There	NULL
is	NULL
relatively	NULL
high	NULL
expression	NULL
of	NULL
the	NULL
RARa403	NULL
mRNA	NULL
in	NULL
both	NULL
the	NULL
MPRO	NULL
and	NULL
EML	NULL
cells	NULL
compared	NULL
with	NULL
that	NULL
of	NULL
normal	NULL
RARa	NULL
mRNA	NULL
(	NULL
53	NULL
,	NULL
54	NULL
)	NULL
.	NULL

Since	NULL
this	NULL
COOH-terminally	NULL
truncated	NULL
RARa403	NULL
retains	NULL
the	NULL
capacity	NULL
to	NULL
heterodimerize	NULL
with	NULL
RXRs	NULL
and	NULL
bind	NULL
to	NULL
RXR-RAR	NULL
DNA	NULL
response	NULL
elements	NULL
(	NULL
11	NULL
,	NULL
15	NULL
)	NULL
,	NULL
it	NULL
is	NULL
likely	NULL
that	NULL
RXR-RARe403	NULL
heterodimers	NULL
are	NULL
predominant	NULL
in	NULL
both	NULL
the	NULL
EML	NULL
and	NULL
the	NULL
MPRO	NULL
cells	NULL
.	NULL

To	NULL
confirm	NULL
this	NULL
,	NULL
we	NULL
utilized	NULL
the	NULL
EMSA	NULL
to	NULL
compare	NULL
complexes	NULL
generated	NULL
by	NULL
nuclear	NULL
extracts	NULL
from	NULL
both	NULL
MPRO	NULL
and	NULL
EML	NULL
cells	NULL
on	NULL
an	NULL
oligonucleotide	NULL
harboring	NULL
an	NULL
RXR-RAR	NULL
consensus	NULL
binding	NULL
sequence	NULL
(	NULL
DR5	NULL
)	NULL
(	NULL
56	NULL
)	NULL
.	NULL

As	NULL
a	NULL
control	NULL
,	NULL
we	NULL
used	NULL
nuclear	NULL
extracts	NULL
from	NULL
Friend	NULL
murine	NULL
erythroleukemia	NULL
cells	NULL
(	NULL
MEL	NULL
)	NULL
stably	NULL
transduced	NULL
with	NULL
full-length	NULL
human	NULL
RARa	NULL
(	NULL
9	NULL
)	NULL
.	NULL

The	NULL
nuclear	NULL
extracts	NULL
from	NULL
these	NULL
different	NULL
cell	NULL
lines	NULL
generated	NULL
two	NULL
higher-mobility	NULL
complexes	NULL
(	NULL
labelled	NULL
B	NULL
and	NULL
C	NULL
on	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

Complex	NULL
C	NULL
in	NULL
both	NULL
EML	NULL
and	NULL
MPRO	NULL
cells	NULL
consistently	NULL
migrated	NULL
at	NULL
a	NULL
slightly	NULL
higher	NULL
mobility	NULL
than	NULL
the	NULL
comparable	NULL
complex	NULL
from	NULL
MEL	NULL
extracts	NULL
harboring	NULL
the	NULL
full-length	NULL
RARa	NULL
,	NULL
suggesting	NULL
that	NULL
this	NULL
complex	NULL
may	NULL
be	NULL
generated	NULL
by	NULL
the	NULL
truncated	NULL
RARa403	NULL
.	NULL

To	NULL
confirm	NULL
this	NULL
,	NULL
we	NULL
performed	NULL
gel	NULL
supershift	NULL
assays	NULL
with	NULL
antibodies	NULL
specific	NULL
for	NULL
the	NULL
amino-terminal	NULL
and	NULL
COOH-terminal	NULL
ends	NULL
of	NULL
RARa	NULL
«	NULL
.	NULL

The	NULL
truncated	NULL
RARa403	NULL
can	NULL
not	NULL
react	NULL
with	NULL
the	NULL
COOH-terminal	NULL
antibody	NULL
but	NULL
will	NULL
react	NULL
with	NULL
the	NULL
amino-terminal	NULL
antibody	NULL
,	NULL
while	NULL
the	NULL
full-length	NULL
RARa	NULL
reacts	NULL
with	NULL
both	NULL
antibodies	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
.	NULL

If	NULL
the	NULL
truncated	NULL
RARa403	NULL
predominates	NULL
in	NULL
the	NULL
DRS	NULL
complexes	NULL
generated	NULL
from	NULL
MPRO	NULL
and	NULL
EML	NULL
extracts	NULL
,	NULL
then	NULL
we	NULL
would	NULL
expect	NULL
these	NULL
complexes	NULL
to	NULL
be	NULL
inhibited	NULL
by	NULL
the	NULL
amino-terminal	NULL
RARa	NULL
antibody	NULL
but	NULL
not	NULL
the	NULL
COOH-terminal	NULL
antibody	NULL
.	NULL

Indeed	NULL
,	NULL
the	NULL
generation	NULL
of	NULL
both	NULL
complex	NULL
B	NULL
and	NULL
complex	NULL
C	NULL
is	NULL
inhibited	NULL
in	NULL
the	NULL
EML	NULL
and	NULL
MPRO	NULL
nuclear	NULL
extracts	NULL
by	NULL
the	NULL
amino-terminal	NULL
RARa	NULL
antibody	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
,	NULL
lanes	NULL
7	NULL
and	NULL
10	NULL
)	NULL
,	NULL
while	NULL
these	NULL
same	NULL
complexes	NULL
are	NULL
not	NULL
inhibited	NULL
by	NULL
the	NULL
COOH-terminal	NULL
RARa	NULL
antibody	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
,	NULL
lanes	NULL
6	NULL
and	NULL
9	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
each	NULL
of	NULL
these	NULL
antibodies	NULL
inhibits	NULL
formation	NULL
of	NULL
the	NULL
higher-mobility	NULL
complex	NULL
C	NULL
in	NULL
the	NULL
control	NULL
MEL	NULL
extracts	NULL
harboring	NULL
the	NULL
full-length	NULL
RARa	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
,	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
.	NULL

These	NULL
studies	NULL
indicate	NULL
that	NULL
in	NULL
EML	NULL
and	NULL
MPRO	NULL
cells	NULL
the	NULL
RARa403	NULL
predominates	NULL
in	NULL
complexes	NULL
interacting	NULL
with	NULL
RXR-RAR	NULL
(	NULL
DR5	NULL
)	NULL
response	NULL
elements	NULL
.	NULL

RXR-	NULL
and	NULL
RAR-specific	NULL
agonists	NULL
and	NULL
antagonists	NULL
.	NULL

As	NULL
noted	NULL
above	NULL
,	NULL
relatively	NULL
high	NULL
concentrations	NULL
of	NULL
ATRA	NULL
appear	NULL
to	NULL
overcome	NULL
the	NULL
effect	NULL
of	NULL
the	NULL
dominant-negative	NULL
RARa403	NULL
construct	NULL
in	NULL
both	NULL
MPRO	NULL
promyelocytes	NULL
(	NULL
where	NULL
ATRA	NULL
induces	NULL
terminal	NULL
granulocyte	NULL
differentiation	NULL
)	NULL
(	NULL
53	NULL
)	NULL
and	NULL
the	NULL
multipotent	NULL
EML	NULL
cells	NULL
(	NULL
where	NULL
ATRA	NULL
potentiates	NULL
IL-3-induced	NULL
commitment	NULL
to	NULL
the	NULL
granulocyte/monocyte	NULL
lineage	NULL
)	NULL
(	NULL
54	NULL
)	NULL
.	NULL

Our	NULL
experimental	NULL
plan	NULL
involved	NULL
utilizing	NULL
synthetic	NULL
retinoids	NULL
displaying	NULL
specific	NULL
RXR-RAR	NULL
agonist	NULL
and	NULL
antagonist	NULL
activity	NULL
to	NULL
determine	NULL
how	NULL
Vor	NULL
.	NULL

19	NULL
,	NULL
1999	NULL
A	NULL
Anti-RARa	NULL
(	NULL
N-Terminal	NULL
)	NULL
(	NULL
10-25	NULL
)	NULL
8	NULL
Anti-RARa	NULL
(	NULL
C-Terminal	NULL
)	NULL
(	NULL
443-462	NULL
)	NULL
DNA	NULL
``	NULL
R	NULL
A	NULL
P	NULL
:	NULL
``	NULL
M	NULL
Binding	NULL
Ligand	NULL
Binding	NULL
,	NULL
Dimerization	NULL
,	NULL
Activation	NULL
8	NULL
153	NULL
198	NULL
403	NULL
462	NULL
RARa	NULL
Anti-RARa	NULL
(	NULL
N-Terminal	NULL
)	NULL
(	NULL
10-25	NULL
)	NULL
8	NULL
551m	NULL
g	NULL
-	NULL
Ligand	NULL
Binding	NULL
,	NULL
Dimerization	NULL
,	NULL
Act	NULL
8	NULL
153	NULL
198	NULL
403	NULL
RARo403	NULL
B	NULL
‘	NULL
#	NULL
2	NULL
102	NULL
B	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
140	NULL
MEL-Cell	NULL
E	NULL
:	NULL
xtract	NULL
|	NULL
C	NULL
hRAR	NULL
MPRO	NULL
EML	NULL
Anti-RARe	NULL
:	NULL
(	NULL
C-terminal	NULL
)	NULL
+	NULL
+	NULL
+	NULL
Anti-RARe	NULL
(	NULL
N-terminal	NULL
)	NULL
+	NULL
+	NULL
+	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

EMSA	NULL
on	NULL
a	NULL
DR5	NULL
(	NULL
RXR-RAR	NULL
)	NULL
oligonucleotide	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Schematic	NULL
of	NULL
the	NULL
molecular	NULL
structure	NULL
of	NULL
both	NULL
the	NULL
full-length	NULL
human	NULL
RARa	NULL
and	NULL
the	NULL
dominant-negative	NULL
,	NULL
truncated	NULL
RARa403	NULL
illustrating	NULL
the	NULL
location	NULL
of	NULL
the	NULL
RARa	NULL
peptides	NULL
utilized	NULL
to	NULL
generate	NULL
both	NULL
the	NULL
N-terminal	NULL
and	NULL
the	NULL
C-terminal	NULL
RARa	NULL
antibodies	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Nuclear	NULL
extracts	NULL
from	NULL
the	NULL
indicated	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
a	NULL
radiolabelled	NULL
DRS	NULL
oligonucleotide	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
the	NULL
indicated	NULL
RARa	NULL
antibodies	NULL
and	NULL
run	NULL
on	NULL
a	NULL
Tris-glycine	NULL
gel	NULL
.	NULL

MEL-hRARa	NULL
cells	NULL
are	NULL
a	NULL
mouse	NULL
erythroleukemia	NULL
cell	NULL
line	NULL
stably	NULL
transduced	NULL
with	NULL
full-length	NULL
human	NULL
RARae	NULL
.	NULL

The	NULL
composition	NULL
of	NULL
complex	NULL
A	NULL
,	NULL
which	NULL
is	NULL
particularly	NULL
predominant	NULL
in	NULL
the	NULL
MEL-hRARa	NULL
«	NULL
nuclear	NULL
extracts	NULL
,	NULL
is	NULL
unknown	NULL
,	NULL
but	NULL
it	NULL
does	NULL
not	NULL
appear	NULL
to	NULL
involve	NULL
RARa	NULL
,	NULL
since	NULL
this	NULL
complex	NULL
is	NULL
not	NULL
inhibited	NULL
by	NULL
either	NULL
of	NULL
the	NULL
RARa	NULL
antibodies	NULL
.	NULL

RA	NULL
RECEPTOR	NULL
ACTIVATION	NULL
IN	NULL
MYELOPOIESIS	NULL
-	NULL
3375	NULL
ATRA	NULL
might	NULL
be	NULL
mediating	NULL
such	NULL
effects	NULL
.	NULL

Such	NULL
synthetic	NULL
retinoids	NULL
were	NULL
previously	NULL
identified	NULL
by	NULL
both	NULL
direct	NULL
ligand	NULL
binding	NULL
assays	NULL
and	NULL
transactivation	NULL
assays	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

The	NULL
compounds	NULL
utilized	NULL
in	NULL
the	NULL
present	NULL
study	NULL
were	NULL
the	NULL
RAR	NULL
selective	NULL
agonist	NULL
(	NULL
AGN	NULL
193695	NULL
)	NULL
and	NULL
the	NULL
RXR	NULL
selective	NULL
agonist	NULL
(	NULL
AGN	NULL
194204	NULL
)	NULL
,	NULL
which	NULL
bind	NULL
to	NULL
their	NULL
respective	NULL
receptors	NULL
with	NULL
high	NULL
affinity	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
and	NULL
transactivate	NULL
reporter	NULL
constructs	NULL
harboring	NULL
RXR-RAR	NULL
or	NULL
RXR-RXR	NULL
response	NULL
elements	NULL
,	NULL
respectively	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
RAR	NULL
antagonist	NULL
(	NULL
AGN	NULL
193109	NULL
)	NULL
and	NULL
the	NULL
RXR	NULL
antagonist	NULL
(	NULL
LGN100849	NULL
)	NULL
also	NULL
bind	NULL
to	NULL
their	NULL
respective	NULL
receptors	NULL
with	NULL
high	NULL
affinity	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
,	NULL
but	NULL
these	NULL
antagonists	NULL
selectively	NULL
inhibit	NULL
ATRA-	NULL
or	NULL
9-cis-RA-mediated	NULL
activation	NULL
of	NULL
reporter	NULL
constructs	NULL
harboring	NULL
RXR-RAR	NULL
or	NULL
RXR-RXR	NULL
response	NULL
elements	NULL
,	NULL
respectively	NULL
.	NULL

Granulocytic	NULL
differentiation	NULL
of	NULL
MPRO	NULL
cells	NULL
is	NULL
selectively	NULL
induced	NULL
by	NULL
an	NULL
RXR-specific	NULL
agonist	NULL
.	NULL

We	NULL
determined	NULL
the	NULL
dif-ferentiative	NULL
responses	NULL
of	NULL
the	NULL
GM-CSF-dependent	NULL
MPRO	NULL
promyelocytes	NULL
to	NULL
these	NULL
RXR	NULL
and	NULL
RAR	NULL
selective	NULL
agonists	NULL
and	NULL
antagonists	NULL
.	NULL

MPRO	NULL
cells	NULL
were	NULL
grown	NULL
in	NULL
liquid	NULL
suspension	NULL
in	NULL
these	NULL
different	NULL
receptor-selective	NULL
retinoids	NULL
,	NULL
and	NULL
granulocyte	NULL
differentiation	NULL
was	NULL
assessed	NULL
by	NULL
morphological	NULL
changes	NULL
after	NULL
5	NULL
days	NULL
of	NULL
culture	NULL
.	NULL

As	NULL
previously	NULL
observed	NULL
(	NULL
53	NULL
)	NULL
,	NULL
relatively	NULL
high	NULL
concentrations	NULL
of	NULL
ATRA	NULL
(	NULL
1	NULL
to	NULL
10	NULL
M	NULL
)	NULL
as	NULL
well	NULL
as	NULL
of	NULL
9-cis-RA	NULL
induce	NULL
granulocytic	NULL
differentiation	NULL
of	NULL
the	NULL
MPRO	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Previous	NULL
studies	NULL
had	NULL
indicated	NULL
that	NULL
ATRA	NULL
binds	NULL
the	NULL
truncated	NULL
RARa403	NULL
with	NULL
approximately	NULL
10-fold-less	NULL
affinity	NULL
than	NULL
it	NULL
does	NULL
the	NULL
normal	NULL
RARa	NULL
«	NULL
(	NULL
52	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
if	NULL
RA	NULL
binding	NULL
to	NULL
RARa403	NULL
is	NULL
involved	NULL
in	NULL
MPRO	NULL
differentiation	NULL
,	NULL
then	NULL
this	NULL
reduced	NULL
binding	NULL
affinity	NULL
might	NULL
account	NULL
for	NULL
the	NULL
relatively	NULL
high	NULL
concentrations	NULL
of	NULL
ATRA	NULL
required	NULL
to	NULL
trigger	NULL
MPRO	NULL
differentiation	NULL
.	NULL

However	NULL
,	NULL
contrary	NULL
to	NULL
this	NULL
hypothesis	NULL
,	NULL
we	NULL
found	NULL
that	NULL
the	NULL
RXR-specific	NULL
agonist	NULL
(	NULL
AGN	NULL
194204	NULL
)	NULL
is	NULL
a	NULL
potent	NULL
inducer	NULL
of	NULL
MPRO	NULL
granulocytic	NULL
differentiation	NULL
while	NULL
the	NULL
RAR-specific	NULL
agonist	NULL
(	NULL
AGN	NULL
193695	NULL
)	NULL
had	NULL
virtually	NULL
no	NULL
activity	NULL
even	NULL
at	NULL
relatively	NULL
high	NULL
concentrations	NULL
(	NULL
10	NULL
pM	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Comparing	NULL
the	NULL
relative	NULL
concentrations	NULL
of	NULL
these	NULL
different	NULL
retinoids	NULL
required	NULL
to	NULL
induce	NULL
maximal	NULL
MPRO	NULL
differentiation	NULL
indicated	NULL
that	NULL
the	NULL
RXR	NULL
agonist	NULL
was	NULL
approximately	NULL
100-	NULL
to	NULL
1,000-fold	NULL
more	NULL
potent	NULL
than	NULL
either	NULL
ATRA	NULL
or	NULL
9-cis-RA	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
neither	NULL
the	NULL
RXR	NULL
antagonist	NULL
nor	NULL
the	NULL
RAR	NULL
antagonist	NULL
induced	NULL
any	NULL
significant	NULL
granulocytic	NULL
differentiation	NULL
of	NULL
MPRO	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
MPRO	NULL
cells	NULL
,	NULL
the	NULL
RXR	NULL
agonist	NULL
preferentially	NULL
triggers	NULL
activation	NULL
of	NULL
RXR-RAR	NULL
heterodimers	NULL
rather	NULL
than	NULL
RXR-RXR	NULL
homodimers	NULL
.	NULL

The	NULL
truncated	NULL
RARa403	NULL
retains	NULL
the	NULL
capacity	NULL
to	NULL
bind	NULL
RXR	NULL
and	NULL
form	NULL
RARa403-RXR	NULL
heterodimers	NULL
which	NULL
can	NULL
bind	NULL
to	NULL
RXR-RAR	NULL
target	NULL
sequences	NULL
(	NULL
11	NULL
,	NULL
15	NULL
)	NULL
.	NULL

Since	NULL
RXR-RARa403	NULL
heterodimers	NULL
appear	NULL
to	NULL
predominate	NULL
in	NULL
MPRO	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
(	NULL
53	NULL
)	NULL
,	NULL
the	NULL
RXR	NULL
agonist	NULL
likely	NULL
mediates	NULL
MPRO	NULL
TABLE	NULL
1	NULL
.	NULL

Binding	NULL
affinities	NULL
and	NULL
transcriptional	NULL
activation	NULL
characteristics	NULL
of	NULL
the	NULL
RAR-	NULL
and	NULL
RXR-specific	NULL
agonists	NULL
and	NULL
antagonists	NULL
``	NULL
AGN	NULL
193695	NULL
(	NULL
RAR	NULL
agonist	NULL
)	NULL
Receptor	NULL
--	NULL
-	NULL
AGN	NULL
194204	NULL
(	NULL
RXR	NULL
agonist	NULL
)	NULL
AGN	NULL
193109	NULL
``	NULL
(	NULL
RAR	NULL
LGN100849®	NULL
(	NULL
RXR	NULL
K	NULL
,	NULL
EGso	NULL
K	NULL
,	NULL
BEGso	NULL
antagonist	NULL
)	NULL
K	NULL
,	NULL
antagonist	NULL
)	NULL
K	NULL
,	NULL
RARa	NULL
44	NULL
31	NULL
>	NULL
30,000	NULL
>	NULL
1,000	NULL
2	NULL
>	NULL
10,000	NULL
28	NULL
4	NULL
>	NULL
30,000	NULL
>	NULL
1,000	NULL
2	NULL
6,000	NULL
RARy	NULL
99	NULL
3	NULL
>	NULL
30,000	NULL
>	NULL
1,000	NULL
3	NULL
>	NULL
10,000	NULL
RXRa	NULL
>	NULL
1,000	NULL
>	NULL
1,000	NULL
<	NULL
3	NULL
1.5	NULL
>	NULL
30,000	NULL
16	NULL
>	NULL
1,000	NULL
>	NULL
1,000	NULL
<	NULL
3	NULL
2.0	NULL
>	NULL
30,000	NULL
3	NULL
RXRy	NULL
>	NULL
1,000	NULL
>	NULL
1,000	NULL
<	NULL
3	NULL
1.0	NULL
>	NULL
30,000	NULL
4	NULL
``	NULL
K	NULL
,	NULL
,	NULL
values	NULL
are	NULL
given	NULL
in	NULL
nanomolar	NULL
concentrations	NULL
.	NULL

Transactivation	NULL
assays	NULL
were	NULL
performed	NULL
with	NULL
CV1	NULL
cells	NULL
transfected	NULL
with	NULL
an	NULL
expression	NULL
vector	NULL
for	NULL
the	NULL
indicated	NULL
retinoid	NULL
receptor	NULL
and	NULL
a	NULL
luciferase	NULL
reporter	NULL
plasmid	NULL
,	NULL
including	NULL
the	NULL
A5-LUC	NULL
for	NULL
the	NULL
RARs	NULL
and	NULL
CRABPII-tk-Luc	NULL
for	NULL
the	NULL
RXRs	NULL
.	NULL

Fifty	NULL
percent	NULL
effective	NULL
concentrations	NULL
(	NULL
EC	NULL
,	NULL
;	NULL
nanomolar	NULL
concentrations	NULL
)	NULL
represent	NULL
the	NULL
retinoid	NULL
concentrations	NULL
giving	NULL
50	NULL
%	NULL
of	NULL
the	NULL
maximal	NULL
activity	NULL
(	NULL
at	NULL
10	NULL
~	NULL
``	NULL
M	NULL
)	NULL
.	NULL

*	NULL
The	NULL
ability	NULL
of	NULL
this	NULL
compound	NULL
to	NULL
antagonize	NULL
transactivation	NULL
by	NULL
RARs	NULL
was	NULL
determined	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
28	NULL
)	NULL
.	NULL

°	NULL
The	NULL
ability	NULL
of	NULL
this	NULL
compound	NULL
to	NULL
antagonize	NULL
transactivation	NULL
by	NULL
RXR	NULL
homodimers	NULL
was	NULL
determined	NULL
by	NULL
a	NULL
previously	NULL
described	NULL
assay	NULL
(	NULL
35	NULL
)	NULL
,	NULL
and	NULL
its	NULL
functional	NULL
utility	NULL
as	NULL
an	NULL
RXR	NULL
antagonist	NULL
has	NULL
been	NULL
previously	NULL
noted	NULL
(	NULL
51	NULL
)	NULL
.	NULL

3376	NULL
JOHNSON	NULL
ET	NULL
AL	NULL
.	NULL

%	NULL
Granulocytic	NULL
Differentiation	NULL
10	NULL
2	NULL
s	NULL
4	NULL
O50	NULL
607	NULL
%	NULL
O9	NULL
do	NULL
1	NULL
d2	NULL
4	NULL
%	NULL
44	NULL
1s	NULL
de	NULL
47	NULL
48s	NULL
19	NULL
20	NULL
No	NULL
Retinoid	NULL
+	NULL
+	NULL
+	NULL
+	NULL
10.0	NULL
uM	NULL
+	NULL
+	NULL
+	NULL
+	NULL
1.0	NULL
uM	NULL
+	NULL
+	NULL
+	NULL
+	NULL
0.1	NULL
uM	NULL
+	NULL
+	NULL
+	NULL
+	NULL
0.01	NULL
pM	NULL
+	NULL
+	NULL
+	NULL
+	NULL
ATRA	NULL
9-cis	NULL
RA	NULL
RAR	NULL
Agonist	NULL
|	NULL
RXR	NULL
Agonist	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

Granulocytic	NULL
differentiation	NULL
of	NULL
MPRO	NULL
in	NULL
response	NULL
to	NULL
different	NULL
retinoids	NULL
.	NULL

MPRO	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
liquid	NULL
suspension	NULL
for	NULL
5	NULL
days	NULL
with	NULL
the	NULL
indicated	NULL
concentration	NULL
of	NULL
retinoids	NULL
.	NULL

The	NULL
percent	NULL
granulocytic	NULL
differentiation	NULL
in	NULL
the	NULL
culture	NULL
(	NULL
myelocytes	NULL
,	NULL
metamyelocytes	NULL
,	NULL
banded	NULL
,	NULL
doughnut	NULL
,	NULL
and	NULL
segmented	NULL
neutro-phils	NULL
)	NULL
was	NULL
then	NULL
determined	NULL
on	NULL
Wright-Giemsa-stained	NULL
cytospin	NULL
preparations	NULL
.	NULL

differentiation	NULL
by	NULL
triggering	NULL
the	NULL
activation	NULL
of	NULL
such	NULL
RXR-RARa403	NULL
heterodimers	NULL
.	NULL

However	NULL
,	NULL
it	NULL
is	NULL
also	NULL
possible	NULL
that	NULL
the	NULL
RXR	NULL
agonist	NULL
may	NULL
be	NULL
mediating	NULL
MPRO	NULL
differentiation	NULL
by	NULL
activating	NULL
any	NULL
RXR-RXR	NULL
homodimers	NULL
that	NULL
also	NULL
might	NULL
be	NULL
present	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

To	NULL
distinguish	NULL
these	NULL
possibilities	NULL
,	NULL
we	NULL
utilized	NULL
reporter	NULL
constructs	NULL
harboring	NULL
DNA	NULL
response	NULL
elements	NULL
that	NULL
are	NULL
selectively	NULL
activated	NULL
by	NULL
either	NULL
RAR-RXR	NULL
or	NULL
RXR-RXR	NULL
complexes	NULL
.	NULL

The	NULL
RXR-RXR	NULL
homodimers	NULL
preferentially	NULL
interact	NULL
with	NULL
specific	NULL
response	NULL
elements	NULL
consisting	NULL
of	NULL
a	NULL
consensus	NULL
binding	NULL
sequence	NULL
separated	NULL
by	NULL
a	NULL
single	NULL
base	NULL
pair	NULL
(	NULL
DR1	NULL
)	NULL
(	NULL
22	NULL
,	NULL
40	NULL
)	NULL
,	NULL
while	NULL
RXR-RAR	NULL
heterodimers	NULL
preferentially	NULL
activate	NULL
consensus	NULL
sequences	NULL
separated	NULL
by	NULL
5	NULL
bp	NULL
(	NULL
DRS	NULL
)	NULL
(	NULL
56	NULL
)	NULL
.	NULL

We	NULL
performed	NULL
-	NULL
transient-transfection	NULL
assays	NULL
of	NULL
retinoid-treated	NULL
MPRO	NULL
cells	NULL
with	NULL
reporter	NULL
constructs	NULL
driven	NULL
by	NULL
promoters	NULL
harboring	NULL
either	NULL
the	NULL
DR1	NULL
or	NULL
DR5	NULL
RA	NULL
response	NULL
element	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

In	NULL
the	NULL
transfected	NULL
MPRO	NULL
cells	NULL
,	NULL
the	NULL
RXR	NULL
agonist	NULL
(	NULL
AGN	NULL
194204	NULL
)	NULL
consistently	NULL
triggered	NULL
an	NULL
8-	NULL
to	NULL
10-fold	NULL
activation	NULL
of	NULL
the	NULL
DR5	NULL
(	NULL
RXR-RAR	NULL
)	NULL
response	NULL
elements	NULL
while	NULL
displaying	NULL
little	NULL
if	NULL
any	NULL
activation	NULL
of	NULL
the	NULL
DR1	NULL
(	NULL
RXR-RXR	NULL
)	NULL
reporter	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
compare	NULL
lane	NULL
5	NULL
with	NULL
lane	NULL
12	NULL
)	NULL
.	NULL

Similar	NULL
to	NULL
its	NULL
potency	NULL
as	NULL
a	NULL
differentiation	NULL
inducer	NULL
of	NULL
MPRO	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
,	NULL
this	NULL
RXR	NULL
agonist	NULL
triggered	NULL
the	NULL
DRS	NULL
reporter	NULL
activation	NULL
in	NULL
MPRO	NULL
cells	NULL
at	NULL
concentrations	NULL
as	NULL
low	NULL
as	NULL
10	NULL
nM	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
ATRA-	NULL
and	NULL
9-cis-RA-induced	NULL
activation	NULL
of	NULL
the	NULL
DRS	NULL
reporter	NULL
was	NULL
consistently	NULL
greater	NULL
than	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
DR1	NULL
reporter	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
compare	NULL
lanes	NULL
2	NULL
and	NULL
3	NULL
with	NULL
lanes	NULL
9	NULL
and	NULL
10	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
RAR	NULL
agonist	NULL
,	NULL
which	NULL
is	NULL
ineffective	NULL
in	NULL
activating	NULL
MPRO	NULL
differentiation	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
,	NULL
mediated	NULL
only	NULL
a	NULL
twofold	NULL
activation	NULL
of	NULL
the	NULL
DR5	NULL
(	NULL
RXR-RAR	NULL
)	NULL
reporter	NULL
and	NULL
no	NULL
activation	NULL
of	NULL
the	NULL
DR1	NULL
(	NULL
RXR-RXR	NULL
)	NULL
reporter	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
lanes	NULL
4	NULL
and	NULL
11	NULL
)	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
the	NULL
RXR	NULL
and	NULL
RAR	NULL
antagonists	NULL
activated	NULL
neither	NULL
reporter	NULL
con-struct	NULL
.	NULL

The	NULL
observation	NULL
that	NULL
the	NULL
RXR	NULL
agonist	NULL
selectively	NULL
activates	NULL
the	NULL
DR5	NULL
(	NULL
RXR-RAR	NULL
)	NULL
rather	NULL
than	NULL
the	NULL
DR1	NULL
(	NULL
RXR-RXR	NULL
)	NULL
reporter	NULL
construct	NULL
suggests	NULL
that	NULL
this	NULL
compound	NULL
triggers	NULL
MPRO	NULL
granulocyte	NULL
differentiation	NULL
by	NULL
activating	NULL
the	NULL
RXR-RARa403	NULL
heterodimers	NULL
rather	NULL
than	NULL
RXR-RXR	NULL
homodimers	NULL
.	NULL

The	NULL
activity	NULL
of	NULL
the	NULL
RXR	NULL
agonist	NULL
in	NULL
MPRO	NULL
cells	NULL
is	NULL
inhibited	NULL
by	NULL
both	NULL
RXR	NULL
and	NULL
RAR	NULL
antagonists	NULL
.	NULL

To	NULL
further	NULL
analyze	NULL
the	NULL
presumed	NULL
RXR	NULL
agonist-mediated	NULL
activation	NULL
of	NULL
the	NULL
RXR-RARa403	NULL
complex	NULL
in	NULL
MPRO	NULL
cells	NULL
,	NULL
we	NULL
assessed	NULL
the	NULL
MPRO	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

16.00	NULL
14.00	NULL
12.00	NULL
}	NULL
10.00	NULL
!	NULL

.	NULL

8.00	NULL
Relative	NULL
Luciferase	NULL
Activity	NULL
0.00	NULL
.	NULL

No	NULL
Retinoid	NULL
+	NULL
+	NULL
ATRA	NULL
(	NULL
10	NULL
uM	NULL
)	NULL
+	NULL
+	NULL
9-cis	NULL
RA	NULL
(	NULL
10	NULL
uM	NULL
)	NULL
+	NULL
+	NULL
RAR	NULL
Agonist	NULL
+	NULL
+	NULL
RXR	NULL
Agonist	NULL
+	NULL
+	NULL
RAR	NULL
Antagonist	NULL
+	NULL
+	NULL
RXR	NULL
Antagonist	NULL
+	NULL
+	NULL
DR-5	NULL
(	NULL
RAR-RXR	NULL
)	NULL
DR-1	NULL
(	NULL
RXR-RXR	NULL
)	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Relative	NULL
activity	NULL
of	NULL
DR5	NULL
and	NULL
DR1	NULL
response	NULL
elements	NULL
in	NULL
retinoid-treated	NULL
MPRO	NULL
cells	NULL
.	NULL

Relative	NULL
luciferase	NULL
activity	NULL
was	NULL
determined	NULL
in	NULL
MPRO	NULL
cells	NULL
which	NULL
were	NULL
transfected	NULL
with	NULL
either	NULL
the	NULL
DR5	NULL
Luc	NULL
(	NULL
RXR-RAR	NULL
responsive	NULL
)	NULL
or	NULL
DR1	NULL
Luc	NULL
(	NULL
RXR-RXR	NULL
responsive	NULL
)	NULL
reporter	NULL
construct	NULL
and	NULL
then	NULL
treated	NULL
for	NULL
24	NULL
h	NULL
with	NULL
the	NULL
indicated	NULL
retinoid	NULL
.	NULL

The	NULL
concentration	NULL
of	NULL
ATRA	NULL
and	NULL
9-cis-RA	NULL
utilized	NULL
was	NULL
10	NULL
wM	NULL
,	NULL
while	NULL
that	NULL
of	NULL
the	NULL
other	NULL
retinoids	NULL
was	NULL
2.5	NULL
M.	NULL
Calculated	NULL
luciferase	NULL
activity	NULL
was	NULL
normalized	NULL
for	NULL
transfection	NULL
efficiency	NULL
with	NULL
the	NULL
cotransfected	NULL
growth	NULL
hormone	NULL
reporter	NULL
(	NULL
pCMVGH	NULL
)	NULL
as	NULL
an	NULL
internal	NULL
control	NULL
.	NULL

Solid	NULL
bars	NULL
represent	NULL
the	NULL
means	NULL
of	NULL
at	NULL
least	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

response	NULL
to	NULL
this	NULL
RXR	NULL
agonist	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
specific	NULL
RXR	NULL
or	NULL
RAR	NULL
antagonists	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
the	NULL
addition	NULL
of	NULL
the	NULL
RXR	NULL
antagonist	NULL
(	NULL
LGN100849	NULL
)	NULL
in	NULL
a	NULL
100-fold	NULL
excess	NULL
inhibited	NULL
both	NULL
RXR	NULL
agonist-induced	NULL
MPRO	NULL
differentiation	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
and	NULL
RXR	NULL
agonist-induced	NULL
activation	NULL
of	NULL
the	NULL
DR5	NULL
(	NULL
RXR-RAR	NULL
)	NULL
reporter	NULL
construct	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

This	NULL
likely	NULL
occurs	NULL
because	NULL
the	NULL
RXR	NULL
antagonist	NULL
directly	NULL
competes	NULL
with	NULL
the	NULL
RXR	NULL
agonist	NULL
for	NULL
binding	NULL
to	NULL
the	NULL
ligand-binding	NULL
domain	NULL
of	NULL
the	NULL
RXR	NULL
partner	NULL
in	NULL
the	NULL
RXR	NULL
100.0	NULL
100.00	NULL
80.0	NULL
80.00	NULL
80.0	NULL
80.00	NULL
70.0	NULL
70.00	NULL
s0.0	NULL
60.00	NULL
50.00	NULL
40.00	NULL
30.00	NULL
50.0	NULL
40.0	NULL
30.0	NULL
20.0	NULL
20.00	NULL
10.0	NULL
10.00	NULL
0.0	NULL
0.00	NULL
%	NULL
Granulocytic	NULL
Differentiation	NULL
Luciferase	NULL
Activity	NULL
(	NULL
%	NULL
of	NULL
Maximum	NULL
)	NULL
No	NULL
Retinoid	NULL
|	NULL
+	NULL
No	NULL
Retinoid	NULL
|	NULL
+	NULL
RXR	NULL
Agonist	NULL
(	NULL
0.1	NULL
uM	NULL
)	NULL
+	NULL
|	NULL
+	NULL
|	NULL
+	NULL
RXR	NULL
Agonist	NULL
(	NULL
0.1	NULL
pM	NULL
)	NULL
+	NULL
|	NULL
+	NULL
|	NULL
+	NULL
RXR	NULL
Antagonist	NULL
(	NULL
10	NULL
uM	NULL
)	NULL
+	NULL
RXR	NULL
Antagonist	NULL
(	NULL
10	NULL
uM	NULL
)	NULL
RAR	NULL
Antagonist	NULL
(	NULL
10	NULL
pM	NULL
)	NULL
+	NULL
RAR	NULL
Antagonist	NULL
(	NULL
10	NULL
uM	NULL
)	NULL
+	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

Both	NULL
RXR	NULL
and	NULL
RAR	NULL
antagonists	NULL
inhibit	NULL
the	NULL
biological	NULL
effects	NULL
of	NULL
the	NULL
RXR	NULL
agonist	NULL
in	NULL
MPRO	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
MPRO	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
liquid	NULL
suspension	NULL
with	NULL
the	NULL
indicated	NULL
concentrations	NULL
of	NULL
retinoid	NULL
agonist	NULL
and/or	NULL
antagonist	NULL
.	NULL

After	NULL
5	NULL
days	NULL
,	NULL
the	NULL
percentage	NULL
of	NULL
morphologically	NULL
mature	NULL
granulocytes	NULL
in	NULL
the	NULL
cultures	NULL
was	NULL
determined	NULL
on	NULL
Wright-Giemsa-stained	NULL
cytospin	NULL
preparations	NULL
.	NULL

(	NULL
B	NULL
)	NULL
MPRO	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
DR5	NULL
Luc	NULL
reporter	NULL
construct	NULL
(	NULL
responsive	NULL
to	NULL
RXR-RAR	NULL
)	NULL
and	NULL
then	NULL
cultured	NULL
overnight	NULL
in	NULL
liquid	NULL
suspension	NULL
with	NULL
the	NULL
indicated	NULL
concentrations	NULL
of	NULL
retinoid	NULL
agonist	NULL
and/or	NULL
antagonist	NULL
.	NULL

Relative	NULL
luciferase	NULL
activity	NULL
was	NULL
then	NULL
determined	NULL
in	NULL
cell	NULL
lysates	NULL
,	NULL
and	NULL
results	NULL
were	NULL
normalized	NULL
for	NULL
transfection	NULL
efficiency	NULL
with	NULL
the	NULL
cotransfected	NULL
pCMVGH	NULL
growth	NULL
hormone	NULL
expression	NULL
plasmid	NULL
as	NULL
an	NULL
internal	NULL
control	NULL
.	NULL

Vor	NULL
.	NULL

19	NULL
,	NULL
1999	NULL
90.0	NULL
E	NULL
3	NULL
80.0	NULL
E	NULL
E	NULL
70.0	NULL
a	NULL
I	NULL
60.0	NULL
put	NULL
2	NULL
50.0	NULL
°\	NULL
.	NULL

40.0	NULL
=	NULL
(	NULL
lb	NULL
30.0	NULL
E	NULL
20.0	NULL
o	NULL
10.0	NULL
0.0	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
T	NULL
8	NULL
SCF	NULL
|	NULL
+	NULL
+	NULL
+	NULL
|	NULL
4+	NULL
|	NULL
4	NULL
IL-3	NULL
+	NULL
+	NULL
|	NULL
+	NULL
|	NULL
+	NULL
ATRA	NULL
+	NULL
RXR	NULL
Agonist	NULL
+	NULL
+	NULL
RAR	NULL
Agonist	NULL
+	NULL
|	NULL
+	NULL
RXR	NULL
Antagonist	NULL
+	NULL
RAR	NULL
Antagonist	NULL
+	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

Generation	NULL
of	NULL
CFU-GM	NULL
in	NULL
EML	NULL
cultures	NULL
treated	NULL
with	NULL
IL-3	NULL
and	NULL
different	NULL
retinoids	NULL
.	NULL

EML	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
liquid	NULL
suspension	NULL
with	NULL
the	NULL
indicated	NULL
concentration	NULL
of	NULL
IL-3	NULL
and/or	NULL
retinoid	NULL
agonist	NULL
or	NULL
antagonist	NULL
.	NULL

After	NULL
2	NULL
to	NULL
3	NULL
days	NULL
of	NULL
this	NULL
liquid	NULL
culture	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
harvested	NULL
,	NULL
and	NULL
the	NULL
numbers	NULL
of	NULL
CFU-GMs	NULL
in	NULL
the	NULL
cultures	NULL
were	NULL
determined	NULL
in	NULL
colony	NULL
assays	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

RARa403	NULL
heterodimer	NULL
.	NULL

Unexpectedly	NULL
,	NULL
we	NULL
noted	NULL
that	NULL
the	NULL
RAR	NULL
antagonist	NULL
also	NULL
inhibits	NULL
both	NULL
RXR	NULL
agonist-induced	NULL
MPRO	NULL
differentiation	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
and	NULL
RXR	NULL
agonist-induced	NULL
activation	NULL
of	NULL
the	NULL
DR5	NULL
(	NULL
RXR-RAR	NULL
)	NULL
reporter	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

This	NULL
was	NULL
surprising	NULL
because	NULL
the	NULL
RAR	NULL
antagonist	NULL
binds	NULL
specifically	NULL
to	NULL
RARs	NULL
,	NULL
displaying	NULL
virtually	NULL
no	NULL
binding	NULL
affinity	NULL
for	NULL
RXRs	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
,	NULL
and	NULL
thus	NULL
would	NULL
not	NULL
be	NULL
expected	NULL
to	NULL
inhibit	NULL
the	NULL
RXR	NULL
agonist	NULL
activity	NULL
.	NULL

This	NULL
observed	NULL
ability	NULL
of	NULL
the	NULL
RAR	NULL
antagonist	NULL
to	NULL
inhibit	NULL
the	NULL
biological	NULL
effects	NULL
of	NULL
the	NULL
RXR	NULL
agonist	NULL
in	NULL
MPRO	NULL
cells	NULL
suggests	NULL
that	NULL
the	NULL
RXR	NULL
and	NULL
RAR	NULL
heterodimeric	NULL
partners	NULL
do	NULL
not	NULL
behave	NULL
independently	NULL
after	NULL
interaction	NULL
with	NULL
their	NULL
respective	NULL
ligands	NULL
.	NULL

Rather	NULL
,	NULL
there	NULL
appears	NULL
to	NULL
be	NULL
considerable	NULL
cross-talk	NULL
between	NULL
the	NULL
RXR	NULL
and	NULL
RAR	NULL
components	NULL
of	NULL
the	NULL
heterodimer	NULL
after	NULL
ligand	NULL
stimulation	NULL
(	NULL
see	NULL
Discussion	NULL
)	NULL
.	NULL

Response	NULL
of	NULL
EML	NULL
cells	NULL
to	NULL
RXR	NULL
and	NULL
RAR	NULL
selective	NULL
retinoids	NULL
.	NULL

We	NULL
next	NULL
wished	NULL
to	NULL
characterize	NULL
the	NULL
response	NULL
of	NULL
the	NULL
multipotent	NULL
EML	NULL
cells	NULL
,	NULL
in	NULL
which	NULL
the	NULL
truncated	NULL
RARa403	NULL
complexes	NULL
are	NULL
also	NULL
predominant	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
,	NULL
to	NULL
different	NULL
RAR-	NULL
and	NULL
RXR	NULL
-specific	NULL
agonists	NULL
and	NULL
antagonists	NULL
.	NULL

Unlike	NULL
the	NULL
GM-CSF-dependent	NULL
MPRO	NULL
cells	NULL
,	NULL
which	NULL
are	NULL
strictly	NULL
committed	NULL
to	NULL
granulocyte	NULL
differentiation	NULL
,	NULL
the	NULL
SCF-dependent	NULL
EML	NULL
cells	NULL
are	NULL
multipotent	NULL
,	NULL
exhibiting	NULL
erythroid	NULL
,	NULL
lymphoid	NULL
,	NULL
and	NULL
myeloid	NULL
potential	NULL
(	NULL
54	NULL
)	NULL
.	NULL

The	NULL
addition	NULL
of	NULL
IL-3	NULL
to	NULL
EML	NULL
cultures	NULL
will	NULL
induce	NULL
commitment	NULL
of	NULL
these	NULL
cells	NULL
to	NULL
the	NULL
monocyte/granulocyte	NULL
lineage	NULL
(	NULL
as	NULL
measured	NULL
by	NULL
CFU-GM	NULL
generation	NULL
)	NULL
,	NULL
and	NULL
this	NULL
IL-3-induced	NULL
commitment	NULL
to	NULL
the	NULL
monocyte/granulocyte	NULL
lineage	NULL
is	NULL
potentiated	NULL
by	NULL
relatively	NULL
high	NULL
concentrations	NULL
of	NULL
ATRA	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
lanes	NULL
1	NULL
to	NULL
3	NULL
)	NULL
(	NULL
54	NULL
)	NULL
.	NULL

As	NULL
in	NULL
the	NULL
above-described	NULL
studies	NULL
of	NULL
MPRO	NULL
cells	NULL
,	NULL
we	NULL
utilized	NULL
the	NULL
synthetic	NULL
retinoids	NULL
specific	NULL
for	NULL
RAR	NULL
and	NULL
RXR	NULL
to	NULL
determine	NULL
whether	NULL
the	NULL
CFU-GM	NULL
generation	NULL
observed	NULL
in	NULL
EML	NULL
cells	NULL
induced	NULL
by	NULL
relatively	NULL
high	NULL
concentrations	NULL
of	NULL
ATRA	NULL
was	NULL
mediated	NULL
through	NULL
RXR	NULL
or	NULL
through	NULL
RAR	NULL
.	NULL

We	NULL
observed	NULL
that	NULL
,	NULL
in	NULL
marked	NULL
contrast	NULL
to	NULL
MPRO	NULL
cells	NULL
,	NULL
where	NULL
the	NULL
RXR	NULL
agonist	NULL
(	NULL
AGN	NULL
194204	NULL
)	NULL
exhibited	NULL
potent	NULL
activity	NULL
in	NULL
inducing	NULL
granulocyte	NULL
differentiation	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
,	NULL
this	NULL
same	NULL
RXR	NULL
agonist	NULL
had	NULL
little	NULL
effect	NULL
in	NULL
potentiating	NULL
the	NULL
IL-3-mediated	NULL
CFU-GM	NULL
production	NULL
in	NULL
the	NULL
EML	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
compare	NULL
lanes	NULL
2	NULL
and	NULL
5	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
RAR	NULL
agonist	NULL
also	NULL
exhibited	NULL
no	NULL
significant	NULL
biological	NULL
effect	NULL
RA	NULL
RECEPTOR	NULL
ACTIVATION	NULL
IN	NULL
MYELOPOIESIS	NULL
-	NULL
3377	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
lane	NULL
6	NULL
)	NULL
,	NULL
and	NULL
the	NULL
combination	NULL
of	NULL
RAR	NULL
and	NULL
RXR	NULL
agonists	NULL
exhibited	NULL
no	NULL
significant	NULL
increase	NULL
compared	NULL
with	NULL
the	NULL
effect	NULL
of	NULL
either	NULL
agonist	NULL
alone	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
lane	NULL
7	NULL
)	NULL
.	NULL

Curiously	NULL
,	NULL
it	NULL
was	NULL
the	NULL
RXR	NULL
antagonist	NULL
that	NULL
exhibited	NULL
slightly	NULL
enhanced	NULL
CFU-GM	NULL
production	NULL
in	NULL
the	NULL
EML	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
lane	NULL
8	NULL
)	NULL
,	NULL
although	NULL
this	NULL
level	NULL
of	NULL
CFU-GM	NULL
production	NULL
was	NULL
consistently	NULL
lower	NULL
than	NULL
that	NULL
observed	NULL
with	NULL
ATRA	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
RAR	NULL
antagonist	NULL
consistently	NULL
diminished	NULL
CFU-GM	NULL
production	NULL
in	NULL
the	NULL
IL-3-treated	NULL
EML	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

The	NULL
relative	NULL
inactivity	NULL
of	NULL
the	NULL
RXR	NULL
agonist	NULL
in	NULL
potentiating	NULL
CFU-GM	NULL
generation	NULL
in	NULL
the	NULL
IL-3-treated	NULL
EML	NULL
cells	NULL
was	NULL
puzzling	NULL
given	NULL
the	NULL
potent	NULL
activity	NULL
of	NULL
this	NULL
agonist	NULL
in	NULL
inducing	NULL
granulocyte	NULL
differentiation	NULL
of	NULL
MPRO	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

To	NULL
further	NULL
explore	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
RXR	NULL
agonist	NULL
in	NULL
EML	NULL
cells	NULL
,	NULL
we	NULL
assessed	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
DR1	NULL
(	NULL
RXR-RXR	NULL
)	NULL
and	NULL
DRS	NULL
(	NULL
RXR-RAR	NULL
)	NULL
reporter	NULL
constructs	NULL
transfected	NULL
into	NULL
retinoid-stimulated	NULL
EML	NULL
cells	NULL
.	NULL

Little	NULL
activation	NULL
of	NULL
the	NULL
DR1	NULL
(	NULL
RXR-RXR	NULL
)	NULL
reporter	NULL
was	NULL
noted	NULL
in	NULL
the	NULL
EML	NULL
cells	NULL
treated	NULL
with	NULL
the	NULL
different	NULL
retinoids	NULL
,	NULL
with	NULL
the	NULL
greatest	NULL
activation	NULL
(	NULL
approximately	NULL
twofold	NULL
)	NULL
observed	NULL
with	NULL
9-cis-RA	NULL
induction	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
lanes	NULL
3	NULL
and	NULL
11	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
IL-3	NULL
had	NULL
little	NULL
if	NULL
any	NULL
effect	NULL
in	NULL
enhancing	NULL
activation	NULL
of	NULL
the	NULL
DR1	NULL
reporter	NULL
in	NULL
EML	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
lanes	NULL
9	NULL
to	NULL
16	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
in	NULL
the	NULL
transfected	NULL
EML	NULL
cells	NULL
the	NULL
DR5	NULL
(	NULL
RAR-RXR	NULL
)	NULL
reporter	NULL
exhibited	NULL
a	NULL
markedly	NULL
reduced	NULL
retinoid-mediated	NULL
activation	NULL
compared	NULL
with	NULL
that	NULL
in	NULL
MPRO	NULL
cells	NULL
(	NULL
compare	NULL
Fig	NULL
.	NULL

6B	NULL
with	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

For	NULL
example	NULL
,	NULL
the	NULL
RXR	NULL
agonist	NULL
,	NULL
which	NULL
markedly	NULL
stimulates	NULL
the	NULL
DR5	NULL
(	NULL
RXR-RAR	NULL
)	NULL
reporter	NULL
in	NULL
MPRO	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
,	NULL
stimulated	NULL
little	NULL
if	NULL
any	NULL
activation	NULL
of	NULL
the	NULL
same	NULL
DRS	NULL
reporter	NULL
in	NULL
the	NULL
transfected	NULL
EML	NULL
cells	NULL
either	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
IL-3	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
lanes	NULL
5	NULL
and	NULL
13	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
while	NULL
neither	NULL
the	NULL
RXR	NULL
nor	NULL
the	NULL
RAR	NULL
agonist	NULL
induced	NULL
any	NULL
DRS	NULL
reporter	NULL
activation	NULL
in	NULL
EML	NULL
cells	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
IL-3	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
lanes	NULL
4	NULL
and	NULL
5	NULL
and	NULL
lanes	NULL
12	NULL
and	NULL
13	NULL
)	NULL
,	NULL
both	NULL
agonists	NULL
together	NULL
reproducibly	NULL
induced	NULL
a	NULL
two-	NULL
to	NULL
threefold	NULL
activation	NULL
of	NULL
this	NULL
reporter	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
lanes	NULL
6	NULL
and	NULL
14	NULL
)	NULL
.	NULL

ATRA	NULL
and	NULL
9-cis-RA	NULL
,	NULL
rather	NULL
than	NULL
any	NULL
of	NULL
the	NULL
synthetic	NULL
agonists	NULL
or	NULL
antagonists	NULL
,	NULL
consistently	NULL
induced	NULL
the	NULL
greatest	NULL
activation	NULL
of	NULL
the	NULL
DRS	NULL
construct	NULL
in	NULL
EML	NULL
cells	NULL
,	NULL
but	NULL
this	NULL
activation	NULL
(	NULL
three-	NULL
to	NULL
fourfold	NULL
)	NULL
was	NULL
consistently	NULL
less	NULL
than	NULL
the	NULL
approximately	NULL
10-fold	NULL
activation	NULL
of	NULL
the	NULL
same	NULL
construct	NULL
induced	NULL
by	NULL
ATRA	NULL
or	NULL
9-cis-RA	NULL
in	NULL
the	NULL
transfected	NULL
MPRO	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
3	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
in	NULL
comparison	NULL
with	NULL
the	NULL
response	NULL
in	NULL
MPRO	NULL
promyelocytes	NULL
,	NULL
in	NULL
the	NULL
more	NULL
immature	NULL
,	NULL
multipotent	NULL
EML	NULL
cells	NULL
the	NULL
DRS	NULL
(	NULL
RXR-RAR	NULL
)	NULL
reporter	NULL
exhibits	NULL
a	NULL
markedly	NULL
blunted	NULL
response	NULL
to	NULL
retinoid-in-duced	NULL
activation	NULL
,	NULL
and	NULL
in	NULL
these	NULL
cells	NULL
,	NULL
the	NULL
RXR	NULL
agonist	NULL
by	NULL
itself	NULL
exhibits	NULL
virtually	NULL
no	NULL
activation	NULL
of	NULL
the	NULL
DRS	NULL
reporter	NULL
.	NULL

Response	NULL
of	NULL
MPRO	NULL
cells	NULL
directly	NULL
derived	NULL
from	NULL
EML	NULL
cells	NULL
to	NULL
the	NULL
RXR	NULL
selective	NULL
retinoids	NULL
.	NULL

The	NULL
MPRO	NULL
and	NULL
EML	NULL
cells	NULL
utilized	NULL
in	NULL
the	NULL
above	NULL
experiments	NULL
were	NULL
derived	NULL
at	NULL
different	NULL
times	NULL
from	NULL
different	NULL
stocks	NULL
of	NULL
retroviral	NULL
vectors	NULL
,	NULL
and	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
subtle	NULL
mutations	NULL
in	NULL
the	NULL
transduced	NULL
construct	NULL
or	NULL
in	NULL
the	NULL
cultured	NULL
hematopoietic	NULL
target	NULL
cells	NULL
could	NULL
account	NULL
for	NULL
the	NULL
observed	NULL
dramatic	NULL
differences	NULL
between	NULL
the	NULL
responses	NULL
of	NULL
MPRO	NULL
and	NULL
EML	NULL
cells	NULL
to	NULL
the	NULL
RXR	NULL
selective	NULL
compounds	NULL
.	NULL

To	NULL
address	NULL
this	NULL
possi-bility	NULL
,	NULL
we	NULL
exploited	NULL
our	NULL
previous	NULL
observation	NULL
that	NULL
GM-CSF-dependent	NULL
MPRO-like	NULL
promyelocytes	NULL
could	NULL
be	NULL
directly	NULL
derived	NULL
from	NULL
the	NULL
SCF-dependent	NULL
EML	NULL
cells	NULL
by	NULL
switching	NULL
the	NULL
hematopoietic	NULL
growth	NULL
factor	NULL
in	NULL
the	NULL
EML	NULL
culture	NULL
from	NULL
SCF	NULL
to	NULL
GM-CSF	NULL
(	NULL
54	NULL
)	NULL
.	NULL

As	NULL
detailed	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
,	NULL
we	NULL
derived	NULL
EML	NULL
subclones	NULL
that	NULL
were	NULL
GM-CSF	NULL
dependent	NULL
and	NULL
exhibited	NULL
the	NULL
morphological	NULL
appearance	NULL
of	NULL
MPRO	NULL
promyelocytes	NULL
.	NULL

These	NULL
EML	NULL
subclones	NULL
exhibited	NULL
responses	NULL
to	NULL
ATRA	NULL
and	NULL
the	NULL
RXR	NULL
selective	NULL
agonists	NULL
and	NULL
antagonists	NULL
that	NULL
were	NULL
virtually	NULL
identical	NULL
to	NULL
those	NULL
of	NULL
the	NULL
MPRO	NULL
cells	NULL
described	NULL
above	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
marked	NULL
differences	NULL
in	NULL
responses	NULL
to	NULL
the	NULL
RXR	NULL
agonist	NULL
that	NULL
we	NULL
have	NULL
observed	NULL
between	NULL
the	NULL
MPRO	NULL
and	NULL
the	NULL
3378	NULL
JOHNSON	NULL
ET	NULL
AL	NULL
.	NULL

5.00	NULL
.	NULL

2.00	NULL
|	NULL
1.00	NULL
Relative	NULL
Luciferase	NULL
Activity	NULL
10	NULL
r	NULL
os	NULL
40	NULL
s	NULL
0	NULL
%	NULL
or	NULL
os	NULL
O8	NULL
do	NULL
Gf	NULL
42	NULL
43	NULL
44	NULL
15	NULL
46	NULL
No	NULL
Retinoid	NULL
+	NULL
+	NULL
IL-3	NULL
+1	NULL
4	NULL
|	NULL
4	NULL
|	NULL
4	NULL
|	NULL
4	NULL
|	NULL
4	NULL
|	NULL
4	NULL
|	NULL
4	NULL
ATRA	NULL
(	NULL
10	NULL
uM	NULL
)	NULL
+	NULL
+	NULL
9-cis	NULL
RA	NULL
(	NULL
10	NULL
pM	NULL
)	NULL
+	NULL
+	NULL
RAR	NULL
Agonist	NULL
+	NULL
+	NULL
+	NULL
RXR	NULL
Agonist	NULL
+	NULL
|	NULL
+	NULL
+	NULL
+	NULL
+	NULL
RAR	NULL
Antagonist	NULL
+	NULL
+	NULL
RXR	NULL
Antagonist	NULL
+	NULL
+	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

2.00	NULL
1.00	NULL
|	NULL
Relative	NULL
Luciferase	NULL
Activity	NULL
0.00	NULL
No	NULL
Retinoid	NULL
+	NULL
+	NULL
IL-3	NULL
+	NULL
|	NULL
4	NULL
|	NULL
+	NULL
]	NULL
4	NULL
]	NULL
4	NULL
|	NULL
4	NULL
[	NULL
4	NULL
|	NULL
4	NULL
ATRA	NULL
(	NULL
10	NULL
uM	NULL
)	NULL
+	NULL
+	NULL
9-cis	NULL
RA	NULL
(	NULL
10	NULL
pM	NULL
)	NULL
+	NULL
+	NULL
RAR	NULL
Agonist	NULL
+	NULL
+	NULL
+	NULL
RXR	NULL
Agonist	NULL
+	NULL
|	NULL
+	NULL
+	NULL
RAR	NULL
Antagonist	NULL
+	NULL
+	NULL
RXR	NULL
Antagonist	NULL
+	NULL
+	NULL
FIG	NULL
.	NULL

6	NULL
.	NULL

Relative	NULL
activities	NULL
of	NULL
DR1	NULL
and	NULL
DR5	NULL
response	NULL
elements	NULL
in	NULL
IL-3-	NULL
and/or	NULL
retinoid-treated	NULL
EML	NULL
cells	NULL
.	NULL

Relative	NULL
luciferase	NULL
activity	NULL
was	NULL
determined	NULL
in	NULL
EML	NULL
cells	NULL
transfected	NULL
with	NULL
either	NULL
the	NULL
DR1	NULL
Luc	NULL
(	NULL
RXR-RXR	NULL
responsive	NULL
)	NULL
(	NULL
A	NULL
)	NULL
or	NULL
the	NULL
DR5	NULL
Luc	NULL
(	NULL
RXR-RAR	NULL
responsive	NULL
)	NULL
(	NULL
B	NULL
)	NULL
reporter	NULL
construct	NULL
and	NULL
treated	NULL
for	NULL
24	NULL
h	NULL
with	NULL
the	NULL
indicated	NULL
retinoid	NULL
and/or	NULL
IL-3	NULL
.	NULL

The	NULL
concentration	NULL
of	NULL
ATRA	NULL
and	NULL
9-cis-RA	NULL
utilized	NULL
was	NULL
10	NULL
M	NULL
,	NULL
while	NULL
that	NULL
of	NULL
the	NULL
other	NULL
retinoids	NULL
was	NULL
2.5	NULL
M.	NULL
Calculated	NULL
luciferase	NULL
activity	NULL
was	NULL
normalized	NULL
for	NULL
transfection	NULL
efficiency	NULL
with	NULL
the	NULL
cotransfected	NULL
growth	NULL
hormone	NULL
reporter	NULL
(	NULL
pCMVGH	NULL
)	NULL
as	NULL
an	NULL
internal	NULL
control	NULL
.	NULL

EML	NULL
cells	NULL
appear	NULL
to	NULL
be	NULL
developmentally	NULL
regulated	NULL
during	NULL
myeloid	NULL
differentiation	NULL
,	NULL
such	NULL
that	NULL
the	NULL
RXR	NULL
selective	NULL
agonist	NULL
is	NULL
active	NULL
in	NULL
the	NULL
committed	NULL
MPRO	NULL
promyelocytes	NULL
but	NULL
inactive	NULL
in	NULL
the	NULL
more	NULL
immature	NULL
,	NULL
uncommitted	NULL
EML	NULL
cells	NULL
.	NULL

Nuclear	NULL
hormone	NULL
receptor	NULL
coactivator	NULL
activity	NULL
in	NULL
EML	NULL
and	NULL
MPRO	NULL
cells	NULL
.	NULL

Our	NULL
observations	NULL
indicate	NULL
that	NULL
the	NULL
RXR-RARa403	NULL
heterodimer	NULL
is	NULL
readily	NULL
activated	NULL
in	NULL
one	NULL
cell	NULL
lineage	NULL
(	NULL
MPRO	NULL
promyelocytes	NULL
)	NULL
but	NULL
not	NULL
in	NULL
another	NULL
closely	NULL
related	NULL
though	NULL
distinct	NULL
lineage	NULL
(	NULL
multipotent	NULL
EML	NULL
cells	NULL
)	NULL
.	NULL

Since	NULL
nuclear	NULL
hormone	NULL
receptors	NULL
regulate	NULL
transcription	NULL
by	NULL
interacting	NULL
with	NULL
a	NULL
complex	NULL
array	NULL
of	NULL
coactivator	NULL
(	NULL
6	NULL
,	NULL
7	NULL
,	NULL
19	NULL
,	NULL
24	NULL
,	NULL
31	NULL
,	NULL
44	NULL
,	NULL
57	NULL
)	NULL
or	NULL
corepressor	NULL
(	NULL
8	NULL
,	NULL
25	NULL
,	NULL
33	NULL
,	NULL
38	NULL
)	NULL
proteins	NULL
,	NULL
our	NULL
observations	NULL
suggest	NULL
that	NULL
there	NULL
may	NULL
be	NULL
significant	NULL
differences	NULL
in	NULL
such	NULL
coactivators	NULL
or	NULL
corepressors	NULL
between	NULL
the	NULL
EML	NULL
and	NULL
MPRO	NULL
cells	NULL
.	NULL

We	NULL
first	NULL
compared	NULL
the	NULL
functional	NULL
activities	NULL
of	NULL
RAR	NULL
transcriptional	NULL
coactivators	NULL
in	NULL
these	NULL
different	NULL
cells	NULL
by	NULL
assessing	NULL
the	NULL
activity	NULL
of	NULL
an	NULL
RA-responsive	NULL
GAL	NULL
,	NULL
,	NULL
;	NULL
-RARa	NULL
hybrid	NULL
on	NULL
a	NULL
luciferase	NULL
reporter	NULL
harboring	NULL
five	NULL
GAL	NULL
binding	NULL
sites	NULL
[	NULL
p	NULL
(	NULL
UAS	NULL
)	NULL
s-	NULL
GL3	NULL
]	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
)	NULL
.	NULL

In	NULL
neither	NULL
EML	NULL
nor	NULL
MPRO	NULL
cells	NULL
does	NULL
this	NULL
GALq	NULL
,	NULL
,4-RARa	NULL
hybrid	NULL
significantly	NULL
repress	NULL
the	NULL
(	NULL
UAS	NULL
)	NULL
,	NULL
reporter	NULL
compared	NULL
with	NULL
the	NULL
GAL	NULL
,	NULL
,	NULL
construct	NULL
alone	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
,	NULL
compare	NULL
lane	NULL
1	NULL
with	NULL
lane	NULL
2	NULL
and	NULL
lane	NULL
6	NULL
with	NULL
lane	NULL
7	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
effect	NULL
of	NULL
ligand	NULL
on	NULL
this	NULL
hybrid	NULL
provides	NULL
a	NULL
relative	NULL
assessment	NULL
of	NULL
nuclear	NULL
hormone	NULL
receptor	NULL
transcriptional	NULL
coactivator	NULL
activity	NULL
in	NULL
these	NULL
different	NULL
cell	NULL
types	NULL
.	NULL

Surprisingly	NULL
,	NULL
we	NULL
noted	NULL
that	NULL
the	NULL
addition	NULL
of	NULL
RA	NULL
triggered	NULL
remarkably	NULL
more	NULL
activity	NULL
of	NULL
the	NULL
luciferase	NULL
reporter	NULL
in	NULL
the	NULL
EML	NULL
cells	NULL
than	NULL
in	NULL
the	NULL
MPRO	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
)	NULL
.	NULL

These	NULL
observations	NULL
,	NULL
indicating	NULL
that	NULL
there	NULL
is	NULL
abundant	NULL
functional	NULL
nuclear	NULL
hormone	NULL
receptor	NULL
coactivator	NULL
activity	NULL
in	NULL
EML	NULL
cells	NULL
,	NULL
suggest	NULL
that	NULL
the	NULL
difference	NULL
in	NULL
RXR-RARa403	NULL
activation	NULL
between	NULL
EML	NULL
and	NULL
MPRO	NULL
cells	NULL
can	NULL
not	NULL
be	NULL
accounted	NULL
for	NULL
by	NULL
a	NULL
relative	NULL
deficiency	NULL
of	NULL
coactivator	NULL
activity	NULL
in	NULL
the	NULL
pluripotent	NULL
EML	NULL
cells	NULL
.	NULL

Nuclear	NULL
hormone	NULL
receptor	NULL
corepressor	NULL
activity	NULL
in	NULL
EML	NULL
and	NULL
MPRO	NULL
cells	NULL
.	NULL

Transcriptional	NULL
repression	NULL
by	NULL
RA	NULL
receptors	NULL
may	NULL
in	NULL
part	NULL
be	NULL
mediated	NULL
by	NULL
specific	NULL
corepressors	NULL
such	NULL
as	NULL
N-CoR	NULL
and	NULL
SMRT	NULL
which	NULL
interact	NULL
with	NULL
nuclear	NULL
hormone	NULL
receptors	NULL
as	NULL
multicomponent	NULL
complexes	NULL
,	NULL
including	NULL
mSin3A	NULL
and	NULL
HDACs	NULL
(	NULL
8	NULL
,	NULL
21	NULL
,	NULL
25	NULL
,	NULL
43	NULL
)	NULL
.	NULL

To	NULL
compare	NULL
the	NULL
activities	NULL
of	NULL
such	NULL
HDAC-contain-	NULL
Luciferase	NULL
A	NULL
___	NULL
Pee	NULL
(	NULL
UAS	NULL
)	NULL
,	NULL
GL3	NULL
GAL	NULL
1-147	NULL
DBD	NULL
tas	NULL
163	NULL
198	NULL
403	NULL
ass	NULL
GAL	NULL
,	NULL
,	NULL
,	NULL
-RARa	NULL
Ligand	NULL
Binding	NULL
,	NULL
Dimerization	NULL
,	NULL
Activation	NULL
.	NULL

Fl	NULL
€	NULL
B	NULL
3	NULL
A	NULL
5	NULL
<	NULL
4	NULL
@	NULL
Pd	NULL
§	NULL
£	NULL
0	NULL
3	NULL
Pal	NULL
o	NULL
2	NULL
=	NULL
<	NULL
0	NULL
s	NULL
(	NULL
UAS	NULL
)	NULL
,	NULL
GL3	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+o	NULL
|	NULL
+	NULL
|	NULL
+	NULL
+	NULL
+	NULL
+	NULL
GALpep	NULL
+	NULL
+	NULL
GALpep-RAReo	NULL
:	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
4	NULL
ATRA	NULL
(	NULL
pM	NULL
)	NULL
.01	NULL
|	NULL
0.1	NULL
|	NULL
1.0	NULL
.01	NULL
|	NULL
0.1	NULL
|	NULL
1.0	NULL
EML	NULL
MPRO	NULL
FIG	NULL
.	NULL

7	NULL
.	NULL

RAR	NULL
coactivator	NULL
activity	NULL
in	NULL
EML	NULL
cells	NULL
compared	NULL
with	NULL
that	NULL
in	NULL
MPRO	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Schematic	NULL
illustrating	NULL
the	NULL
upstream	NULL
activation	NULL
sequence	NULL
(	NULL
UAS	NULL
)	NULL
luciferase	NULL
reporter	NULL
[	NULL
p	NULL
(	NULL
UAS	NULL
)	NULL
;	NULL
-GL3	NULL
]	NULL
and	NULL
the	NULL
construction	NULL
of	NULL
the	NULL
GALq	NULL
,	NULL
q-RARa	NULL
hybrid	NULL
.	NULL

(	NULL
B	NULL
)	NULL
The	NULL
EML	NULL
and	NULL
MPRO	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
20	NULL
pg	NULL
of	NULL
each	NULL
of	NULL
the	NULL
indicated	NULL
plasmids	NULL
and	NULL
then	NULL
cultured	NULL
for	NULL
24	NULL
h	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
different	NULL
concentrations	NULL
of	NULL
ATRA	NULL
.	NULL

Relative	NULL
luciferase	NULL
activity	NULL
was	NULL
then	NULL
determined	NULL
in	NULL
cell	NULL
lysates	NULL
.	NULL

Vor	NULL
.	NULL

19	NULL
,	NULL
1999	NULL
30	NULL
._	NULL
25	NULL
L	NULL
20	NULL
Relative	NULL
Luciferase	NULL
Activity	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
8	NULL
10	NULL
11	NULL
12	NULL
13	NULL
14	NULL
Tsa	NULL
o	NULL
|	NULL
3	NULL
|	NULL
e	NULL
|	NULL
12	NULL
|	NULL
2s	NULL
|	NULL
so	NULL
|100	NULL
]	NULL
o	NULL
|	NULL
3	NULL
|	NULL
6	NULL
|	NULL
12	NULL
|	NULL
2s	NULL
|	NULL
so	NULL
|	NULL
100	NULL
EML	NULL
MPRO	NULL
FIG	NULL
.	NULL

8	NULL
.	NULL

TSA	NULL
activates	NULL
the	NULL
DR5	NULL
(	NULL
RXR-RAR	NULL
)	NULL
reporter	NULL
in	NULL
EML	NULL
but	NULL
not	NULL
MPRO	NULL
cells	NULL
.	NULL

EML	NULL
and	NULL
MPRO	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
40	NULL
pg	NULL
of	NULL
the	NULL
DRS	NULL
Luc	NULL
(	NULL
RXR-RAR	NULL
responsive	NULL
)	NULL
reporter	NULL
construct	NULL
and	NULL
then	NULL
cultured	NULL
for	NULL
24	NULL
h	NULL
with	NULL
the	NULL
indicated	NULL
concentration	NULL
of	NULL
TSA	NULL
.	NULL

Relative	NULL
luciferase	NULL
activity	NULL
was	NULL
then	NULL
determined	NULL
in	NULL
cell	NULL
lysates	NULL
.	NULL

ing	NULL
repressor	NULL
complexes	NULL
in	NULL
EML	NULL
cells	NULL
with	NULL
those	NULL
in	NULL
MPRO	NULL
cells	NULL
,	NULL
we	NULL
assessed	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
HDAC	NULL
inhibitor	NULL
TSA	NULL
(	NULL
62	NULL
)	NULL
to	NULL
activate	NULL
the	NULL
DR5	NULL
(	NULL
RAR-RXR	NULL
)	NULL
reporter	NULL
in	NULL
these	NULL
different	NULL
cell	NULL
types	NULL
.	NULL

We	NULL
observed	NULL
that	NULL
TSA	NULL
readily	NULL
activated	NULL
this	NULL
reporter	NULL
in	NULL
EML	NULL
cells	NULL
but	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
activating	NULL
this	NULL
same	NULL
reporter	NULL
in	NULL
the	NULL
MPRO	NULL
cells	NULL
even	NULL
at	NULL
higher	NULL
concentrations	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
repression	NULL
of	NULL
DRS	NULL
appears	NULL
dependent	NULL
on	NULL
HDAC	NULL
activity	NULL
in	NULL
the	NULL
EML	NULL
but	NULL
not	NULL
the	NULL
MPRO	NULL
cells	NULL
,	NULL
indicating	NULL
that	NULL
there	NULL
are	NULL
significant	NULL
differences	NULL
in	NULL
transcriptional	NULL
repressor	NULL
complexes	NULL
in	NULL
these	NULL
different	NULL
cell	NULL
types	NULL
.	NULL

DISCUSSION	NULL
Our	NULL
present	NULL
observations	NULL
can	NULL
be	NULL
summarized	NULL
as	NULL
follows	NULL
.	NULL

(	NULL
i	NULL
)	NULL
In	NULL
MPRO	NULL
promyelocytes	NULL
,	NULL
which	NULL
overexpress	NULL
the	NULL
truncated	NULL
,	NULL
dominant-negative	NULL
RARa403	NULL
construct	NULL
,	NULL
an	NULL
RXR	NULL
rather	NULL
than	NULL
an	NULL
RAR	NULL
agonist	NULL
is	NULL
a	NULL
potent	NULL
inducer	NULL
of	NULL
granulocytic	NULL
differentiation	NULL
.	NULL

(	NULL
ii	NULL
)	NULL
This	NULL
RXR	NULL
agonist-induced	NULL
granulocytic	NULL
differentiation	NULL
is	NULL
associated	NULL
with	NULL
activation	NULL
of	NULL
RXR-RAR	NULL
rather	NULL
than	NULL
RXR-RXR	NULL
response	NULL
elements	NULL
(	NULL
Fig	NULL
.	NULL

9A	NULL
)	NULL
.	NULL

(	NULL
iii	NULL
)	NULL
The	NULL
same	NULL
RXR	NULL
agonist	NULL
exhibits	NULL
virtually	NULL
no	NULL
activity	NULL
in	NULL
the	NULL
more	NULL
immature	NULL
EML	NULL
cells	NULL
,	NULL
which	NULL
express	NULL
the	NULL
same	NULL
dominant-negative	NULL
RARa403	NULL
as	NULL
the	NULL
MPRO	NULL
promyelocytes	NULL
(	NULL
Fig	NULL
.	NULL

9C	NULL
)	NULL
.	NULL

(	NULL
iv	NULL
)	NULL
There	NULL
are	NULL
functionally	NULL
significant	NULL
differences	NULL
in	NULL
HDAC-containing	NULL
repressor	NULL
complexes	NULL
between	NULL
the	NULL
multipotent	NULL
EML	NULL
cells	NULL
and	NULL
the	NULL
committed	NULL
MPRO	NULL
promyelocytes	NULL
.	NULL

RA	NULL
receptors	NULL
and	NULL
myeloid	NULL
differentiation	NULL
.	NULL

The	NULL
important	NULL
role	NULL
that	NULL
RA	NULL
receptors	NULL
play	NULL
in	NULL
hematopoietic	NULL
differentiation	NULL
is	NULL
emphasized	NULL
by	NULL
our	NULL
previous	NULL
observation	NULL
that	NULL
overexpressing	NULL
a	NULL
truncated	NULL
RA	NULL
receptor	NULL
exhibiting	NULL
dominant-negative	NULL
activity	NULL
(	NULL
RARa403	NULL
)	NULL
in	NULL
normal	NULL
mouse	NULL
hematopoietic	NULL
progenitors	NULL
generates	NULL
hematopoietic	NULL
growth	NULL
factor-dependent	NULL
cell	NULL
lines	NULL
blocked	NULL
at	NULL
distinct	NULL
stages	NULL
of	NULL
myeloid	NULL
development	NULL
(	NULL
53	NULL
,	NULL
54	NULL
)	NULL
.	NULL

The	NULL
MPRO	NULL
cell	NULL
line	NULL
consists	NULL
of	NULL
GM-CSF-dependent	NULL
promyelocytes	NULL
and	NULL
is	NULL
firmly	NULL
committed	NULL
to	NULL
granulocyte	NULL
differentiation	NULL
(	NULL
53	NULL
)	NULL
,	NULL
while	NULL
the	NULL
SCF-dependent	NULL
EML	NULL
cells	NULL
are	NULL
multipotent	NULL
,	NULL
exhibiting	NULL
erythroid	NULL
,	NULL
lymphoid	NULL
,	NULL
and	NULL
myeloid	NULL
potential	NULL
(	NULL
54	NULL
)	NULL
.	NULL

Both	NULL
of	NULL
these	NULL
cell	NULL
lines	NULL
overexpress	NULL
the	NULL
C-terminally	NULL
truncated	NULL
dominant-negative	NULL
RARa403	NULL
,	NULL
which	NULL
lacks	NULL
the	NULL
C-terminal	NULL
activation	NULL
domain	NULL
(	NULL
AF2	NULL
)	NULL
but	NULL
retains	NULL
the	NULL
capacity	NULL
to	NULL
heterodimerize	NULL
with	NULL
RXRs	NULL
and	NULL
bind	NULL
to	NULL
RXR-RAR	NULL
response	NULL
elements	NULL
(	NULL
11	NULL
,	NULL
15	NULL
)	NULL
.	NULL

Utilizing	NULL
gel	NULL
shift	NULL
assays	NULL
,	NULL
we	NULL
observed	NULL
that	NULL
EML	NULL
and	NULL
MPRO	NULL
complex	NULL
formation	NULL
on	NULL
a	NULL
DRS	NULL
(	NULL
RXR-RAR	NULL
)	NULL
oligonucleotide	NULL
shifted	NULL
with	NULL
an	NULL
antibody	NULL
directed	NULL
against	NULL
the	NULL
amino	NULL
terminus	NULL
of	NULL
RA	NULL
RECEPTOR	NULL
ACTIVATION	NULL
IN	NULL
MYELOPOIESIS	NULL
-	NULL
3379	NULL
A	NULL
)	NULL
RXR	NULL
RARa	NULL
403	NULL
rxr	NULL
~	NULL
\-agonist	NULL
Promyelocyte	NULL
Transcriptional	NULL
Activation	NULL
{	NULL
/	NULL
V	NULL
\	NULL
--	NULL
I	NULL
]	NULL
5	NULL
bp	NULL
|	NULL
--	NULL
»	NULL
AGGTCA	NULL
AGGTCA	NULL
Granulocyte	NULL
DR-5	NULL
RARE	NULL
B	NULL
)	NULL
RXR	NULL
RARe	NULL
:	NULL
403	NULL
\_	NULL
exist	NULL
Promyelocyte	NULL
antagonist	NULL
v	NULL
ma	NULL
m	NULL
ma	NULL
mm	NULL
>	NULL
X	NULL
No	NULL
Activation	NULL
lﬂV/	NULL
5	NULL
bp	NULL
|	NULL
--	NULL
a	NULL
»	NULL
AGGTCA	NULL
AGGTCA	NULL
Granulocyte	NULL
DR-5	NULL
RARE	NULL
C	NULL
)	NULL
RXR	NULL
RARa	NULL
403	NULL
RXR	NULL
\	NULL
agonist	NULL
mm	NULL
mm	NULL
me	NULL
m	NULL
i	NULL
>	NULL
V	NULL
<	NULL
No	NULL
Activation	NULL
AAM	NULL
5	NULL
bp	NULL
|	NULL
--	NULL
»	NULL
AGGTCA	NULL
AGGTCA	NULL
DR-5	NULL
RARE	NULL
CFU-GM	NULL
FIG	NULL
.	NULL

9	NULL
.	NULL

Summary	NULL
of	NULL
RXR-RARad403	NULL
activation	NULL
in	NULL
MPRO	NULL
and	NULL
EML	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
The	NULL
RXR	NULL
agonist	NULL
selectively	NULL
activates	NULL
DR5	NULL
response	NULL
elements	NULL
and	NULL
induces	NULL
granulocytic	NULL
differentiation	NULL
of	NULL
MPRO	NULL
cells	NULL
.	NULL

(	NULL
B	NULL
)	NULL
In	NULL
MPRO	NULL
cells	NULL
,	NULL
this	NULL
RXR	NULL
agonist-induced	NULL
DRS	NULL
activation	NULL
and	NULL
differentiation	NULL
are	NULL
inhibited	NULL
by	NULL
an	NULL
RARa	NULL
antagonist	NULL
.	NULL

(	NULL
C	NULL
)	NULL
In	NULL
EML	NULL
cells	NULL
,	NULL
the	NULL
RXR	NULL
agonist	NULL
is	NULL
inactive	NULL
in	NULL
inducing	NULL
DR5	NULL
activation	NULL
.	NULL

RARE	NULL
,	NULL
RA	NULL
response	NULL
element	NULL
;	NULL
DBD	NULL
,	NULL
DNA-binding	NULL
domain	NULL
;	NULL
LBD	NULL
,	NULL
ligand-binding	NULL
domain	NULL
.	NULL

RARa	NULL
but	NULL
not	NULL
with	NULL
an	NULL
antibody	NULL
against	NULL
the	NULL
RARa	NULL
COOH	NULL
terminus	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
COOH-terminally	NULL
truncated	NULL
RARa	NULL
complexes	NULL
are	NULL
predominant	NULL
in	NULL
these	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

These	NULL
predominant	NULL
RXR-RARa403	NULL
heterodimers	NULL
present	NULL
in	NULL
EML	NULL
and	NULL
MPRO	NULL
cells	NULL
likely	NULL
interfere	NULL
with	NULL
normal	NULL
RXR-RAR	NULL
function	NULL
,	NULL
which	NULL
somehow	NULL
leads	NULL
to	NULL
the	NULL
block	NULL
in	NULL
hematopoietic	NULL
differentiation	NULL
that	NULL
characterizes	NULL
these	NULL
cells	NULL
.	NULL

However	NULL
,	NULL
this	NULL
block	NULL
is	NULL
not	NULL
absolute	NULL
because	NULL
relatively	NULL
high	NULL
,	NULL
pharmacological	NULL
concentrations	NULL
(	NULL
1	NULL
to	NULL
10	NULL
wM	NULL
)	NULL
of	NULL
ATRA	NULL
induce	NULL
terminal	NULL
granulocyte	NULL
differentiation	NULL
of	NULL
MPRO	NULL
cells	NULL
while	NULL
similar	NULL
ATRA	NULL
concentrations	NULL
potentiate	NULL
IL-3-mediated	NULL
CFU-GM	NULL
generation	NULL
in	NULL
the	NULL
EML	NULL
cells	NULL
(	NULL
53	NULL
,	NULL
54	NULL
)	NULL
.	NULL

The	NULL
question	NULL
addressed	NULL
in	NULL
the	NULL
present	NULL
study	NULL
was	NULL
how	NULL
such	NULL
pharmacological	NULL
concentrations	NULL
of	NULL
ATRA	NULL
might	NULL
activate	NULL
these	NULL
aberrant	NULL
RXR-RARa403	NULL
heterodimers	NULL
.	NULL

RXR	NULL
agonist-mediated	NULL
activation	NULL
of	NULL
RXR-RARa403	NULL
heterodimers	NULL
in	NULL
MPRO	NULL
cells	NULL
.	NULL

In	NULL
the	NULL
course	NULL
of	NULL
these	NULL
experiments	NULL
,	NULL
we	NULL
made	NULL
a	NULL
number	NULL
of	NULL
unexpected	NULL
observations	NULL
.	NULL

First	NULL
,	NULL
we	NULL
noted	NULL
that	NULL
an	NULL
RXR	NULL
agonist	NULL
(	NULL
AGN	NULL
194204	NULL
)	NULL
,	NULL
known	NULL
to	NULL
specifically	NULL
bind	NULL
to	NULL
RXRs	NULL
rather	NULL
than	NULL
to	NULL
RARs	NULL
,	NULL
exhibited	NULL
potent	NULL
induction	NULL
of	NULL
MPRO	NULL
granulocyte	NULL
terminal	NULL
differentiation	NULL
while	NULL
the	NULL
RAR	NULL
3380	NULL
JOHNSON	NULL
ET	NULL
AL	NULL
.	NULL

agonist	NULL
(	NULL
AGN	NULL
193695	NULL
)	NULL
exhibited	NULL
virtually	NULL
no	NULL
such	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
the	NULL
RXR	NULL
agonist	NULL
was	NULL
likely	NULL
mediated	NULL
through	NULL
activation	NULL
of	NULL
aberrant	NULL
RXR-RARa403	NULL
heterodimers	NULL
rather	NULL
than	NULL
any	NULL
residual	NULL
RXR-RXR	NULL
homodimers	NULL
,	NULL
because	NULL
in	NULL
MPRO	NULL
cells	NULL
the	NULL
RXR	NULL
-specific	NULL
agonist	NULL
consistently	NULL
activated	NULL
a	NULL
reporter	NULL
construct	NULL
harboring	NULL
DRS	NULL
(	NULL
RXR-RAR	NULL
)	NULL
response	NULL
elements	NULL
while	NULL
inducing	NULL
little	NULL
if	NULL
any	NULL
activation	NULL
of	NULL
a	NULL
similar	NULL
reporter	NULL
harboring	NULL
DR1	NULL
(	NULL
RXR-RXR	NULL
)	NULL
elements	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
it	NULL
is	NULL
very	NULL
unlikely	NULL
that	NULL
this	NULL
RXR	NULL
agonist-mediated	NULL
DR5	NULL
activation	NULL
is	NULL
triggered	NULL
through	NULL
normal	NULL
residual	NULL
wild-type	NULL
RXR-RAR	NULL
heterodimers	NULL
,	NULL
because	NULL
previous	NULL
studies	NULL
have	NULL
indicated	NULL
that	NULL
there	NULL
is	NULL
an	NULL
allosteric	NULL
block	NULL
that	NULL
inhibits	NULL
binding	NULL
of	NULL
RXR-specific	NULL
agonists	NULL
to	NULL
the	NULL
RXR	NULL
partner	NULL
of	NULL
normal	NULL
RXR-RAR	NULL
heterodimers	NULL
(	NULL
32	NULL
,	NULL
37	NULL
)	NULL
.	NULL

Consistent	NULL
with	NULL
this	NULL
,	NULL
we	NULL
have	NULL
noted	NULL
in	NULL
our	NULL
screening	NULL
assays	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
that	NULL
the	NULL
RXR	NULL
agonist	NULL
utilized	NULL
in	NULL
our	NULL
studies	NULL
(	NULL
AGN	NULL
194204	NULL
)	NULL
specifically	NULL
activated	NULL
RXR-RXR	NULL
response	NULL
elements	NULL
and	NULL
exhibited	NULL
no	NULL
activation	NULL
of	NULL
normal	NULL
RXR-RAR	NULL
heterodimers	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
RXR	NULL
agonist-mediated	NULL
activation	NULL
of	NULL
the	NULL
RXR-RARa403	NULL
heterodimers	NULL
in	NULL
MPRO	NULL
cells	NULL
suggests	NULL
that	NULL
the	NULL
conformation	NULL
of	NULL
the	NULL
RXR-RARa403	NULL
heterodimer	NULL
must	NULL
differ	NULL
significantly	NULL
from	NULL
that	NULL
of	NULL
the	NULL
normal	NULL
RXR-RAR	NULL
heterodimer	NULL
to	NULL
allow	NULL
binding	NULL
of	NULL
the	NULL
RXR-specific	NULL
retinoid	NULL
to	NULL
the	NULL
RXR	NULL
partner	NULL
with	NULL
consequent	NULL
activation	NULL
of	NULL
the	NULL
RXR-RARa403	NULL
heterodimer	NULL
.	NULL

Indeed	NULL
,	NULL
recent	NULL
in	NULL
vitro	NULL
binding	NULL
studies	NULL
indicate	NULL
that	NULL
RXR-specific	NULL
li-gands	NULL
preferentially	NULL
trigger	NULL
recruitment	NULL
of	NULL
coactivators	NULL
to	NULL
RXR-RARa403	NULL
heterodimers	NULL
compared	NULL
with	NULL
wild-type	NULL
RXR-RAR	NULL
heterodimers	NULL
,	NULL
indicating	NULL
an	NULL
important	NULL
role	NULL
for	NULL
the	NULL
RARa	NULL
«	NULL
C-terminal	NULL
AF2	NULL
domain	NULL
(	NULL
the	NULL
domain	NULL
that	NULL
has	NULL
been	NULL
truncated	NULL
in	NULL
the	NULL
RAR	NULL
«	NULL
403	NULL
construct	NULL
)	NULL
in	NULL
inhibiting	NULL
RXR	NULL
li-gand-specific	NULL
activation	NULL
of	NULL
RXR-RAR	NULL
complexes	NULL
(	NULL
60	NULL
)	NULL
.	NULL

In	NULL
this	NULL
respect	NULL
,	NULL
the	NULL
behavior	NULL
of	NULL
the	NULL
aberrant	NULL
RXR-RARa403	NULL
heterodimer	NULL
mimics	NULL
that	NULL
of	NULL
other	NULL
RXR	NULL
heterodimers	NULL
which	NULL
are	NULL
activated	NULL
by	NULL
RXR-specific	NULL
agonists	NULL
,	NULL
including	NULL
RXR-Nurrl	NULL
(	NULL
16	NULL
)	NULL
,	NULL
RXR-LXR	NULL
(	NULL
61	NULL
)	NULL
,	NULL
and	NULL
RXR-PPAR	NULL
(	NULL
14	NULL
)	NULL
complexes	NULL
.	NULL

Cross-talk	NULL
between	NULL
partners	NULL
of	NULL
the	NULL
RXR-RARa403	NULL
heterodimer	NULL
.	NULL

Curiously	NULL
,	NULL
we	NULL
observed	NULL
that	NULL
in	NULL
MPRO	NULL
cells	NULL
the	NULL
RARa	NULL
antagonist	NULL
inhibited	NULL
the	NULL
RXR	NULL
agonist-induced	NULL
differentiation	NULL
of	NULL
MPRO	NULL
as	NULL
well	NULL
as	NULL
the	NULL
RXR	NULL
agonist-induced	NULL
transactivation	NULL
of	NULL
the	NULL
DRS	NULL
element	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

This	NULL
was	NULL
unexpected	NULL
because	NULL
the	NULL
RARa	NULL
«	NULL
antagonist	NULL
has	NULL
virtually	NULL
no	NULL
affinity	NULL
for	NULL
RXRs	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
and	NULL
thus	NULL
can	NULL
not	NULL
interfere	NULL
with	NULL
the	NULL
RXR	NULL
agonist-induced	NULL
activation	NULL
by	NULL
competitively	NULL
binding	NULL
to	NULL
the	NULL
RXR	NULL
ligand-binding	NULL
domain	NULL
.	NULL

Instead	NULL
,	NULL
this	NULL
observation	NULL
suggests	NULL
that	NULL
there	NULL
is	NULL
considerable	NULL
cross-talk	NULL
between	NULL
the	NULL
RXR	NULL
and	NULL
RARa403	NULL
partners	NULL
such	NULL
that	NULL
RXR	NULL
agonist-induced	NULL
conformational	NULL
changes	NULL
might	NULL
trigger	NULL
activation	NULL
of	NULL
the	NULL
complex	NULL
through	NULL
the	NULL
RAR	NULL
partner	NULL
.	NULL

Such	NULL
communication	NULL
between	NULL
heterodimeric	NULL
partners	NULL
has	NULL
been	NULL
previously	NULL
observed	NULL
for	NULL
RXR-LXR	NULL
heterodimers	NULL
,	NULL
where	NULL
9-cis-RA	NULL
binding	NULL
to	NULL
the	NULL
RXR	NULL
partner	NULL
triggers	NULL
transcriptional	NULL
activation	NULL
that	NULL
is	NULL
mediated	NULL
through	NULL
the	NULL
LXR	NULL
AF2	NULL
domain	NULL
(	NULL
61	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
binding	NULL
of	NULL
the	NULL
RXR	NULL
antagonist	NULL
LG10074	NULL
(	NULL
35	NULL
)	NULL
to	NULL
the	NULL
RXR	NULL
subunit	NULL
of	NULL
RXR-RAR	NULL
heterodimers	NULL
triggers	NULL
activation	NULL
of	NULL
the	NULL
complex	NULL
by	NULL
inducing	NULL
conformational	NULL
changes	NULL
in	NULL
the	NULL
RAR	NULL
partner	NULL
,	NULL
a	NULL
phenomenon	NULL
termed	NULL
the	NULL
``	NULL
phantom	NULL
ligand	NULL
``	NULL
effect	NULL
(	NULL
49	NULL
)	NULL
.	NULL

Our	NULL
observation	NULL
for	NULL
MPRO	NULL
cells	NULL
that	NULL
an	NULL
RARa	NULL
antagonist	NULL
blocks	NULL
RXR	NULL
agonist-induced	NULL
granulocyte	NULL
differentiation	NULL
and	NULL
DRS	NULL
(	NULL
RXR-RARa	NULL
)	NULL
activation	NULL
suggests	NULL
that	NULL
similar	NULL
cross-talk	NULL
mechanisms	NULL
are	NULL
also	NULL
involved	NULL
in	NULL
activation	NULL
of	NULL
the	NULL
RXR-RARa403	NULL
complex	NULL
in	NULL
MPRO	NULL
cells	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
occupation	NULL
of	NULL
the	NULL
RARa403	NULL
ligand-binding	NULL
domain	NULL
by	NULL
the	NULL
RARa	NULL
antagonist	NULL
might	NULL
interfere	NULL
with	NULL
RXR	NULL
agonist-induced	NULL
conformational	NULL
changes	NULL
that	NULL
trigger	NULL
activation	NULL
of	NULL
the	NULL
complex	NULL
through	NULL
the	NULL
RAR	NULL
partner	NULL
.	NULL

Alternatively	NULL
,	NULL
conformational	NULL
changes	NULL
in	NULL
the	NULL
RARa403	NULL
partner	NULL
resulting	NULL
from	NULL
binding	NULL
to	NULL
the	NULL
RARa	NULL
antagonist	NULL
might	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

interfere	NULL
with	NULL
RXR	NULL
agonist	NULL
binding	NULL
to	NULL
the	NULL
RXR	NULL
partner	NULL
.	NULL

In	NULL
either	NULL
case	NULL
,	NULL
the	NULL
inhibition	NULL
of	NULL
RXR	NULL
agonist	NULL
activity	NULL
by	NULL
the	NULL
RARa	NULL
antagonist	NULL
suggests	NULL
considerable	NULL
cross-talk	NULL
between	NULL
the	NULL
individual	NULL
partners	NULL
of	NULL
the	NULL
RXR-RARa403	NULL
heterodimer	NULL
(	NULL
Fig	NULL
.	NULL

9B	NULL
)	NULL
.	NULL

l	NULL
)	NULL
3	NULL
]	NULL
unted	NULL
activation	NULL
of	NULL
the	NULL
RXR-RARa	NULL
«	NULL
403	NULL
heterodimer	NULL
in	NULL
the	NULL
more	NULL
immature	NULL
EML	NULL
cells	NULL
.	NULL

Another	NULL
unexpected	NULL
observation	NULL
was	NULL
the	NULL
relative	NULL
lack	NULL
of	NULL
activity	NULL
of	NULL
the	NULL
RXR	NULL
agonist	NULL
in	NULL
activating	NULL
the	NULL
DRS	NULL
(	NULL
RXR-RAR	NULL
)	NULL
reporter	NULL
in	NULL
the	NULL
multipotent	NULL
EML	NULL
cells	NULL
,	NULL
which	NULL
harbor	NULL
the	NULL
same	NULL
RXR-RARa403	NULL
complex	NULL
as	NULL
the	NULL
MPRO	NULL
promyelocytes	NULL
.	NULL

Nevertheless	NULL
,	NULL
from	NULL
these	NULL
multipotent	NULL
EML	NULL
cells	NULL
we	NULL
have	NULL
repeatedly	NULL
established	NULL
cultures	NULL
of	NULL
MPRO-like	NULL
promyelocytes	NULL
which	NULL
readily	NULL
exhibit	NULL
,	NULL
unlike	NULL
the	NULL
parental	NULL
EML	NULL
cells	NULL
,	NULL
RXR	NULL
agonist-induced	NULL
activation	NULL
of	NULL
the	NULL
DRS	NULL
(	NULL
RXR-RAR	NULL
)	NULL
reporter	NULL
.	NULL

Why	NULL
would	NULL
the	NULL
RXR-RARa403	NULL
complex	NULL
be	NULL
readily	NULL
activated	NULL
in	NULL
one	NULL
cell	NULL
lineage	NULL
(	NULL
MPRO	NULL
promyelocytes	NULL
)	NULL
but	NULL
not	NULL
in	NULL
another	NULL
closely	NULL
related	NULL
though	NULL
distinct	NULL
lineage	NULL
(	NULL
multipotent	NULL
EML	NULL
cells	NULL
)	NULL
?	NULL

To	NULL
address	NULL
this	NULL
question	NULL
,	NULL
we	NULL
assessed	NULL
nuclear	NULL
hormone	NULL
receptor	NULL
coactivator	NULL
and	NULL
corepressor	NULL
function	NULL
in	NULL
these	NULL
two	NULL
cell	NULL
types	NULL
.	NULL

Utilizing	NULL
an	NULL
RA-inducible	NULL
GAL	NULL
,	NULL
;	NULL
hybrid	NULL
,	NULL
we	NULL
observed	NULL
no	NULL
functional	NULL
deficiency	NULL
of	NULL
hormone	NULL
receptor	NULL
coactivator	NULL
activity	NULL
in	NULL
EML	NULL
cells	NULL
compared	NULL
with	NULL
activity	NULL
in	NULL
MPRO	NULL
cells	NULL
.	NULL

Indeed	NULL
,	NULL
in	NULL
EML	NULL
cells	NULL
the	NULL
(	NULL
UAS	NULL
)	NULL
,	NULL
reporter	NULL
unexpectedly	NULL
exhibited	NULL
an	NULL
enhanced	NULL
response	NULL
to	NULL
ligand-induced	NULL
activation	NULL
of	NULL
the	NULL
hybrid	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
our	NULL
observations	NULL
suggest	NULL
that	NULL
differences	NULL
in	NULL
corepressor	NULL
activity	NULL
more	NULL
likely	NULL
account	NULL
for	NULL
the	NULL
differential	NULL
activation	NULL
of	NULL
DRS	NULL
between	NULL
EML	NULL
and	NULL
MPRO	NULL
cells	NULL
.	NULL

Transcriptional	NULL
repression	NULL
by	NULL
RA	NULL
receptors	NULL
involves	NULL
interaction	NULL
with	NULL
multiprotein	NULL
complexes	NULL
that	NULL
include	NULL
N-CoR	NULL
,	NULL
SMRT	NULL
,	NULL
mSin3A	NULL
,	NULL
and	NULL
HDACs	NULL
(	NULL
8	NULL
,	NULL
21	NULL
,	NULL
25	NULL
,	NULL
43	NULL
)	NULL
.	NULL

Our	NULL
observation	NULL
that	NULL
the	NULL
HDAC	NULL
inhibitor	NULL
TSA	NULL
readily	NULL
activates	NULL
(	NULL
derepresses	NULL
)	NULL
the	NULL
DRS	NULL
reporter	NULL
in	NULL
EML	NULL
but	NULL
not	NULL
in	NULL
MPRO	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
suggests	NULL
that	NULL
there	NULL
are	NULL
functionally	NULL
significant	NULL
differences	NULL
in	NULL
repressor	NULL
complexes	NULL
harboring	NULL
HDAC	NULL
activity	NULL
in	NULL
these	NULL
different	NULL
hematopoietic	NULL
lineages	NULL
.	NULL

Indeed	NULL
,	NULL
recent	NULL
biochemical	NULL
evidence	NULL
suggests	NULL
that	NULL
mul-tiple	NULL
,	NULL
functionally	NULL
distinct	NULL
HDAC	NULL
complexes	NULL
may	NULL
indeed	NULL
exist	NULL
in	NULL
vivo	NULL
(	NULL
34	NULL
,	NULL
63	NULL
)	NULL
.	NULL

The	NULL
specific	NULL
compositions	NULL
of	NULL
such	NULL
repressor	NULL
complexes	NULL
in	NULL
EML	NULL
compared	NULL
with	NULL
those	NULL
in	NULL
MPRO	NULL
cells	NULL
is	NULL
presently	NULL
unknown	NULL
,	NULL
but	NULL
determining	NULL
the	NULL
nature	NULL
of	NULL
such	NULL
complexes	NULL
in	NULL
these	NULL
different	NULL
cell	NULL
types	NULL
will	NULL
likely	NULL
be	NULL
critical	NULL
in	NULL
determining	NULL
the	NULL
molecular	NULL
basis	NULL
for	NULL
the	NULL
difference	NULL
in	NULL
RA	NULL
receptor	NULL
activity	NULL
that	NULL
we	NULL
have	NULL
observed	NULL
in	NULL
these	NULL
distinct	NULL
stages	NULL
of	NULL
myeloid	NULL
development	NULL
.	NULL

RA	NULL
receptor	NULL
activity	NULL
in	NULL
normal	NULL
and	NULL
malignant	NULL
hematopoie-sis	NULL
.	NULL

RA	NULL
as	NULL
a	NULL
differentiating	NULL
agent	NULL
induces	NULL
complete	NULL
remissions	NULL
in	NULL
human	NULL
APL	NULL
(	NULL
5	NULL
,	NULL
26	NULL
,	NULL
59	NULL
)	NULL
but	NULL
is	NULL
generally	NULL
inactive	NULL
in	NULL
other	NULL
subtypes	NULL
of	NULL
acute	NULL
myelogenous	NULL
leukemia	NULL
(	NULL
4	NULL
,	NULL
42	NULL
)	NULL
.	NULL

Such	NULL
clinical	NULL
observations	NULL
are	NULL
indeed	NULL
paradoxical	NULL
because	NULL
the	NULL
RA-responsive	NULL
leukemias	NULL
harbor	NULL
the	NULL
aberrant	NULL
PML-RARa	NULL
fusion	NULL
gene	NULL
(	NULL
2	NULL
,	NULL
13	NULL
,	NULL
29	NULL
)	NULL
while	NULL
the	NULL
RA-resistant	NULL
leukemias	NULL
express	NULL
normal	NULL
RA	NULL
receptors	NULL
(	NULL
42	NULL
)	NULL
.	NULL

The	NULL
PML-RARa	NULL
«	NULL
fusion	NULL
protein	NULL
appears	NULL
to	NULL
inhibit	NULL
normal	NULL
RA	NULL
receptor	NULL
function	NULL
by	NULL
selectively	NULL
recruiting	NULL
corepressors	NULL
to	NULL
RAR	NULL
target	NULL
gene	NULL
promoters	NULL
(	NULL
18	NULL
,	NULL
20	NULL
,	NULL
39	NULL
)	NULL
and	NULL
thus	NULL
likely	NULL
mediates	NULL
transformation	NULL
,	NULL
at	NULL
least	NULL
in	NULL
part	NULL
,	NULL
by	NULL
inhibiting	NULL
normal	NULL
RA	NULL
receptors	NULL
.	NULL

The	NULL
specific	NULL
presence	NULL
of	NULL
this	NULL
aberrant	NULL
fusion	NULL
protein	NULL
in	NULL
malignant	NULL
promyelocytes	NULL
rather	NULL
than	NULL
in	NULL
leukemias	NULL
of	NULL
a	NULL
more	NULL
immature	NULL
lineage	NULL
suggests	NULL
that	NULL
inhibition	NULL
of	NULL
RA	NULL
receptor	NULL
activity	NULL
is	NULL
an	NULL
important	NULL
event	NULL
in	NULL
the	NULL
transformation	NULL
of	NULL
normal	NULL
promyelocytes	NULL
but	NULL
that	NULL
it	NULL
has	NULL
little	NULL
effect	NULL
in	NULL
mediating	NULL
transformation	NULL
of	NULL
other	NULL
more	NULL
immature	NULL
hematopoietic	NULL
cells	NULL
.	NULL

Our	NULL
observation	NULL
that	NULL
DR5	NULL
(	NULL
RXR-RAR	NULL
)	NULL
is	NULL
readily	NULL
activated	NULL
by	NULL
certain	NULL
retinoids	NULL
in	NULL
committed	NULL
promyelocytes	NULL
(	NULL
MPRO	NULL
)	NULL
but	NULL
not	NULL
in	NULL
more	NULL
immature	NULL
multipotent	NULL
hematopoietic	NULL
cells	NULL
(	NULL
EML	NULL
)	NULL
may	NULL
be	NULL
related	NULL
to	NULL
this	NULL
differential	NULL
response	NULL
of	NULL
human	NULL
leukemia	NULL
cells	NULL
to	NULL
RA	NULL
.	NULL

The	NULL
murine	NULL
MPRO	NULL
cells	NULL
closely	NULL
Vor	NULL
.	NULL

19	NULL
,	NULL
1999	NULL
resemble	NULL
human	NULL
promyelocytic	NULL
leukemia	NULL
cells	NULL
in	NULL
their	NULL
block	NULL
to	NULL
differentiation	NULL
at	NULL
the	NULL
promyelocytic	NULL
stage	NULL
and	NULL
the	NULL
terminal	NULL
granulocytic	NULL
differentiation	NULL
that	NULL
they	NULL
display	NULL
in	NULL
response	NULL
to	NULL
RA	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
multipotent	NULL
,	NULL
more	NULL
primitive	NULL
EML	NULL
cells	NULL
resemble	NULL
cells	NULL
from	NULL
those	NULL
other	NULL
cases	NULL
of	NULL
myelogenous	NULL
leukemia	NULL
that	NULL
are	NULL
generally	NULL
less	NULL
well	NULL
differentiated	NULL
than	NULL
promyelocytic	NULL
leukemia	NULL
cells	NULL
and	NULL
which	NULL
exhibit	NULL
little	NULL
if	NULL
any	NULL
therapeutic	NULL
response	NULL
to	NULL
RA	NULL
.	NULL

Thus	NULL
,	NULL
determining	NULL
the	NULL
molecular	NULL
basis	NULL
for	NULL
the	NULL
marked	NULL
difference	NULL
in	NULL
retinoid-mediated	NULL
activation	NULL
of	NULL
the	NULL
RXR-RARa403	NULL
heterodimer	NULL
between	NULL
the	NULL
MPRO	NULL
promyelocytes	NULL
and	NULL
the	NULL
more	NULL
undifferentiated	NULL
EML	NULL
cells	NULL
may	NULL
have	NULL
direct	NULL
relevance	NULL
to	NULL
the	NULL
question	NULL
of	NULL
why	NULL
RA	NULL
is	NULL
an	NULL
effective	NULL
differentiating	NULL
agent	NULL
in	NULL
one	NULL
form	NULL
of	NULL
human	NULL
myelogenous	NULL
leukemia	NULL
but	NULL
not	NULL
in	NULL
others	NULL
.	NULL

Our	NULL
observations	NULL
suggest	NULL
that	NULL
such	NULL
a	NULL
molecular	NULL
analysis	NULL
should	NULL
emphasize	NULL
potential	NULL
differences	NULL
in	NULL
HDAC-containing	NULL
repressor	NULL
complexes	NULL
that	NULL
might	NULL
exist	NULL
among	NULL
leukemias	NULL
of	NULL
different	NULL
hematopoietic	NULL
lineages	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
thank	NULL
Grant	NULL
McArthur	NULL
and	NULL
Bob	NULL
Eisenman	NULL
for	NULL
a	NULL
critical	NULL
reading	NULL
of	NULL
the	NULL
manuscript	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
NIH	NULL
grant	NULL
CA58292	NULL
to	NULL
S.J.C	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Agura	NULL
,	NULL
E.	NULL
,	NULL
M.	NULL
Howard	NULL
,	NULL
and	NULL
S.	NULL
J.	NULL
Collins	NULL
.	NULL

1992	NULL
.	NULL

Identification	NULL
and	NULL
sequence	NULL
analysis	NULL
of	NULL
the	NULL
promoter	NULL
for	NULL
the	NULL
leukocyte	NULL
integrin	NULL
beta	NULL
subunit	NULL
(	NULL
CD18	NULL
)	NULL
:	NULL
a	NULL
retinoic	NULL
acid-inducible	NULL
gene	NULL
.	NULL

Blood	NULL
79:602-609	NULL
.	NULL

2	NULL
.	NULL

Alcalay	NULL
,	NULL
M.	NULL
,	NULL
D.	NULL
Zangrilli	NULL
,	NULL
P.	NULL
Pandolfi	NULL
,	NULL
L.	NULL
Longo	NULL
,	NULL
A.	NULL
Mencarelli	NULL
,	NULL
A.	NULL
Giaco-mucci	NULL
,	NULL
M.	NULL
Rocchi	NULL
,	NULL
A.	NULL
Biondi	NULL
,	NULL
A.	NULL
Rambaldi	NULL
,	NULL
F.	NULL
LoCoco	NULL
,	NULL
D.	NULL
Diverioi	NULL
,	NULL
E.	NULL
Donti	NULL
,	NULL
F.	NULL
Grignani	NULL
,	NULL
and	NULL
P.	NULL
Pelicci	NULL
.	NULL

1991	NULL
.	NULL

Translocation	NULL
breakpoint	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
lies	NULL
within	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor	NULL
a	NULL
locus	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88:1977-1981	NULL
.	NULL

3	NULL
.	NULL

Allegretto	NULL
,	NULL
E.	NULL
,	NULL
M.	NULL
R.	NULL
McClurg	NULL
,	NULL
S.	NULL
B.	NULL
Lazarchik	NULL
,	NULL
D.	NULL
L.	NULL
Clemm	NULL
,	NULL
S.	NULL
A.	NULL
Kerner	NULL
,	NULL
M.	NULL
G.	NULL
Elgort	NULL
,	NULL
M.	NULL
F.	NULL
Boehm	NULL
,	NULL
S.	NULL
K.	NULL
White	NULL
,	NULL
J.	NULL
W.	NULL
Pike	NULL
,	NULL
and	NULL
R.	NULL
A.	NULL
Heyman	NULL
.	NULL

1993	NULL
.	NULL

Transactivation	NULL
properties	NULL
of	NULL
retinoic	NULL
acid	NULL
and	NULL
retinoid	NULL
X	NULL
receptors	NULL
in	NULL
mammalian	NULL
cells	NULL
and	NULL
yeast	NULL
:	NULL
correlation	NULL
with	NULL
hormone	NULL
binding	NULL
and	NULL
effects	NULL
of	NULL
metabolism	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268:26625-26633	NULL
.	NULL

4	NULL
.	NULL

Breitman	NULL
,	NULL
T.	NULL
,	NULL
S.	NULL
J.	NULL
Collins	NULL
,	NULL
and	NULL
B.	NULL
Keene	NULL
.	NULL

1981	NULL
.	NULL

Terminal	NULL
differentiation	NULL
of	NULL
human	NULL
promyelocytic	NULL
leukemia	NULL
cells	NULL
in	NULL
primary	NULL
culture	NULL
in	NULL
response	NULL
to	NULL
retinoic	NULL
acid	NULL
.	NULL

Blood	NULL
57:1000-1004	NULL
.	NULL

5	NULL
.	NULL

Castaigne	NULL
,	NULL
S.	NULL
,	NULL
C.	NULL
Chomienne	NULL
,	NULL
M.	NULL
Daniel	NULL
,	NULL
N.	NULL
Berger	NULL
,	NULL
P.	NULL
Fenaux	NULL
,	NULL
and	NULL
L.	NULL
Degos	NULL
.	NULL

1990	NULL
.	NULL

All-trans	NULL
retinoic	NULL
acid	NULL
as	NULL
a	NULL
differentiation	NULL
therapy	NULL
for	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

I	NULL
.	NULL

Clinical	NULL
results	NULL
.	NULL

Blood	NULL
76:1704-1712	NULL
.	NULL

6	NULL
.	NULL

Cavailles	NULL
,	NULL
V.	NULL
,	NULL
S.	NULL
Dauvois	NULL
,	NULL
F.	NULL
L'Horset	NULL
,	NULL
G.	NULL
Lopez	NULL
,	NULL
S.	NULL
Hoare	NULL
,	NULL
P.	NULL
Kushner	NULL
,	NULL
and	NULL
M.	NULL
Parker	NULL
.	NULL

1995	NULL
.	NULL

Nuclear	NULL
factor	NULL
RIP140	NULL
modulates	NULL
transcriptional	NULL
activation	NULL
by	NULL
the	NULL
estrogen	NULL
receptor	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

14:3741-3751	NULL
.	NULL

7	NULL
.	NULL

Chen	NULL
,	NULL
H.	NULL
,	NULL
R.	NULL
J.	NULL
Lin	NULL
,	NULL
R.	NULL
L.	NULL
Schiltz	NULL
,	NULL
D.	NULL
Chakravarti	NULL
,	NULL
A.	NULL
Nash	NULL
,	NULL
L.	NULL
Nagy	NULL
,	NULL
M.	NULL
L.	NULL
Privalsky	NULL
,	NULL
Y.	NULL
Nakatani	NULL
,	NULL
and	NULL
R.	NULL
Evans	NULL
.	NULL

1997	NULL
.	NULL

Nuclear	NULL
receptor	NULL
coactivator	NULL
ACTR	NULL
is	NULL
a	NULL
novel	NULL
histone	NULL
acetyltransferase	NULL
and	NULL
forms	NULL
a	NULL
multimeric	NULL
activation	NULL
complex	NULL
with	NULL
P/CAF	NULL
and	NULL
CBP/p300	NULL
.	NULL

Cell	NULL
90:569-580	NULL
.	NULL

8	NULL
.	NULL

Chen	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
and	NULL
R.	NULL
Evans	NULL
.	NULL

1995	NULL
.	NULL

A	NULL
transcriptional	NULL
co-repressor	NULL
that	NULL
interacts	NULL
with	NULL
nuclear	NULL
hormone	NULL
receptors	NULL
.	NULL

Nature	NULL
377:454-457	NULL
.	NULL

9	NULL
.	NULL

Collins	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
K.	NULL
A.	NULL
Robertson	NULL
,	NULL
and	NULL
L.	NULL
Mueller	NULL
.	NULL

1990	NULL
.	NULL

Retinoic	NULL
acid-induced	NULL
granulocytic	NULL
differentiation	NULL
of	NULL
HL-60	NULL
myeloid	NULL
leukemia	NULL
cells	NULL
is	NULL
mediated	NULL
directly	NULL
through	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor	NULL
(	NULL
RAR-a	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

10	NULL
:	NULL
2154-2163	NULL
.	NULL

10	NULL
.	NULL

Costa	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
and	NULL
M.	NULL
W.	NULL
McBurney	NULL
.	NULL

1996	NULL
.	NULL

Dominant	NULL
negative	NULL
mutant	NULL
of	NULL
retinoic	NULL
acid	NULL
receptor-a	NULL
inhibits	NULL
retinoic	NULL
acid-induced	NULL
P19	NULL
cell	NULL
differentiation	NULL
by	NULL
binding	NULL
to	NULL
DNA	NULL
.	NULL

Exp	NULL
.	NULL

Cell	NULL
Res	NULL
.	NULL

225:35-43	NULL
.	NULL

11	NULL
.	NULL

Damm	NULL
,	NULL
K.	NULL
,	NULL
R.	NULL
A.	NULL
Heyman	NULL
,	NULL
K.	NULL
Umesono	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Evans	NULL
.	NULL

1993	NULL
.	NULL

Functional	NULL
inhibition	NULL
of	NULL
retinoic	NULL
acid	NULL
response	NULL
by	NULL
dominant	NULL
negative	NULL
retinoic	NULL
acid	NULL
receptor	NULL
mutants	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90:2989-2993	NULL
.	NULL

12.	NULL
de	NULL
The	NULL
,	NULL
H.	NULL
,	NULL
A.	NULL
Marchio	NULL
,	NULL
P.	NULL
Tiollais	NULL
,	NULL
and	NULL
A.	NULL
Dejean	NULL
.	NULL

1989	NULL
.	NULL

Differential	NULL
expression	NULL
and	NULL
ligand	NULL
regulation	NULL
of	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor	NULL
alpha	NULL
and	NULL
beta	NULL
genes	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

8:429-439	NULL
.	NULL

13.	NULL
de	NULL
The	NULL
,	NULL
H.	NULL
,	NULL
C.	NULL
Layfau	NULL
,	NULL
A.	NULL
Marchio	NULL
,	NULL
C.	NULL
Chomienne	NULL
,	NULL
L.	NULL
Degos	NULL
,	NULL
and	NULL
A.	NULL
Dejean	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
PML-RARa	NULL
fusion	NULL
mRNA	NULL
generated	NULL
by	NULL
the	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
translocation	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
encodes	NULL
a	NULL
functionally	NULL
altered	NULL
RAR	NULL
.	NULL

Cell	NULL
66:675-684	NULL
.	NULL

14	NULL
.	NULL

DiRenzo	NULL
,	NULL
J.	NULL
,	NULL
M.	NULL
Soderstrom	NULL
,	NULL
R.	NULL
Kurokawa	NULL
,	NULL
M.-H.	NULL
Ogliastro	NULL
,	NULL
M.	NULL
Ricote	NULL
,	NULL
S.	NULL
Ingrey	NULL
,	NULL
A.	NULL
Horlein	NULL
,	NULL
M.	NULL
Rosenfeld	NULL
,	NULL
and	NULL
C.	NULL
Glass	NULL
.	NULL

1997	NULL
.	NULL

Peroxisome	NULL
prolifera-tor-activated	NULL
receptors	NULL
and	NULL
retinoic	NULL
acid	NULL
receptors	NULL
differentially	NULL
control	NULL
the	NULL
interactions	NULL
of	NULL
retinoid	NULL
X	NULL
receptor	NULL
heterodimers	NULL
with	NULL
ligands	NULL
,	NULL
coactivators	NULL
,	NULL
and	NULL
corepressors	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

17:2166-2176	NULL
.	NULL

15	NULL
.	NULL

Durand	NULL
,	NULL
B.	NULL
,	NULL
M.	NULL
Saunders	NULL
,	NULL
C.	NULL
Gaudon	NULL
,	NULL
B.	NULL
Roy	NULL
,	NULL
R.	NULL
Losson	NULL
,	NULL
and	NULL
P.	NULL
Chambon	NULL
.	NULL

1994	NULL
.	NULL

Activation	NULL
function	NULL
2	NULL
(	NULL
AF-2	NULL
)	NULL
of	NULL
retinoic	NULL
acid	NULL
receptor	NULL
and	NULL
9-cis	NULL
retinoic	NULL
16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

RA	NULL
RECEPTOR	NULL
ACTIVATION	NULL
IN	NULL
MYELOPOIESIS	NULL
-	NULL
3381	NULL
acid	NULL
receptor	NULL
:	NULL
presence	NULL
of	NULL
a	NULL
conserved	NULL
autonomous	NULL
constitutive	NULL
activating	NULL
domain	NULL
and	NULL
influence	NULL
of	NULL
the	NULL
nature	NULL
of	NULL
the	NULL
response	NULL
element	NULL
on	NULL
AF-2	NULL
activity	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

13:5370-5382	NULL
.	NULL

Forman	NULL
,	NULL
B.	NULL
,	NULL
K.	NULL
Umesono	NULL
,	NULL
J.	NULL
Chen	NULL
,	NULL
and	NULL
R.	NULL
Evans	NULL
.	NULL

1995	NULL
.	NULL

Unique	NULL
response	NULL
pathways	NULL
are	NULL
established	NULL
by	NULL
allosteric	NULL
interactions	NULL
among	NULL
nuclear	NULL
hormone	NULL
receptors	NULL
.	NULL

Cell	NULL
81:541-550	NULL
.	NULL

Giguere	NULL
,	NULL
V.	NULL
,	NULL
E.	NULL
Ong	NULL
,	NULL
P.	NULL
Segui	NULL
,	NULL
and	NULL
R.	NULL
Evans	NULL
.	NULL

1987	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
receptor	NULL
for	NULL
the	NULL
morphogen	NULL
retinoic	NULL
acid	NULL
.	NULL

Nature	NULL
330:624-629	NULL
.	NULL

Grignani	NULL
,	NULL
F.	NULL
,	NULL
S.	NULL
De	NULL
Matteis	NULL
,	NULL
C.	NULL
Nervi	NULL
,	NULL
L.	NULL
Tomassoni	NULL
,	NULL
V.	NULL
Gelmetti	NULL
,	NULL
M.	NULL
Cioce	NULL
,	NULL
M.	NULL
Fanelli	NULL
,	NULL
M.	NULL
Ruthardt	NULL
,	NULL
F.	NULL
Ferrara	NULL
,	NULL
I.	NULL
Zamir	NULL
,	NULL
C.	NULL
Seiser	NULL
,	NULL
F.	NULL
Grignani	NULL
,	NULL
M.	NULL
Lazar	NULL
,	NULL
S.	NULL
Minucci	NULL
,	NULL
and	NULL
P.	NULL
G.	NULL
Pelicci	NULL
.	NULL

1998	NULL
.	NULL

Fusion	NULL
proteins	NULL
of	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor-	NULL
«	NULL
recruit	NULL
histone	NULL
deacetylase	NULL
in	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

Nature	NULL
319:815-818	NULL
.	NULL

Halachmi	NULL
,	NULL
S.	NULL
,	NULL
E.	NULL
Marden	NULL
,	NULL
G.	NULL
Martin	NULL
,	NULL
H.	NULL
MacKay	NULL
,	NULL
C.	NULL
Abbondanza	NULL
,	NULL
and	NULL
M.	NULL
Brown	NULL
.	NULL

1994	NULL
.	NULL

Estrogen	NULL
receptor-associated	NULL
proteins	NULL
:	NULL
possible	NULL
mediators	NULL
of	NULL
hormone-induced	NULL
transcription	NULL
.	NULL

Science	NULL
264:1455-1458	NULL
.	NULL

He	NULL
,	NULL
L.-Z	NULL
.	NULL

,	NULL
F.	NULL
Guidez	NULL
,	NULL
C.	NULL
Tribioli	NULL
,	NULL
D.	NULL
Peruzzi	NULL
,	NULL
M.	NULL
Ruthardt	NULL
,	NULL
A.	NULL
Zelent	NULL
,	NULL
and	NULL
P.	NULL
P.	NULL
Pandolfi	NULL
.	NULL

1998	NULL
.	NULL

Distinct	NULL
interactions	NULL
of	NULL
PML-RARa	NULL
and	NULL
PLZF-RARa	NULL
«	NULL
with	NULL
co-repressors	NULL
determine	NULL
differential	NULL
responses	NULL
to	NULL
RA	NULL
in	NULL
APL	NULL
.	NULL

Nat	NULL
.	NULL

Genet	NULL
.	NULL

18:126-135	NULL
.	NULL

Heinzel	NULL
,	NULL
T.	NULL
,	NULL
R.	NULL
Lavinsky	NULL
,	NULL
T.	NULL
M.	NULL
Mullen	NULL
,	NULL
M.	NULL
Soderstrom	NULL
,	NULL
C.	NULL
Laherty	NULL
,	NULL
J.	NULL
Torchia	NULL
,	NULL
W.-M.	NULL
Yang	NULL
,	NULL
G.	NULL
Brard	NULL
,	NULL
S.	NULL
Ngo	NULL
,	NULL
J.	NULL
Davie	NULL
,	NULL
E.	NULL
Seto	NULL
,	NULL
R.	NULL
Eisenman	NULL
,	NULL
D.	NULL
Rose	NULL
,	NULL
C.	NULL
Glass	NULL
,	NULL
and	NULL
M.	NULL
Rosenfeld	NULL
.	NULL

1997	NULL
.	NULL

A	NULL
complex	NULL
containing	NULL
N-CoR	NULL
,	NULL
mSin3	NULL
and	NULL
histone	NULL
deacetylase	NULL
mediates	NULL
transcriptional	NULL
repression	NULL
.	NULL

Nature	NULL
387:43-48	NULL
.	NULL

Heyman	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
D.	NULL
J.	NULL
Mangelsdorf	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Dyck	NULL
,	NULL
R.	NULL
B.	NULL
Stein	NULL
,	NULL
G.	NULL
Kichele	NULL
,	NULL
R.	NULL
M.	NULL
Evans	NULL
,	NULL
and	NULL
C.	NULL
Thaller	NULL
.	NULL

1992	NULL
.	NULL

9-Cis	NULL
retinoic	NULL
acid	NULL
is	NULL
a	NULL
high	NULL
affinity	NULL
ligand	NULL
for	NULL
the	NULL
retinoid	NULL
X	NULL
receptor	NULL
.	NULL

Cell	NULL
68:397-406	NULL
.	NULL

Hollenberg	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
R.	NULL
Evans	NULL
.	NULL

1988	NULL
.	NULL

Multiple	NULL
and	NULL
cooperative	NULL
transactivation	NULL
domains	NULL
of	NULL
the	NULL
human	NULL
glucocorticoid	NULL
receptor	NULL
.	NULL

Cell	NULL
55:899-906	NULL
.	NULL

Hong	NULL
,	NULL
H.	NULL
,	NULL
K.	NULL
Kohli	NULL
,	NULL
M.	NULL
Garabedian	NULL
,	NULL
and	NULL
M.	NULL
Stallcup	NULL
.	NULL

1997	NULL
.	NULL

Grip1	NULL
,	NULL
a	NULL
transcriptional	NULL
coactivator	NULL
for	NULL
the	NULL
AF-2	NULL
transactivation	NULL
domain	NULL
of	NULL
steroid	NULL
,	NULL
thy-roid	NULL
,	NULL
retinoid	NULL
,	NULL
and	NULL
vitamin	NULL
D	NULL
receptors	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

17:2735-2744	NULL
.	NULL

Horlein	NULL
,	NULL
A.	NULL
,	NULL
A.	NULL
Naar	NULL
,	NULL
T.	NULL
Heinzel	NULL
,	NULL
J.	NULL
Torchia	NULL
,	NULL
B	NULL
.	NULL

Gloss	NULL
,	NULL
R.	NULL
Kurokawa	NULL
,	NULL
A.	NULL
Ryan	NULL
,	NULL
Y.	NULL
Kamei	NULL
,	NULL
M.	NULL
Soderstrom	NULL
,	NULL
C.	NULL
Glass	NULL
,	NULL
and	NULL
M.	NULL
Rosenfeld	NULL
.	NULL

1995	NULL
.	NULL

Ligand-inde-pendent	NULL
repression	NULL
by	NULL
the	NULL
thyroid	NULL
hormone	NULL
receptor	NULL
mediated	NULL
by	NULL
a	NULL
nuclear	NULL
receptor	NULL
co-repressor	NULL
.	NULL

Nature	NULL
377:397-404	NULL
.	NULL

Huang	NULL
,	NULL
M.	NULL
,	NULL
Y.	NULL
C.	NULL
Ye	NULL
,	NULL
S.	NULL
R.	NULL
Chen	NULL
,	NULL
J.	NULL
R.	NULL
Chai	NULL
,	NULL
J.	NULL
X.	NULL
Lu	NULL
,	NULL
L.	NULL
Zhoa	NULL
,	NULL
L.	NULL
J.	NULL
Gu	NULL
,	NULL
and	NULL
Z.	NULL
Y.	NULL
Wang	NULL
.	NULL

1988	NULL
.	NULL

Use	NULL
of	NULL
all	NULL
trans	NULL
retinoic	NULL
acid	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

Blood	NULL
72:567-574	NULL
.	NULL

Imakado	NULL
,	NULL
S.	NULL
,	NULL
J.	NULL
Bickenbach	NULL
,	NULL
D.	NULL
Bund	NULL
J.	NULL
Rothnagel	NULL
,	NULL
P.	NULL
Attar	NULL
,	NULL
X.~-J	NULL
.	NULL

Wang	NULL
,	NULL
V.	NULL
Walczak	NULL
,	NULL
S.	NULL
Wisniewski	NULL
,	NULL
J.	NULL
Pote	NULL
,	NULL
J.	NULL
Gordon	NULL
,	NULL
R.	NULL
Heyman	NULL
,	NULL
R.	NULL
Evans	NULL
,	NULL
and	NULL
D.	NULL
Roop	NULL
.	NULL

1995	NULL
.	NULL

Targeting	NULL
expression	NULL
of	NULL
a	NULL
dominant-negative	NULL
retinoic	NULL
acid	NULL
receptor	NULL
mutant	NULL
in	NULL
the	NULL
epidermis	NULL
of	NULL
transgenic	NULL
mice	NULL
results	NULL
in	NULL
loss	NULL
of	NULL
barrier	NULL
function	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

9:317-329	NULL
.	NULL

Johnson	NULL
,	NULL
A.	NULL
T.	NULL
,	NULL
E.	NULL
S.	NULL
Klein	NULL
,	NULL
S.	NULL
J.	NULL
Gillet	NULL
,	NULL
L.	NULL
Wang	NULL
,	NULL
T.	NULL
K.	NULL
Song	NULL
,	NULL
M.	NULL
E.	NULL
Pino	NULL
,	NULL
and	NULL
R.	NULL
A.	NULL
S.	NULL
Chandraratna	NULL
.	NULL

1995	NULL
.	NULL

Synthesis	NULL
and	NULL
characterization	NULL
of	NULL
a	NULL
highly	NULL
potent	NULL
and	NULL
effective	NULL
antagonist	NULL
of	NULL
retinoic	NULL
acid	NULL
receptors	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

Chem	NULL
.	NULL

38:4764-4767	NULL
.	NULL

Kakizuka	NULL
,	NULL
A.	NULL
,	NULL
W.	NULL
Miller	NULL
,	NULL
K.	NULL
Umesono	NULL
,	NULL
R.	NULL
Warrell	NULL
,	NULL
S.	NULL
Frankel	NULL
,	NULL
V.	NULL
Murty	NULL
,	NULL
E.	NULL
Dmitrovsky	NULL
,	NULL
and	NULL
R.	NULL
Evans	NULL
.	NULL

1991	NULL
.	NULL

Chromosomal	NULL
translocation	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
in	NULL
human	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
fuses	NULL
RARa	NULL
«	NULL
with	NULL
a	NULL
novel	NULL
putative	NULL
transcription	NULL
factor	NULL
,	NULL
PML	NULL
.	NULL

Cell	NULL
66:663-674	NULL
.	NULL

Kastner	NULL
,	NULL
P.	NULL
,	NULL
M.	NULL
Mark	NULL
,	NULL
and	NULL
P.	NULL
Chambon	NULL
.	NULL

1995	NULL
.	NULL

Nonsteroid	NULL
nuclear	NULL
receptors	NULL
:	NULL
what	NULL
are	NULL
genetic	NULL
studies	NULL
telling	NULL
us	NULL
about	NULL
their	NULL
role	NULL
in	NULL
real	NULL
life	NULL
?	NULL

Cell	NULL
83:859-869	NULL
.	NULL

Kawasaki	NULL
,	NULL
H.	NULL
,	NULL
R.	NULL
Eckner	NULL
,	NULL
T.-P.	NULL
Yao	NULL
,	NULL
K.	NULL
Taira	NULL
,	NULL
R.	NULL
Chiu	NULL
,	NULL
D.	NULL
Livingston	NULL
,	NULL
and	NULL
K.	NULL
Yokoyama	NULL
.	NULL

1998	NULL
.	NULL

Distinct	NULL
roles	NULL
of	NULL
the	NULL
co-activators	NULL
p300	NULL
and	NULL
CBP	NULL
in	NULL
retinoic	NULL
acid-induced	NULL
F9	NULL
cell	NULL
differentiation	NULL
.	NULL

Nature	NULL
393:284-288	NULL
.	NULL

Kurokawa	NULL
,	NULL
R.	NULL
,	NULL
J.	NULL
DiRenzo	NULL
,	NULL
M.	NULL
Boehm	NULL
,	NULL
J.	NULL
Sugarman	NULL
,	NULL
B	NULL
.	NULL

Gloss	NULL
,	NULL
M.	NULL
Rosenfeld	NULL
,	NULL
R.	NULL
Heyman	NULL
,	NULL
and	NULL
C.	NULL
Glass	NULL
.	NULL

1994	NULL
.	NULL

Regulation	NULL
of	NULL
retinoid	NULL
signalling	NULL
by	NULL
receptor	NULL
polarity	NULL
and	NULL
allosteric	NULL
control	NULL
of	NULL
ligand	NULL
binding	NULL
.	NULL

Nature	NULL
371:528-531.	NULL
.	NULL

Kurokawa	NULL
,	NULL
R.	NULL
,	NULL
M.	NULL
Soderstrom	NULL
,	NULL
A.	NULL
Horlein	NULL
,	NULL
S.	NULL
Halachmi	NULL
,	NULL
M.	NULL
Brown	NULL
,	NULL
M.	NULL
Rosenfeld	NULL
,	NULL
and	NULL
C.	NULL
Glass	NULL
.	NULL

1995	NULL
.	NULL

Polarity-specific	NULL
activities	NULL
of	NULL
retinoic	NULL
acid	NULL
receptors	NULL
determined	NULL
by	NULL
a	NULL
co-repressor	NULL
.	NULL

Nature	NULL
377:451-454	NULL
.	NULL

Laherty	NULL
,	NULL
C.	NULL
,	NULL
A.	NULL
Billin	NULL
,	NULL
R.	NULL
Lavinsky	NULL
,	NULL
G.	NULL
Yochum	NULL
,	NULL
A.	NULL
Bush	NULL
,	NULL
J.-M.	NULL
Sun	NULL
,	NULL
T.-M.	NULL
Mullen	NULL
,	NULL
J.	NULL
Davie	NULL
,	NULL
D.	NULL
Rose	NULL
,	NULL
C.	NULL
Glass	NULL
,	NULL
M.	NULL
Rosenfeld	NULL
,	NULL
D.	NULL
Ayer	NULL
,	NULL
and	NULL
R.	NULL
Eisen-man	NULL
.	NULL

1998	NULL
.	NULL

SAP30	NULL
,	NULL
a	NULL
component	NULL
of	NULL
the	NULL
mSin3	NULL
corepressor	NULL
complex	NULL
involved	NULL
in	NULL
N-CoR-mediated	NULL
repression	NULL
by	NULL
specific	NULL
transcription	NULL
factors	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
2133-42	NULL
.	NULL

Lala	NULL
,	NULL
D.	NULL
,	NULL
R.	NULL
Mukherjee	NULL
,	NULL
L	NULL
Schulman	NULL
,	NULL
S.	NULL
Canan	NULL
Koch	NULL
,	NULL
L.	NULL
Dardashti	NULL
,	NULL
A.	NULL
Nadzan	NULL
,	NULL
G.	NULL
Croston	NULL
,	NULL
R.	NULL
Evans	NULL
,	NULL
and	NULL
R.	NULL
Heyman	NULL
.	NULL

1996	NULL
.	NULL

Activation	NULL
of	NULL
specific	NULL
RXR	NULL
heterodimers	NULL
by	NULL
an	NULL
antagonist	NULL
of	NULL
RXR	NULL
homodimers	NULL
.	NULL

Nature	NULL
383:450-453	NULL
.	NULL

Largman	NULL
,	NULL
C.	NULL
,	NULL
K.	NULL
Detmer	NULL
,	NULL
J.	NULL
Corral	NULL
,	NULL
F.	NULL
Hack	NULL
,	NULL
and	NULL
H.	NULL
J.	NULL
Lawrence	NULL
.	NULL

1989	NULL
.	NULL

Expression	NULL
of	NULL
retinoic	NULL
acid	NULL
receptor	NULL
alpha	NULL
in	NULL
mRNA	NULL
in	NULL
human	NULL
leukemia	NULL
cells	NULL
.	NULL

Blood	NULL
74:99-102	NULL
.	NULL

Leblanc	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
H.	NULL
Stunnenberg	NULL
.	NULL

1995	NULL
.	NULL

9-Cis	NULL
retinoic	NULL
acid	NULL
signaling	NULL
:	NULL
changing	NULL
partners	NULL
causes	NULL
some	NULL
excitement	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

9:1811-1816	NULL
.	NULL

Li	NULL
,	NULL
H.	NULL
,	NULL
C.	NULL
Leo	NULL
,	NULL
D.	NULL
Schroen	NULL
,	NULL
and	NULL
J.	NULL
D.	NULL
Chen	NULL
.	NULL

1997	NULL
.	NULL

Characterization	NULL
of	NULL
receptor	NULL
interaction	NULL
and	NULL
transcriptional	NULL
repression	NULL
by	NULL
the	NULL
corepressor	NULL
SMRT	NULL
.	NULL

Mol	NULL
.	NULL

Endocrinol	NULL
.	NULL

11:2025-2037	NULL
.	NULL

3382	NULL
39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

JOHNSON	NULL
ET	NULL
AL	NULL
.	NULL

Lin	NULL
,	NULL
R.	NULL
,	NULL
L.	NULL
Nagy	NULL
,	NULL
S.	NULL
Inoue	NULL
,	NULL
W.	NULL
Shao	NULL
,	NULL
W.	NULL
Miller	NULL
,	NULL
and	NULL
R.	NULL
Evans	NULL
.	NULL

1998	NULL
.	NULL

Role	NULL
of	NULL
the	NULL
histone	NULL
deacetylase	NULL
complex	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

Nature	NULL
391:811-814	NULL
.	NULL

Mangelsdorf	NULL
,	NULL
D.	NULL
,	NULL
K.	NULL
Umesono	NULL
,	NULL
S.	NULL
Kliewer	NULL
,	NULL
U.	NULL
Borgmeyer	NULL
,	NULL
E.	NULL
Ong	NULL
,	NULL
and	NULL
R.	NULL
Evans	NULL
.	NULL

1991	NULL
.	NULL

A	NULL
direct	NULL
repeat	NULL
in	NULL
the	NULL
cellular	NULL
retinol-binding	NULL
protein	NULL
type	NULL
II	NULL
gene	NULL
confers	NULL
differential	NULL
regulation	NULL
by	NULL
RXR	NULL
and	NULL
RAR	NULL
.	NULL

Cell	NULL
66:555-561	NULL
.	NULL

Mangelsdorf	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
R.	NULL
Evans	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
RXR	NULL
and	NULL
orphan	NULL
receptors	NULL
.	NULL

Cell	NULL
83:841-850	NULL
.	NULL

Morosetti	NULL
,	NULL
R.	NULL
,	NULL
F.	NULL
Grignani	NULL
,	NULL
C.	NULL
Liberatore	NULL
,	NULL
P.	NULL
Pelicci	NULL
,	NULL
G.	NULL
Schiller	NULL
,	NULL
M.	NULL
Kizaki	NULL
,	NULL
C.	NULL
Bartram	NULL
,	NULL
C.	NULL
Miller	NULL
,	NULL
and	NULL
H.	NULL
P.	NULL
Koeffler	NULL
.	NULL

1996	NULL
.	NULL

Infrequent	NULL
alterations	NULL
of	NULL
the	NULL
RAR	NULL
alpha	NULL
gene	NULL
in	NULL
acute	NULL
myelogenous	NULL
leukemias	NULL
,	NULL
retinoic	NULL
acid-resistant	NULL
acute	NULL
promyelocytic	NULL
leukemias	NULL
,	NULL
myelodysplastic	NULL
syndromes	NULL
and	NULL
cell	NULL
lines	NULL
.	NULL

Blood	NULL
87:4399-4403	NULL
.	NULL

Nagy	NULL
,	NULL
L.	NULL
,	NULL
H.-Y	NULL
.	NULL

Kao	NULL
,	NULL
D.	NULL
Chakravarti	NULL
,	NULL
R.	NULL
Lin	NULL
,	NULL
C.	NULL
Hassig	NULL
,	NULL
D.	NULL
Ayer	NULL
,	NULL
S.	NULL
Schreiber	NULL
,	NULL
and	NULL
R.	NULL
Evans	NULL
.	NULL

1997	NULL
.	NULL

Nuclear	NULL
receptor	NULL
repression	NULL
mediated	NULL
by	NULL
a	NULL
complex	NULL
containing	NULL
SMRT	NULL
,	NULL
mSin3A	NULL
,	NULL
and	NULL
histone	NULL
deacetylase	NULL
.	NULL

Cell	NULL
89:373-380	NULL
.	NULL

Onate	NULL
,	NULL
S.	NULL
,	NULL
S.	NULL
Tsai	NULL
,	NULL
M.-J	NULL
.	NULL

Tsai	NULL
,	NULL
and	NULL
B.	NULL
W.	NULL
O'Malley	NULL
.	NULL

1995	NULL
.	NULL

Sequence	NULL
and	NULL
characterization	NULL
of	NULL
a	NULL
coactivator	NULL
for	NULL
the	NULL
steroid	NULL
hormone	NULL
receptor	NULL
super-family	NULL
.	NULL

Science	NULL
270:1354-1357	NULL
.	NULL

Robertson	NULL
,	NULL
K.	NULL
,	NULL
B.	NULL
Emami	NULL
,	NULL
and	NULL
S.	NULL
J.	NULL
Collins	NULL
.	NULL

1992	NULL
.	NULL

Retinoic	NULL
acid-resistant	NULL
HL-60R	NULL
cells	NULL
harbor	NULL
a	NULL
point	NULL
mutation	NULL
in	NULL
the	NULL
RA	NULL
receptor	NULL
ligand	NULL
binding	NULL
domain	NULL
that	NULL
confers	NULL
dominant	NULL
negative	NULL
activity	NULL
.	NULL

Blood	NULL
80:1885-1889	NULL
.	NULL

Sadowski	NULL
,	NULL
L	NULL
,	NULL
and	NULL
M.	NULL
Ptashne	NULL
.	NULL

1989	NULL
.	NULL

A	NULL
vector	NULL
for	NULL
expressing	NULL
GALA	NULL
(	NULL
1-147	NULL
)	NULL
fusions	NULL
in	NULL
mammalian	NULL
cells	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

17:753	NULL
.	NULL

Saitou	NULL
,	NULL
M.	NULL
,	NULL
S.	NULL
Narumiya	NULL
,	NULL
and	NULL
A.	NULL
Kakizuka	NULL
.	NULL

1994	NULL
.	NULL

Alteration	NULL
of	NULL
a	NULL
single	NULL
amino	NULL
acid	NULL
residue	NULL
in	NULL
retinoic	NULL
acid	NULL
receptor	NULL
causes	NULL
dominant-negative	NULL
phe-notype	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269:19101-19107	NULL
.	NULL

Saitou	NULL
,	NULL
M.	NULL
,	NULL
S.	NULL
Sugai	NULL
,	NULL
T.	NULL
Tanaka	NULL
,	NULL
K.	NULL
Shimouchi	NULL
,	NULL
E.	NULL
Fuchs	NULL
,	NULL
S.	NULL
Narumiya	NULL
,	NULL
and	NULL
A.	NULL
Kakizuka	NULL
.	NULL

1995	NULL
.	NULL

Inhibition	NULL
of	NULL
skin	NULL
development	NULL
by	NULL
targeted	NULL
expression	NULL
of	NULL
a	NULL
dominant-negative	NULL
retinoic	NULL
acid	NULL
receptor	NULL
.	NULL

Nature	NULL
374:159-162	NULL
.	NULL

Schulman	NULL
,	NULL
L	NULL
,	NULL
C.	NULL
Li	NULL
,	NULL
J.	NULL
W.	NULL
R.	NULL
Schwabe	NULL
,	NULL
and	NULL
R.	NULL
Evans	NULL
.	NULL

1997	NULL
.	NULL

The	NULL
phantom	NULL
ligand	NULL
effect	NULL
:	NULL
allosteric	NULL
control	NULL
of	NULL
transcription	NULL
by	NULL
the	NULL
retinoid	NULL
X	NULL
receptor	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

11:299-308	NULL
.	NULL

Seewaldt	NULL
,	NULL
V.	NULL
L.	NULL
,	NULL
L.	NULL
E.	NULL
Caldwell	NULL
,	NULL
B.	NULL
S.	NULL
Johnson	NULL
,	NULL
K.	NULL
Swisshelm	NULL
,	NULL
S.	NULL
J.	NULL
Collins	NULL
,	NULL
and	NULL
S.	NULL
Tsai	NULL
.	NULL

1997	NULL
.	NULL

Inhibition	NULL
of	NULL
retinoic	NULL
acid	NULL
receptor	NULL
function	NULL
in	NULL
normal	NULL
human	NULL
mammary	NULL
epithelial	NULL
cells	NULL
results	NULL
in	NULL
increased	NULL
cellular	NULL
proliferation	NULL
and	NULL
inhibits	NULL
the	NULL
formation	NULL
of	NULL
a	NULL
polarized	NULL
epithelium	NULL
in	NULL
vitro	NULL
.	NULL

Exp	NULL
.	NULL

Cell	NULL
Res	NULL
.	NULL

236:16-28	NULL
.	NULL

Solomin	NULL
,	NULL
L.	NULL
,	NULL
C.	NULL
Johansson	NULL
,	NULL
R.	NULL
Zetterstrom	NULL
,	NULL
R.	NULL
Bissonnette	NULL
,	NULL
R.	NULL
Heyman	NULL
,	NULL
L.	NULL
Olson	NULL
,	NULL
U.	NULL
Lendabl	NULL
,	NULL
J.	NULL
Frisen	NULL
,	NULL
and	NULL
T.	NULL
Perlmann	NULL
.	NULL

1998	NULL
.	NULL

Retinoid-X	NULL
receptor	NULL
signalling	NULL
in	NULL
the	NULL
developing	NULL
spinal	NULL
cord	NULL
.	NULL

Nature	NULL
395:398-401	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

59	NULL
.	NULL

60	NULL
.	NULL

61	NULL
.	NULL

62	NULL
.	NULL

63	NULL
.	NULL

Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

Tate	NULL
,	NULL
B.	NULL
,	NULL
G.	NULL
Allenby	NULL
,	NULL
R.	NULL
Janocha	NULL
,	NULL
S.	NULL
Kazmer	NULL
,	NULL
J.	NULL
Speck	NULL
,	NULL
L.	NULL
Sturzenbecker	NULL
,	NULL
P.	NULL
Abarzua	NULL
,	NULL
A.	NULL
Levin	NULL
,	NULL
and	NULL
J.	NULL
Grippo	NULL
.	NULL

1994	NULL
.	NULL

Distinct	NULL
binding	NULL
determinants	NULL
for	NULL
9-cis	NULL
retinoic	NULL
acid	NULL
are	NULL
located	NULL
within	NULL
AF-2	NULL
of	NULL
retinoic	NULL
acid	NULL
receptor	NULL
«	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:2323-2330	NULL
.	NULL

Tsai	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
S.	NULL
Collins	NULL
.	NULL

1993	NULL
.	NULL

A	NULL
dominant	NULL
negative	NULL
retinoic	NULL
acid	NULL
receptor	NULL
blocks	NULL
neutrophil	NULL
differentiation	NULL
at	NULL
the	NULL
promyelocyte	NULL
stage	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90:7153-7157	NULL
.	NULL

Tsai	NULL
,	NULL
S.	NULL
,	NULL
S.	NULL
Bartelmez	NULL
,	NULL
E.	NULL
Sitnicka	NULL
,	NULL
and	NULL
S.	NULL
Collins	NULL
.	NULL

1994	NULL
.	NULL

Lymphohemato-poietic	NULL
progenitors	NULL
immortalized	NULL
by	NULL
a	NULL
retroviral	NULL
vector	NULL
harboring	NULL
a	NULL
dominant	NULL
negative	NULL
retinoic	NULL
acid	NULL
receptor	NULL
can	NULL
recapitulate	NULL
lymphoid	NULL
,	NULL
myeloid	NULL
and	NULL
ery-throid	NULL
development	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

8:2831-2842	NULL
.	NULL

Umesono	NULL
,	NULL
K.	NULL
,	NULL
V.	NULL
Giguere	NULL
,	NULL
C.	NULL
Glass	NULL
,	NULL
M.	NULL
Rosenfeld	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Evans	NULL
.	NULL

1988	NULL
.	NULL

Retinoic	NULL
acid	NULL
and	NULL
thyroid	NULL
hormone	NULL
induce	NULL
gene	NULL
expression	NULL
through	NULL
a	NULL
common	NULL
responsive	NULL
element	NULL
.	NULL

Nature	NULL
336:262-265	NULL
.	NULL

Umesono	NULL
,	NULL
K.	NULL
,	NULL
K.	NULL
Murakami	NULL
,	NULL
C.	NULL
Thompson	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Evans	NULL
.	NULL

1991	NULL
.	NULL

Direct	NULL
repeats	NULL
as	NULL
selective	NULL
response	NULL
elements	NULL
for	NULL
the	NULL
thyroid	NULL
hormone	NULL
,	NULL
retinoic	NULL
acid	NULL
and	NULL
vitamin	NULL
Ds	NULL
receptors	NULL
.	NULL

Cell	NULL
65:1255-1266	NULL
.	NULL

Voegel	NULL
,	NULL
J.	NULL
,	NULL
M.	NULL
J.	NULL
S.	NULL
Heine	NULL
,	NULL
C.	NULL
Zechel	NULL
,	NULL
P.	NULL
Chambon	NULL
,	NULL
and	NULL
H.	NULL
Gronemeyer	NULL
.	NULL

1996	NULL
.	NULL

TIF2	NULL
,	NULL
a	NULL
160	NULL
kDa	NULL
transcriptional	NULL
mediator	NULL
for	NULL
the	NULL
ligand-dependent	NULL
activation	NULL
function	NULL
AF-2	NULL
of	NULL
nuclear	NULL
receptors	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

15:3667-3675	NULL
.	NULL

Vuligonda	NULL
,	NULL
V.	NULL
,	NULL
Y.	NULL
Lin	NULL
,	NULL
and	NULL
R.	NULL
A.	NULL
S.	NULL
Chandraratna	NULL
.	NULL

1996	NULL
.	NULL

Synthesis	NULL
of	NULL
highly	NULL
potent	NULL
RXR-specific	NULL
retinoids	NULL
:	NULL
the	NULL
use	NULL
of	NULL
a	NULL
cyclopropyl	NULL
group	NULL
as	NULL
a	NULL
double	NULL
bond	NULL
isostere	NULL
.	NULL

Biorg	NULL
.	NULL

Med	NULL
.	NULL

Chem	NULL
.	NULL

Lett	NULL
.	NULL

6:213-218	NULL
.	NULL

Warrell	NULL
,	NULL
R.	NULL
,	NULL
S.	NULL
Frankel	NULL
,	NULL
W.	NULL
Miller	NULL
,	NULL
L.	NULL
Itri	NULL
,	NULL
M.	NULL
Andreef	NULL
,	NULL
A.	NULL
Jabukowski	NULL
,	NULL
J.	NULL
Gabrilove	NULL
,	NULL
M.	NULL
Gordon	NULL
,	NULL
and	NULL
E.	NULL
Dmitrovsky	NULL
.	NULL

1991	NULL
.	NULL

Differentiation	NULL
therapy	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
with	NULL
tretinoin	NULL
(	NULL
all-trans	NULL
retinoic	NULL
acid	NULL
)	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

324:1385-1390	NULL
.	NULL

Westin	NULL
,	NULL
S.	NULL
,	NULL
R.	NULL
Kurokawa	NULL
,	NULL
R.	NULL
Nolte	NULL
,	NULL
G.	NULL
Wisely	NULL
,	NULL
E.	NULL
Mclnerney	NULL
,	NULL
D.	NULL
Rose	NULL
,	NULL
M.	NULL
Milburn	NULL
,	NULL
M.	NULL
Rosenfeld	NULL
,	NULL
and	NULL
C.	NULL
Glass	NULL
.	NULL

1998	NULL
.	NULL

Interactions	NULL
controlling	NULL
the	NULL
assembly	NULL
of	NULL
nuclear-receptor	NULL
heterodimers	NULL
and	NULL
co-activators	NULL
.	NULL

Nature	NULL
395	NULL
:	NULL
199-202	NULL
.	NULL

Willy	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
D.	NULL
J.	NULL
Mangelsdorf	NULL
.	NULL

1997	NULL
.	NULL

Unique	NULL
requirements	NULL
for	NULL
retinoid-dependent	NULL
transcriptional	NULL
activation	NULL
by	NULL
the	NULL
orphan	NULL
receptor	NULL
LXR	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

11:289-298	NULL
.	NULL

Yoshida	NULL
,	NULL
M.	NULL
,	NULL
M.	NULL
Kijima	NULL
,	NULL
M.	NULL
Akita	NULL
,	NULL
and	NULL
T.	NULL
Beppu	NULL
.	NULL

1990	NULL
.	NULL

Potent	NULL
and	NULL
specific	NULL
inhibition	NULL
of	NULL
mammalian	NULL
histone	NULL
deacetylase	NULL
both	NULL
in	NULL
vivo	NULL
and	NULL
in	NULL
vitro	NULL
by	NULL
trichostatin	NULL
A.	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

265:17174-17179	NULL
.	NULL

Zhang	NULL
,	NULL
Y.	NULL
,	NULL
ZW	NULL
.	NULL

Sun	NULL
,	NULL
R.	NULL
Iratoi	NULL
,	NULL
H.	NULL
Erdjument-Bromage	NULL
,	NULL
P.	NULL
Tempst	NULL
,	NULL
M.	NULL
Hampsey	NULL
,	NULL
and	NULL
D.	NULL
Reinberg	NULL
.	NULL

1998	NULL
.	NULL

SAP30	NULL
,	NULL
a	NULL
novel	NULL
protein	NULL
conserved	NULL
between	NULL
human	NULL
and	NULL
yeast	NULL
,	NULL
is	NULL
a	NULL
component	NULL
of	NULL
a	NULL
histone	NULL
deacetylase	NULL
complex	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
1:1021-1031	NULL
.	NULL

